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Preface
For the last twenty years, monotherapy with antiepileptic drugs (AEDs) has been promoted 
as the rational basis for the treatment of patients with epilepsy. This has partly been due 
to the unfavorable reputation of AED polytherapy. The disadvantages of polytherapy are 
deemed to be increased toxicity, drug interactions, failure to evaluate the effect of 
individual drugs and in some patients even seizure exacerbation (203). These conclusions 
were drawn from a number of open trials, in which patients on polytherapy were changed 
over to monotherapy. Many patients in these studies experienced a decrease in adverse 
effects and some even an improvement in seizure control.
However, apart from the fact that these trials were open and uncontrolled, the concept of 
drug load was neglected in their study design and analysis. One of the basic hypotheses of 
this thesis is that the drug loads of medication regimens should be equal before conclusions 
can be reached on differences of intrinsic efficacy and toxicity. Drug load is defined as the 
amount of drug exposure for a certain indication and a method to calculate drug load was 
developed and used by our group, the Nijmegen Epilepsy Research Group (NERG), in 
previous studies (133-135). In an earlier observational study our group in fact found that 
polytherapy is not associated with more toxicity than monotherapy when drug loads are 
equal (135). As polytherapy is often given at higher drug loads, this may very well be the 
most important reason for the increased toxicity associated with AED polytherapy.
This leads us to the main question of this thesis: do certain AED combinations offer 
advantages over their individual constituents ? This question may seem easy to answer, 
however there are a number of problems to consider. The first problem, in animal and in 
human studies, is the selection of adequate methods: which study design and statistical 
analysis should be used to study combination therapy; how should efficacy and toxicity be 
assessed; which neuropsychological tests should be used ? In chapter 1, the introduction, 
the history of the polytherapy controversy is examined and the different methodologies our 
group has employed in recent studies are briefly reviewed. In chapter 2, background 
information on these methodologies is given for the interested reader, and in chapter 3 our 
methods are put to the test: a literature review is performed to evaluate whether the number 
of drugs or drug load determines the number of adverse effects and another literature
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review is carried out to assess the effect of different detection methods (i.e. spontaneous 
reporting and use of a clinimetric scale) on the frequencies of adverse effects.
The second problem our main question poses, is that it is unclear which pharmacodynamic 
combinations will lead to increased efficacy or reduced toxicity. In other words, which 
mechanisms of action should be combined to offer added value ? In recent years, some 
authors have claimed that drugs that act on the same ion channels or the same 
neurotransmitters should be combined whereas others believe that combinations should 
consist of drugs that do not share their targets. In chapter 4 the available polytherapy 
studies in animals and humans will be reviewed to evaluate this, but also to assess which 
designs and methodologies these studies used.
In chapter 5 and 6 our own studies on AED combinations are described. In chapter 5 
polytherapy is evaluated in an animal model of absence epilepsy. The combination of 
sodium valproate (which will be referred to as valproate in this thesis) and ethosuximide 
is compared to its individual components with regards to efficacy and toxicity. In chapter
6, a randomized double-blind trial comparing monotherapy and combination therapy in 
patients with newly-diagnosed epilepsy is described. This is the first time a double-blind 
randomized trial has been carried out to evaluate the merits of combination therapy with 
AEDs.
Finally, in chapter 7 our findings and their relevance will be discussed and 
recommendations for future studies will be made.
vii
In summary, the aims of this thesis are the following:
1. To investigate whether drug load, rather than the number of antiepileptic drugs, is 
responsible for adverse effects.
2. To evaluate whether polytherapy is a good alternative for monotherapy when 
prescribed at equal drug loads.
3. To assess the possibility of selecting AED combinations by mechanisms of action.
4. To determine the best methodologies to evaluate polytherapy with antiepileptic 
drugs.
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A bbreviations and glossary
•  additive
•  AED
•  AHD
•  AMPA
•  ATL
•  AToxL
•  BZD
•  CBZ
•  CI
•  CII
•  CNS
•  clinimetrics
DDD
drug load 
i EEG
• effectiveness
• efficacy 
I ESM
I FBM
FePsy
GABA 
I GABA-T
i GAD
i GBP
the sum of the drug fractions of the combination, needed for an effect 
equal to that of the individual drugs, equals 1 
antiepileptic drug 
anxiolytic-hypnotic drug
a-amino-3-hydroxic-5-methylisoxazole-4-propionic acid 
average therapeutic level; average therapeutic serum level of a drug used in its 
main indication in adults 
average toxic level
benzodiazepine; group of drugs, which are used for epilepsy and other 
indications 
carbamazepine; antiepileptic drug 
confidence interval
Composite Index of Impairments; clinimetric epilepsy scale 
central nervous system
the domain concerned with indexes, ratings scales, and other expressions 
that are used to describe and measure symptoms, physical signs, and 
other distinct phenomena in clinical medicine
Defined Daily Dose; average maintenance dose per day for a drug used 
in its main indication in adults 
the amount of drug exposure for a certain indication 
electro-encephalogram
measure encompassing both efficacy and tolerability 
level of seizure control 
ethosuximide; antiepileptic drug 
felbamate; antiepileptic drug
FerroPsychologist; computerized neuropsychological test battery 
developed at the SEIN, Heemstede 
y-aminobutyric acid; neurotransmitter
GABA-transaminase; enzyme drugs which converts GABA into succinic 
semialdehyde
glutamic acid decarboxylase; enzyme which converts glutamate to 
GABA
gabapentin; antiepileptic drug
xGHB y-hydroxybutyrate; GABA-metabolite
infra-additive the sum of the drug fractions of the combination, needed for an effect
equal to that of the individual drugs, is greater than 1 (synonym: 
antagonistic)
Index of Seizures, subscale of the Seizure Activity index 
low threshold calcium current; thought to be involved in absence epilepsy 
lamotrigine; antiepileptic drug
maximal electroshock; animal epilepsy model 
Nijmegen Epilepsy Research Group 
^-methyl-D-aspartate; type of glutamate receptor 
Neurotoxicity Index, subscale of the CII
observed serum level; serum level of a drug measured in a patient or 
average serum level measured in a group of patients 
oxcarbazepine; antiepileptic drug 
phenobarbital; antiepileptic drug
Prescribed Daily Dose; the dose of a drug a patient uses per day or the 
average dose of a drug used daily in a group of patients 
phenytoin; antiepileptic drug
primidone; antiepileptic drug
pentylenetetrazole; drug which can induce seizures in animals and is used 
as epilepsy model
Seizure Activity index, subscale of the CII 
Systemic Toxicity index, subscale of the CII
the sum of the drug fractions of the combination, needed for an effect 
equal to that of the individual drugs, is less than 1 (synonym: synergistic) 
spike wave discharge 
tiagabine; antiepileptic drug 
level of adverse effects 
topiramate; antiepileptic drug 
valproate; antiepileptic drug
•  IS
•  LTCC
•  LTG
•  MES
•  NERG
•  NMDA
•  NTX
•  OSL
•  OXC
•  PB
•  PDD
•  PHT
•  PRM
•  Ptz
•  SA
•  STX
•  supra-additive
•  SWD
•  TGB
•  tolerability
•  TPM
•  VPA
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11.1 The monotherapy versus polytherapy controversy
The rise and fall of polytherapy
Before 1960 the only drugs available for the treatment of epilepsy were bromides, 
barbiturates, phenytoin, tridiones and succinimides. These were all efficacious drugs, but 
their use was also associated with considerable side effects, most notably somnolence. It 
was believed that combining lower dosages of two of these drugs would be as efficacious 
but less toxic to patients than exposure to a full dose of one drug. Therefore it was 
customary, till around 1980, to start patients off on combinations of antiepileptic drugs 
(AEDs) (88). These compound preparations, which were often given in one capsule, would 
often also include substances known to counteract somnolence, such as caffeine, 
amphetamine, or atropine. In Italy for example Dintospina contained 100 mg of phenytoin, 
60 mg of mephobarbital and 3 mg of amphetamine. In the Netherlands compound 
preparations were ready made by pharmacists.
An additional reason for the use of combination therapy according to Genton and Roger 
was that combination therapy was believed to be more efficacious (88). For example 
phenobarbital was considered to be especially efficacious against generalized tonic clonic 
seizures and phenytoin against both focal seizures and generalized tonic clonic seizures. 
The combination was supposed to increase protection against both seizure types, for 
example in partial epilepsy with secondary generalized seizures. Gram and Reynolds et al. 
however claim that it actually was a lack of agreement as to which drug was best for a 
certain seizure disorder and as to which drug to start first which had led to polytherapy 
(95, 203). All of these authors do agree that the absence of serum level measurements also 
contributed to the use of polytherapy, as some AEDs have unpredictable pharmacokinetics, 
e.g. phenytoin.
In the latter part of the seventies however, a number of reports by Reynolds and Shorvon 
led to the rise of monotherapy as the preferred treatment for epilepsy. In 1976, they found 
that only a small proportion of patients were truly resistant to phenytoin monotherapy when 
doses could be adjusted on the basis of serum levels (202). Of the 31 patients with 
generalized or focal epilepsy, only 3 needed a second drug during a mean follow-up period
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o f  15 m onths. In 1977, they reported that adding a second drug w as only o f  benefit in about 
one th ird  o f  the patients poorly controlled by m onotherapy. W hen serum  levels w ere 
m easured in these patients, it w as found that the im proved control was significantly related 
to  an optim um  serum  level o f  at least one o f  the drugs (228). They concluded that aim ing 
for an optim um  serum  level m ay be o f  m ore benefit than adding a second drug. In 1978 
Shorvon et al. reported that w hen carbam azepine or phenytoin w as given to  51 newly 
referred untreated patients and blood levels w ere in the optim um  range, a 98%  reduction 
in ‘grand m al’ attacks and a 92-93%  reduction in partial seizures was achieved (227). This 
w as a m uch higher success rate than w as achieved in previous studies and w as attributed 
to  drug-level m onitoring, w ithout w hich an estim ated 60-70%  o f  patients w ould have been 
treated w ith polytherapy. How ever, as G oldsm ith et al. rem ark in their review , there w ere 
no patients w ith m ajor neurological or psychiatric handicaps in that 1978 study, w hich may 
have been a m ajor factor in its high success rate (91). In 1979 finally, Shorvon and 
Reynolds reported about a group o f  40 patients in w hich they had tried to  reduce the 
num ber o f  AED s to  one (229). They succeeded in doing so in 29 patients, and seizure 
control actually im proved in 16 o f  these patients. A lso, m ental function im proved in 16 o f 
the 29 patients. Sim ilar findings o f  im proved seizure control in som e patients and an 
overall decrease in toxicity after reduction o f  polytherapy to  m onotherapy w ere reported 
by a num ber o f  researchers (1, 16, 35, 78, 141, 218, 243, 245).
The advantages o f  m onotherapy had becom e clear: better tolerability, few er interactions, 
easier clinical m onitoring and in some patients even better efficacy. Furtherm ore, tw o 
prom ising new  drugs (carbam azepine and valproate) w ith less CN S (central nervous 
system) toxicity  had becom e available and w ere proving to  be useful in m onotherapy. In 
1981, after the publication o f  the revised international classification o f  epileptic seizures, 
studies w ere carried out in which the efficacy o f  different AED s was evaluated per seizure 
type. G enton and R oger claim  that the increased understanding o f  epilepsy and the fact that 
specific A ED s could now  be recom m ended for specific seizure types w ere the m ost 
enduring reasons that m onotherapy has becom e the gold standard for epilepsy treatm ent 
(88).
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Two of the best known comparative monotherapy trials were executed by the Veteran 
Affairs Epilepsy Cooperative Study Group (173, 174). In the first trial carbamazepine, 
phenobarbital, phenytoin and primidone were evaluated in partial and secondary 
generalized tonic-clonic seizures (total number of patients 622) . The results can be 
summarized as follows: there was no difference in efficacy for tonic-clonic seizures 
between the drugs; carbamazepine was more efficacious for partial seizures than primidone 
and phenobarbital; primidone and phenobarbital were discontinued more often than 
carbamazepine and phenytoin due to treatment failure or adverse effects.
In the second trial valproate and carbamazepine were compared in patients with complex 
partial and secondary generalized tonic-clonic seizures (total number of patients 480). 
These drugs were equally efficacious for generalized tonic-clonic seizures, but 
carbamazepine was more efficacious for complex partial seizures. It is remarkable that less 
than 50% of patients with either seizure type and treated with either drug remained seizure 
free in the first year of drug treatment. Mattson, one of the principal investigators of the 
VA Group, acknowledges that once an appropriately selected antiepileptic drug has been 
started, seizures still may occur during the period of adjustment. He stresses however that, 
if  clinically acceptable, it may be appropriate to continue the initial medication (171). In 
the first VA trial, 58% of the patients experiencing seizures in the first 6 months of 
treatment were seizure free during the next 6 months while continuing to take the original 
drug (175). Some of these patients will have breakthrough seizures, but others will enter 
long-term remission. Overall, after one to two years 60% of patients have almost complete 
control of seizures (174). In the second VA trial approximately 75% of patients were still 
on their initial drug at 12 months (173). In the first VA trial approximately 60% of 
phenytoin and carbamazepine users stayed on their drug for more than two years (174). 
In the British EPITEG-trial carbamazepine and valproate monotherapy were compared in 
adult onset epilepsy (total number of patients 281). Both drugs were associated with a high 
degree of seizure control, regardless of seizure type, and both had good long term 
tolerability. At the end of the 3 year trial period over 70% of the available patients were 
still on their randomized treatment or had recently stopped treatment after achieving full 
seizure control (204).
In patients whose first drug fails because of insufficient seizure control or adverse effects
an alternative m onotherapy  is often tried. In the first V A  trial the alternative drug 
succeeded in 46%  o f  patients (171). In a study by Schm idt et al. 31%  o f  patients reached 
total seizure control or m ore than 75%  seizure reduction w ith alternative m onotherapy 
(total num ber o f  patients 59) (220). In a trial by H akkarainen about h a lf  o f  the patients 
receiving carbam azepine or phenytoin w ere seizure-free at one year (total num ber o f 
patients 100) (52). W hen the non-responders were switched to  the alternative m onotherapy, 
another 17% becam e seizure free.
In conclusion, as these data also indicate, it is generally accepted that 70%  o f  epilepsy 
patients will have adequate seizure control w ith a single drug, either the initial drug or an 
alternative.
Effectiveness of combination therapy
W hen alternative m onotherapy fails, the sw itch to  polytherapy is made. A ccording to 
Perucca, only a small group o f  the patients w ho w ere not effectively controlled w ith 
m onotherapy, will benefit from  a com bination o f  tw o AEDs, often at the expense o f 
adverse effects (194). In a trial by Schm idt et al., only 4 o f  30 patients had m ore than 75%  
seizure reduction after the 2nd drug w as added (217).
In the first V A  trial however, it w as found that approxim ately 40%  o f  patients w ho had not 
benefitted from  m onotherapy, had im proved control w ith tw o drug therapy, although only 
10% achieved seizure rem ission. In another trial, D ean and Penry used valproate as add-on 
treatm ent in patients w ith inadequate seizure control on carbam azepine (total num ber o f 
patients 100) (52). M arked im provem ent w ith at least 50%  seizure reduction w as achieved 
in 49%  o f  patients, w ith 17% being seizure free after 1 year.
Especially partial epilepsy or sym ptom atic generalized epilepsy m ay turn  out to  be 
refractory to  m onotherapy. K räm er claim s that in clinical practice, only 30%  o f  patients 
w ith severe chronic epilepsy are satisfactorily controlled by m onotherapy (127). He 
furtherm ore estim ates that approxim ately 35%  o f  patients w ith severe chronic epilepsy 
benefit from  AED com binations. In a hom e for m entally retarded, Idzinga et al. reported 
that o f  168 inhabitants w ith epilepsy, 24%  w ere seizure free on m onotherapy, and another 
8% on tw o drugs (114). U sing the criteria o f  K räm er for satisfactory control these num bers 
becom e 35%  on one drug and an additional 27%  on tw o or more. In a trial by W illm ore et
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al., patients were randomized to add-on valproate or add-on placebo after failing on 
phenytoin or carbamazepine monotherapy (total number of patients 137) (268). Forty-six 
percent of patients receiving add-on valproate experienced a greater than 50% reduction 
in seizure frequency compared to only 12% of patients who received add-on placebo. In 
a study by Walker and Koon 16 of 43 patients with refractory partial epilepsy responded 
to carbamazepine with a 50-100 % seizure reduction (258). Twenty-five of the non­
responders were subsequently given valproate monotherapy, and 7 of them experienced a 
50-100% seizure reduction. Finally, in 17 patients CBZ was then added to VPA, and 6 out 
of the 17 experienced complete control and 6 had >50% seizure reduction in seizure 
frequency compared to their best control on either monotherapy. The same combination 
of carbamazepine and valproate was also very successful in a study by Fröscher et al. 
involving patients with difficult-to-treat epilepsy: 28 of 37 patients with generalized tonic- 
clonic seizures experienced a 50-100% decrease in seizure frequency, whereas this was 
accomplished in 5 of 17 patients with complex partial seizures (84).
These are not the only trials in patients with refractory partial epilepsy. New antiepileptic 
drugs first have to prove their efficacy in add-on trials in patients with uncontrolled partial 
epilepsy before they are licensed. In these trials the new drug is added to baseline 
medication in patients with uncontrolled partial epilepsy. Many of the new drugs are found 
to achieve a greater than 50% seizure reduction in approximately 25 to 50% of these 
patients (82).
The aforementioned results strongly suggest that when needed and when properly selected, 
polytherapy with antiepileptic drugs can improve seizure control. The exacerbation of 
seizures due to polytherapy seen in the past, may have been due to intoxication or 
inappropriate AED selection (195).
Rational polytherapy
In the 1990s interest in combination therapy with AEDs has rekindled. There may be 
several reasons for this: 1. Clinical necessity because of the limitations of monotherapy.
2. An increased insight into the mechanisms underlying epilepsy and into the mechanisms 
of action of AEDs. 3. The introduction of several new AEDs, which are costly, but often 
have more predictable pharmacokinetics and less adverse effects than the established
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In other fields of medicine, such as in the treatment of hypertension, cancer and infectious 
diseases, combination therapy has already proven to be of great value. The added value of 
polytherapy can be due to either increased efficacy or reduced toxicity or both. The 
theoretical basis for reduced toxicity of combination therapy can be derived from the log­
linear dose-response curve, as Fagan has discussed in an editorial in the Archives of 
Internal Medicine (69). The dose-response curve for toxic effects of a drug generally lies 
to the right of the curve for the desired therapeutic curve of that drug. Therefore, if  two 
drugs are combined at dosages with 50% effect, the toxicity of such a combination may be 
minimal, provided their effects result from different mechanisms of action.
Figure 1.1a illustrates this principle.
Figure 1.1a Theoretical therapeutic and toxic dose-response curve
The horizontal axis is a logarithmic scale with arbitrary dose units. The vertical axis is a linear scale showing 
percent of maximum possible response
It is important to realize however, that the summation of dose-independent adverse effects 
might prove disadvantageous when using combination therapy, as Fenickel and Lipicky 
point out in the same issue of the Archives ofInternal Medicine (73). Nevertheless, except 
for the aforementioned open trials knowledge about the merits of polytherapy is scarce. 
Notably, there have been no double blind randomized clinical trials to evaluate AED 
monotherapy versus combination therapy. The Commission on Antiepileptic Drugs of the
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International League Against Epilepsy (ILAE) recognizes “that there is urgent need to 
evaluate these different policies” (115). The reason that we have fallen behind other 
disciplines in this respect, may be due to the unfavorable reputation that AED polytherapy 
has acquired. The reason cannot be that the present monotherapy is considered sufficiently 
efficient, as even the most optimistic reports do not claim more than 80% success. 
However, is the reputation of AED polytherapy really justified ? As mentioned, 
exacerbation of seizures may have been due to ignorance about specific effects of AEDs, 
e.g. worsening of absence seizures due to certain AEDs. As far as drug interactions are 
concerned, much more knowledge has been acquired about the interactions of the 
established AEDs. Finally, the new drugs generally have more predictable 
pharmacokinetics and less drug interactions, which makes them more suitable for 
combination therapy (28).
Perhaps the greatest concern about polytherapy has been the reputed risk of increased 
toxicity. When our group compared the drug loads of patients on monotherapy and patients 
on polytherapy, we found that on average patients on polytherapy received higher drug 
loads. When we subsequently compared groups of patients with equal drug loads of 
monotherapy and polytherapy, we found that under that condition polytherapy is not 
associated with more toxicity (135). This seems to take away one of the last objections to 
the evaluation of certain AED combinations. In fact, this observation led us to start a 
double-blind randomized clinical trial which will be presented in chapter 6.
1.2 Drug load
A structural problem in the comparison of multiple drug regimens is the neglect of 
differences in drug load. Drug load can be defined as the amount of drug exposure for a 
certain indication. What is seldom realized, is that differences in drug load may be 
responsible for differences in effects when drugs are combined. For example, when a 
patient who takes a 1000 mg carbamazepine per day is compared to a patient who takes a 
1000 mg carbamazepine plus 300 mg phenytoin per day, differences in efficacy and 
toxicity may very well be found but do they prove that combination therapy is both more 
efficacious and toxic ? We claim that drug loads have to be equal for a valid comparison
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of treatments.
Lammers et al. developed the Prescribed Daily Dose/Defined Daily Dose (PDD/DDD) 
ratio as an instrument to calculate drug loads (135). The Defined Daily Dose signifies the 
assumed average dose per day for the drug used in its main indication in adults. For each 
drug a DDD is assigned by the WHO Collaborating Center for Drug Statistics 
Methodology based on international textbooks, journals and documentation approved by 
drug control authorities (264, 265). The assigned DDD values for the AEDs are given in 
table 1.2 .
Table 1.2a Defined Daily Dose values of antiepileptic drugs as assigned by the World 
Health Organization
Drug Defined Daily Dose 
(mg)
Carbamazepine (CBZ) 1000
Phenytoin (PHT) 300
Valproate (VPA) 1500
Phenobarbitone (PB) 100
Ethosuximide (ESM) 1250
Primidone (PRM) 1250
Clonazepam (CLZP) 8
Oxcarbazepine (OXC) 1500
Vigabatrin (VGB) 2000
Lamotrigine (LTG) 300
For information on assigned Defined Daily Dose values, contact the WHO Collaborating Center for Drug 
Statistics Methodology, c/o Norsk Medisinaldepot AS, P.O. Box 100, Veitvet, N-0158 Oslo, Norway ( tel: 
+47 22169810; fax: +47 22169818 ).
Pharmaco-epidemiologists use the term ‘Prescribed Daily Dose’ to express the average 
dose actually prescribed in a given patient population. The argument for this was that the 
DDD recommended by the WHO did not accurately reflect the drug exposure in selected 
populations and that the PDD is more accurate than the WHO-DDD because it is based on 
the actual dose prescribed by physicians for a new prescription, as obtained from databases 
referring to the groups studied.
Our group uses the PDD and DDD terminology in a slightly different fashion. First of all,
it is posited that drugs used for the sam e indication prescribed at a D efined D aily D ose are 
equipotent (132). Secondly, based on the severity o f  the disease different doses o f  a drug 
will be prescribed by physicians for individual patients. This is the Prescribed D aily D ose 
as used in our group and in this thesis. In order to  com pare the exposure o f each individual 
patient, regardless o f  w hich AED  they used, w e em ploy the PD D /D D D  ratio. The 
PD D /D D D  ratio thus serves as a m easure for the degree o f  drug exposure o f  each 
individual patient i.e. the drug load. To give an exam ple o f  drug load calculation, the DD D 
o f  sodium  valproate is 1500 m g and patient A  using 1200 m g o f valproate w ould have a 
drug load o f  1200/1500 i.e. 0.8 PD D /D D D . The D D D  o f  carbam azepine is 1000 m g and 
patient B using 800 m g o f  carbam azepine w ould have a drug load o f  800/1000, which is 
also 0.8 PD D /D D D . W hen patients uses several drugs for the sam e indication the drug 
fractions can be added to  each other, as the D D D ’s are the average m aintenance dose and 
thus represent equally  effective doses o f  these different com pounds for that indication. 
Patient C using 600 m g o f  valproate and 400 m g o f  carbam azepine has a drug load o f 
600/1500 + 400/1000 = 0.8 PD D /D D D . Patients A, B and C all use equal drug loads, 
w hich m akes them  eligible for com parison.
In chapter 2 background inform ation o f  the PD D  and the D D D  will be given and the 
accuracy o f  the current D D D ’s fo r A ED s will be evaluated. In chapter 3, the theoretical 
background and possible applications o f  the PD D /D D D  m ethod are discussed.
1.3 Outcome measures
In AED trials there has been a large variety o f  efficacy and toxicity m easures, w hich has 
affected the com parability  o f  these trials. Recently the Com m issions on Outcom e 
M easurem ent in Epilepsy and on A ntiepileptic D rugs o f  the International League A gainst 
Epilepsy (ILAE) have published reports in w hich these issues are addressed and 
recom m endations are m ade (115, 116).
The prim ary endpoint for m any studies, and the m ost clinically relevant one, is considered 
to  be effectiveness. E ffectiveness is a m easure encom passing both efficacy (i.e. seizure 
control) and tolerability (i.e. adverse effects) (115). It is best m easured by the so-called 
retention time. This is the tim e to  w ithdraw al from  a study after random ization because o f
Introduction 9
10 Chapter 1
inadequate efficacy and/or poor tolerability. Naturally, one also has to look at efficacy and 
tolerability when interpreting effectiveness, but their assessment is much more 
complicated.
Assessment of seizures
Efficacy is defined as a reduction in seizure frequency and/or severity directly attributable 
to treatment. Efficacy can be evaluated in several ways, depending on the seizure frequency 
before treatment: Time to first seizure, estimation of time to one year remission, change 
in seizure frequency, percentage seizure-free at a certain time are all measures based on 
seizure frequency.
These measures do not take seizure type and severity into account, which is an important 
flaw. When a drug changes a patient’s usual four tonic-clonic seizures per month into four 
complex partial seizures per month, this effect will not be reflected in the seizure 
frequency. Usually complex partial seizures are less severe than generalized tonic-clonic 
seizures, and therefore the patient has benefitted from the treatment, without it being 
shown in the results. Furthermore, a 50% decrease in seizure frequency has a different 
impact in a patient who has 2 seizures per year than in a patient who has 10 seizures per 
year (123).
Even if seizure types are taken into consideration, a patient can benefit from a drug 
although he still has as many complex partial seizures as before, but the seizures are less 
severe and he or she recovers more quickly from them. Furthermore, clustering of seizures, 
the presence of an aura and the difference between nocturnal and diurnal seizures must be 
taken into account (123). Therefore, seizure severity should somehow be measured next 
to seizure frequency. Special clinimetric scales have been developed in order to measure 
seizure severity, which will be discussed later in this chapter.
Assessment of adverse effects
Tolerability is assessed by the incidence, severity and impact of drug-induced adverse 
effects. The most important measure of tolerability is deemed to be discontinuation of a 
drug due to intolerable or life-threatening adverse effects.
Adverse effects of AEDs can be very diverse, but may be classified into three major
categories: 1. dose-dependent neurotoxic effects (e.g. somnolence, cognitive impairment 
and cerebellar signs), 2 . dose-dependent systemic effects (e.g. gastro-intestinal complaints, 
weight changes), and 3. idiosyncratic effects (e.g. hypersensitivity syndrome, liver failure 
and bone marrow suppression). For a detailed description of adverse effects per drug, the 
reader is referred to Antiepileptic Drugs (142).
In most clinical epilepsy studies, the detection of adverse effects has been flawed in two 
respects: adverse effects were only detected by self-reporting and the severity of adverse 
effects was not quantified. Self-reporting may result in an under-reporting of adverse 
effects, because of the patient’s unfamiliarity with adverse effects and because the patient 
may attribute certain complaints to other causes (172). Use of a checklist will maximize 
reporting but may also produce complaints unrelated to the use of the drug or to epilepsy. 
In chapter 3 the frequency of adverse effects as measured by self-reporting and by use of 
a checklist will be compared.
Quantification of the severity of adverse effects is important, because AEDs may differ in 
the degree of adverse effects they cause. For example, are patients sleepy only after they 
return home from work or are they sleepy the whole day ? For all the adverse effects AEDs 
cause, such as ataxia, headache and hair loss, there is a need to know the severity for a 
more rational comparison.
The Commission on Antiepileptic Drugs considers the assessment of adverse effects to be 
the most in need of improvement, and therefore makes special recommendations for its 
assessment in clinical trials: Assessment should be clearly described in the protocol. 
Tolerability should be assessed preferably by checklists, if not by some form of 
standardized interview or examination. Incidence and prevalence of adverse effects should 
be measured at different time points, and preferably the severity of adverse effects should 
also be assessed. Specialized tests, such as laboratory tests and neuropsychological tests 
are considered to be of value and finally, post- marketing surveillance should be stimulated 
(115). Clinimetric scales have also been designed for the assessment of adverse effects and 
will be discussed in section 1.4.
In its report,, the Commission on Antiepileptic Drugs also acknowledges that it is often 
hard to demonstrate differences in efficacy, as has been shown in the large comparative 
monotherapy trials of the established AEDs (107, 173, 174, 204). It is easier to find
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differences in adverse effects or in w ithdraw al rates due to  adverse effects, as has been 
shown in the aforem entioned trials by differences in retention time.
Assessment ofQuality of Life (QoL)
Quality o f  life has becom e an im portant outcom e m easure for patients w ith  chronic 
illnesses requiring long-term  therapy. Som e even claim  it is the ultim ate outcom e m easure. 
M any QoL scales have been developed, how ever generic QoL scales leave m any im portant 
disease-specific topics uncovered. Therefore the num ber o f  disease-specific quality o f  life 
instrum ents has also increased dram atically, especially concerning cancer, renal disease 
and diabetes (13). Seizure activity and A ED -adverse effects are obviously im portant 
epilepsy-specific issues, bu t psycho-social factors m ay have an even larger effect on the 
lives o f  patients. Furtherm ore, even w hen seizure frequency is low, these problem s, such 
as seizure w orry and unem ploym ent, m ay continue to  exist. Psycho-social issues to  be 
considered are shown in table 1.3 (60).
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Table 1.3 Psychosocial issues in epilepsy
General issues
Self-esteem, dependence, driving, cognitive and 
behavioral problems, fear and embarrassment of 
seizures, stigma (real or perceived) and 
discrimination
Recreation
Sports, hobbies, alcohol consumption, 
reproductive behavior
Education
Learning problems and social interactions
Home
Family relationships and social activities
Work
Discrimination, unemployment, 
underemployment, ability to perform
Insurance
Health, life, handicaps
As is clear in this table, Q oL scales are dearly needed in a field w here traditionally seizure 
frequency w as the all-im portant outcom e. Therefore tools to  m easure quality o f  life o f 
epilepsy patients have been developed or are being developed. The sensitivity o f  these 
tools, especially  fo r efficacy and tolerability is currently uncertain. There is some 
suggestion that QoL outcom es are still too dependent on seizure freedom  to add valuable 
extra inform ation (117). One o f  these scales, the Quality O f Life In Epilepsy (QOLIE) 
scale, will be discussed in paragraph 1.4.
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1.4 Clinimetric epilepsy scales
In everyday practice physicians are used to work with so-called ‘soft’ data, such as the 
medical history of the patient and findings on physical examination, and ‘hard’ data, such 
as the results of laboratory or microbiology investigations, or of imaging techniques. What 
makes laboratory data ‘hard’ data, is that international laboratory standards have been 
defined and thus the results of a test are scientifically trustworthy. No such standard 
procedures have been developed for the appraisal of clinical data, such as the magnitude 
of symptoms or disability. When comparing treatments for angina pectoris for example, 
a patient can have less complaints of chest pain and his functional status can be improved 
but we do not know exactly how much he has improved. Similarly, for many findings on 
physical examination large inter-rater variabilities have been found. Because these 
important clinical data are usually not quantified, statistical comparison between therapies 
is difficult (71).
An example in epilepsy treatment which has already been mentioned is the evaluation of 
adverse effects. Lammers et al. found that often only the incidence of adverse effects is 
reported in anti-epileptic drug trials, which may render misleading data (136). For example 
treatment A and B can be found to result in sleepiness in 20% of patients. Theoretically 
treatment A could have resulted in a light feeling of drowsiness in the evening in 20% of 
patients, whereas the same proportion of patients using treatment B could have been near- 
comatose, without this difference being reflected in the results of the trial.
Obviously, methods for the classification or quantification of clinical data need to be 
developed. The science for the measurement of clinical data has appropriately been called 
clinimetrics and has been extensively discussed by Feinstein in his classic book of the same 
name (71). The subject of clinimetrics and the construction of clinimetrics is briefly 
discussed in chapter 2 .
In the last 20 years a number of scales have been developed for the clinimetric evaluation 
of epilepsy. Four scales have been developed specifically to quantify seizure severity: the 
Veterans Affairs (VA) Seizure Frequency and Severity Rating Scale (45), the Liverpool 
Seizure Severity Scale (14, 15), the National Hospital Seizure Severity Scale (189) (a 
modification of the Chalfont Seizure Severity Scale (65)) and the Occupational Hazard 
Scale (118). These scales have been compared by Cramer et al. and by Lammers (43, 132). 
The VA Seizure Frequency and Severity Rating Scale is the only scale which takes seizure
type (i.e. sim ple partial, com plex partial or generalized tonic clonic), seizure frequency and 
seizure severity all into account. A nother three scales have been developed to  evaluate 
antiepileptic drug adverse effects: the V eterans A ffairs (VA) N eurotoxicity  and Systemic 
Toxicity ratings (45), Liverpool A dverse Events Profile (89) and the N eurotoxicity  Scale
(5, 6).
The V A  Seizure Frequency and Severity R ating Scale and N eurotoxicity  and Systemic 
Toxicity ratings can be added to  produce a com posite score that reflects the total effect o f 
seizures and o f  A ED s on the quality o f  life o f  the patient (45). These scales w ere used in 
the tw o V A  m onotherapy trials that w ere discussed in paragraph 1.1. In these trials all 
toxicity  w as com pared to  pre-entry values for each patient, thus only increased problem s 
resulting from  A ED  therapy w ould be scored. The com posite score w as considered a 
sensitive m easure o f  change, dem onstrating differences betw een drugs (173, 174).
As the com posite form at enables the evaluation o f  both efficacy and toxicity, the N E R G  
chose the VA R atings as the m ethod to  be used to  in its studies (266). In our slightly 
adapted scale, nam ed the C om posite Index o f  Im pairm ents (CII), serum  levels w ere left out 
as a m odifying factor and other m odifying factors w ere som ew hat differently defined. The 
other item s o f  the V A  Ratings were left unchanged. H ow ever, as some o f  the item s o f  the 
V A  R atings were changed by its authors based on the experiences after the first V A  trail, 
these changes have been adopted in the CII (43, 172).
The CII consists o f  three subscales: the Seizure A ctivity Index, the N eurotoxicity  Rating, 
and the System ic Toxicity Rating. The outcom es o f  all three subscales are dim ensionless 
units, enabling the addition o f  the results to  a single com posite score. In the usual 
outpatient epilepsy population the CII score will vary betw een 0 and 50. A  score o f  zero 
is the u ltim ate goal: no seizures and no adverse effects. A  score reduction o f  > 10 points 
signifies a clinically relevant change. A  score above 50 is indicative o f  an unacceptable 
am ount o f  seizures, severe adverse effects, or a com bination o f high seizure activity and 
high toxicity. I f  a patient is using A ED s and has a score > 50, a m edication change (dose 
adjustm ent, drug substitution, adding another drug) is in order. Table 1.4a illustrates this.
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Table 1.4a Clinical relevance of CII scores
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CII Impairments
0 none
1-10 mild
11-49 moderate
>50 severe
The range of scores from 0 to 50 is designed to reflect the usual outpatient population. The 
SA index will render higher scores than 50 in patients with frequent seizures, such as in 
some people with severe brain damage. The subscales will be reviewed in detail in chapter
2, and the CII is shown in full detail in appendix A. The CII is used in the trial described 
in chapter 6.
Quality of life
As w as described in paragraph 1.3, the QO LIE-89 w as developed to  assess health-related 
quality o f life in a general epilepsy population (61). H ealth-related QoL (HRQL) refers to 
the w ay in w hich individuals function and to  their perceived w ell-being in physical, m ental 
and social dom ains o f  life. The W H O  defines health as “a state o f  com plete physical, 
m ental and social w ell-being and not m erely the absence o f  disease or infirm ity” .
The QO LIE-89 includes the RA N D  36-Item  H ealth  Survey 1.0 as a generic score coupled 
w ith epilepsy-specific item s grouped into four dom ains: epilepsy-targeted, cognitive, 
m ental health, and physical health. G eneric m easures evaluate global functioning and w ell­
being and allow  com parisons w ith patients w ith different diseases or the general 
population. D isease-targeted m easures focus on issues relevant to  the disease and allow  
m ore detailed and sensitive com parison am ong epilepsy patients. Item  selection w as based 
on patient and physician input and on a literature review, thus m axim izing content validity 
(61). In a study o f  304 adult epilepsy patients reliability and construct validity o f  the 
QO LIE-89 w ere supported.
Tw o abbreviated instrum ents w ere derived from  this scale (QOLIE-31 and QOLIE-10) 
(44). The QO LIE-10 questionnaire w as extracted from  the QO LIE-89 to  provide a b rie f 
screening instrum ent to  be used in daily practice. This instrum ent w as selected for the trial 
described in chapter 6, to  have an indicator for possible differences in QoL w ithout 
entering the question why and in w hat respect such differences w ould occur. The QOLIE- 
10 w ill be described in detail in chapter 2.
1.5 Neuropsychological effects of antiepileptic drugs
In the last tw enty years, it has becom e clear that AED  treatm ent m ay have a m uch greater 
im pact on cognitive function than previously had been expected. H ow ever, the evaluation 
o f  these effects is not straightforw ard, as pre-existing brain damage, interictal discharges, 
seizure activity and the epileptogenic focus m ay affect cognitive functioning as well (and 
even m ore !) (3, 249). The type o f  pre-existing neuro-psychological im pairm ent is largely 
dependent on the site o f the brain lesion or brain dysfunction. A relationship has been 
reported to  exist betw een m em ory im pairm ent and tem poral lobe epilepsy, bu t also 
betw een im paired attention and high frequency tonic-clonic seizures and betw een impaired 
m ental speed and use o f  high dose AED or A ED  polytherapy (3). T ransitory cognitive
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impairment can occur during interictal discharges (also discharges < 3 seconds or focal 
discharges) and absence seizures.
The literature is not clear on the effects AEDs have on cognitive functioning. Vermeulen 
and Aldenkamp reviewed over 90 reports in which the cognitive effects of AEDs were 
studied (253). Many of these studies failed to meet the basic standards for methodology, 
design and analysis. Therefore no evidence-based answer could be given to the most 
important question, i.e. whether AEDs in therapeutic dosages do have negative cognitive 
effects in a significant proportion of patients. However, there is some consensus that newer 
AEDs such as lamotrigine and gabapentin (GBP) may have less effect on cognition than 
the established AEDs.
The neuropsychological department of the SEIN (Stichting Epilepsie Instellingen 
Nederland: an Epilepsy Center based in Heemstede and Zwolle in the Netherlands), has 
developed a computerized program for neuropsychological assessment (7). This test 
battery, called FePsy, was designed for the detection of drug-induced effects and for pre- 
surgical evaluation. The battery covers a broad spectrum of neuro-psychological functions 
such as memory, attention, problem solving, visuo-motor performance, language and 
cerebral dominance (3). The investigator can make a selection of tests he or she wishes to 
administer, depending on the research questions. Three tests from the FePsy battery are 
described in detail in chapter 2 and have been used in the clinical trial described in chapter
6.
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In this chapter background information is given on the methods used in our studies. These 
methods include the PDD/DDD ratio, the clinimetric epilepsy outcome scales and the 
neuropsychological tests. Furthermore, a method to calculate drug loads from serum levels, 
which was used in an earlier study, is re-introduced (133). In chapter 3 the drug load 
concept will be used to compare monotherapy and polytherapy in a number of trials by 
other researchers and the theoretical background and possible applications for its use are 
discussed. Readers familiar with our methodologies may want to continue with chapter 3.
2.1 Drug load
Studies on the use o f  drugs have becom e a m ajor issue in recent years. Com parisons have 
shown large differences in drug utilization for sim ilar indications betw een countries. An 
internationally accepted m ethodology allow ing these com parisons is the D efined Daily 
D ose m ethod, w hich w as introduced by the W H O  D rug U tilization Research Group as a 
tool to  convert drug consum ption data from  different sources into com parable units (19). 
The W H O  G roup determ ines and assigns the average m aintenance dose o f  a drug for its 
m ain indication, i.e. the D efined D aily D ose (DDD), for each individual drug by analyzing 
literature and drug registration data. The W H O  has thus assigned D D D s to all w idely used 
drugs for their m ain indication; the list is available from  the W HO . The D D D  o f  the 
antiepileptic drug carbam azepine for exam ple is 1000 m g (263).
A lthough the D D D  is considered to  be the average m aintenance dose, it is m eant to  be used 
as a technical un it o f  m easurem ent and com parison rather than  as a target dose (20). 
A nalyzing the D D D s sold per 1000 inhabitants in a population for different drugs creates 
insight into prescrip tion patterns and allow s com parison w ith other regions, other tim e 
periods, other drugs etc..
The analysis o f D D D prescription rates m ay also be used as a “therapeutic audit to  follow  
and influence therapeutic habits o f  health personnel” (20). Analysis o f  the use o f 
anxiolytic-hypnotic drugs (AHD ) betw een different cities and counties in Sweden and 
differences in suicide rates, revealed that the city o f  M alm ö had both the highest AH D 
prescription rate and the highest suicide frequency in 1978 (178). Prescription surveillance 
and an inform ation cam paign in M alm ö w ere accom panied by a 4-year decrease in AH D- 
prescribing (12%), in A H D -abuse (40%), in barbiturate prescribing (45% ) and in 
barbiturate suicides (70%). In Göteborg, w here no surveillance or inform ation cam paign 
w ere undertaken, barbiturate suicides decreased by 45% , but there w as an increase in 
overall A H D (± 12%) and benzodiazepine (± 24% ) prescribing, surpassing M alm ö after 
five years.
In hospitals, the total D D D  per 100 bed days can be analyzed per drug to  give an indication 
o f  the num ber o f  patients treated  w ith a particular drug in different hospitals (18, 106). 
Such an analysis showed that the introduction o f  new  guidelines for the use o f  antibiotics 
for prophylaxis and treatm ents in the surgical departm ents o f  the N ijm egen U niversity 
M edical Center had resulted in a decrease o f  prophylactic drug consum ption per operation
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and a h igher quality o f  both prophylaxis and infection therapy (101).
The D D D  does not how ever reflect the actual prescribed dose in all situations. Therefore 
the Prescribed D aily  D ose (PDD) as the average prescribed dose in a population was 
introduced. Several authors have studied differences betw een PD D  and D D D  in large 
populations using a particular drug. W essling and Böethius, for exam ple, com pared sales 
figures (DDD data) w ith actual prescription data (individuals for w hich a prescription had 
been dispensed) for 8 different drugs (260). For antibiotics (phenoxym ethyl-penicillin, 
erythrom ycin) the num ber o f  users based on the D D D  figure ranged from  4%  below  to 28%  
above the m anifest use, w hich m eans that the D D D  w as set below  the actual PDD. For 
naproxen the D D D -derived figure was 80% below  the apparent use, w hich m eans that the 
D D D  w as set m uch too high relative to  the PDD. D igoxin had the closest correlation 
betw een the D D D figure and the apparent use. The PD D  appears to  approxim ate the DD D 
value better w hen it concerns drugs w hich are prescribed chronically instead o f  for one or 
tw o short periods, and when drugs are used for only one indication. D efined Daily D oses 
are based on cross-sectional data and PD D s can deviate from  D D D s according to  the 
population studied. Friesen et al. for exam ple showed that the PD D s for N SA ID s differ 
betw een populations v isiting outpatient clinics and patients adm itted to  the hospital (80). 
For the PD D /D D D  ratio to  be an accurate indicator o f  drug load in polytherapy, it is 
required that the DD D s approxim ate the average therapeutic dose for the drugs concerned 
(i.e. their average PD D s). As the D D D  data for certain AED s did not seem correct at 
inspection, prescription data o f  AED s w ere collected to  determ ine possible differences in 
PD D s and DD Ds. The PH A R M O  database o f  the university o f  U trecht w hich contains all 
prescription data from  6 representative D utch tow ns in 1992 (total population ± 300.000), 
w as used to  determ ine the average PD D s for AED s in a com m unity-based population 
(108). For data from  a secondary center records o f  the neurology departm ent o f  the 
N ijm egen U niversity H ospital w ere studied. The SEIN in H eem stede supplied figures o f 
the average dosages o f  antiepileptic drugs prescribed at a tertiary center. The average 
dosages o f  A ED s in m onotherapy and the average dosages in polytherapy are shown as 
PD D  data in table 2.1. To allow  com parison, the D D D s for these AEDs as assigned by the 
W orld H ealth  O rganization are also given in these tables (263).
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Table 2.1 PDD data for monotherapy and polytherapy
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Drug DDD
(mg/day)
Mono
PHARMO
(n=1995)
Mono
Nijmegen
(n=280)
Mono
Heemstede
(n=840)
Poly
PHARMO
(n=435)
Poly
Nijmegen
(n=102)
Poly
Heemstede
(n=2361)
CBZ 1000 0.50
(n=909)
0.68
(n=131)
0.81
(n=412)
0.77
(n=260)
0.81 (n=76) 1.05
(n=1678)
VPA 1500 0.66
(n=321)
0.68 (n=94) 0.71
(n=236)
0.83
(n=214)
1.04 (n=48) 1.01
(n=1279)
PHT 300 0.86
(n=389)
1.01 (n=38) 1.00 (n=80) 0.84
(n=218)
0.96 (n=38) 1.04
(n=847)
PB 100 0.96
(n=167)
1.21 (n=10) 1.17 (n=18) 1.03
(n=124)
1.34 (n=20) 1.05
(n=335)
VGB 2000 0.71 (n=6) - 0.83 (n=10) 0.73 (n=66) 0.92 (n=26) 0.84
(n=287)
OXC 1500 0.90 (n=2) 0.60 (n=1) 1.2 (n=74) 1.40 (n=3) - 1.62
(n=235)
ESM 1250 0.46 (n=11) - 0.8 (n=2) 0.57 (n=18) - 0.62
(n=116)
CLZP 8 0.30
(n=169)
0.38 (n=5) 0.39 (n=6) 0.34 (n=46) 0.3 (n=8) 0.4 (n=80)
PRM 1250 0.44 (n=21) 0.48 (n=1) 0.25 (n=2) 0.45 (n=22) 0.55 (n=2) 0.42 (n=81)
Data from the PHARMO database, the University Hospital Nijmegen and the SEIN in Heemstede, the Netherlands. The 
DDD as assigned by the WHO are listed. The PDD/DDD ratio for each drug is given per database and per monotherapy 
(“mono”) or polytherapy (“poly“), and the number of patients the drug is given in brackets. In Heemstede, in addition 
to the given data, 434 patients used an average 222 mg lamotrigine daily (DDD=300 mg) and 470 patients used an 
average 17 mg clobazam daily (no DDD assigned).
The PDDs of phenytoin, phenobarbital and vigabatrin when given as monotherapy 
corresponded reasonably well with their official DDDs. The PDDs of ethosuximide, 
clonazepam and primidone monotherapy were considerably lower than their assigned 
DDDs, although patient numbers were very small. It is important to note however that the 
DDDs of the two most widely used AEDs, carbamazepine and valproate, also appeared to 
be incorrect. Their PDDs for epilepsy patients visiting a university hospital and an epilepsy 
clinic were only approximately 0.6 to 0.8 of their assigned DDDs. The even lower PDD 
value for carbamazepine in the PHARMO database may have been influenced by the 
prescription of the drug for other indications in the community-based population (e.g. 
neuralgia, headache), although only prescriptions which had been maintained for over six 
months were admitted to the PHARMO database. Furthermore individual drug exposure 
is of course influenced by a variety of factors, such as socio-economic status, disease 
severity, co-morbidity, compliance etc. (108). However, the PDDs of carbamazepine in 
large monotherapy trials published from 1991 to 1995 were also only between 450 and 722
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mg (33, 55, 173, 204, 252). The PDDs of valproate in large monotherapy trials of the past 
five years were between 688 and 1082 (42, 70, 204, 252), with the exception of the trial 
by Mattson et al., where the PDD was 2099 mg (173). Giuliani et al. found very low PDDs 
of anti-epileptic drugs in an Italian community: carbamazepine 442 mg, valproate 389 mg, 
phenytoin 103 mg and primidone 239 mg (90). In this group 61,5 % of the AED users had 
active epilepsy; the remaining 38,6 % of patients had experienced a single convulsion 
(12,5%) or a febrile convulsion (11%) or used AEDs for other indications. In view of all 
this evidence, it seems unlikely that the deviation of our PDD figures from the DDD values 
is limited to the Netherlands. We have therefore recommended to the WHO Collaborating 
Center for Drug Methodology to adjust the DDD figures for carbamazepine and valproate. 
Another noticeable phenomenon is that antiepileptic drugs are given in higher dosages 
when given in a multiple drug regimen. A possible explanation is that a dichotomy exists 
in the epilepsy population: a large group of patients that respond well to low dosages of 
one antiepileptic drug and a second, smaller group of patients that need a high total drug 
load of AEDs. In the literature similar findings have been reported (90, 171). Thus the 
PDD/DDD ratio may also be used as a parameter indicating average severity of the 
disorder in the population concerned.
Meinardi and Meijer have shown that in a special center for epilepsy the average amount 
of antiepileptic drug, expressed in DDDs, used per patient in 1972, was almost the same 
as in 1985 notwithstanding a substantial change in the choice of drugs prescribed (167). 
This supports the rationale of adding up different PDD/DDD ratio's.
Serum levels
An analogous ratio was developed for the serum levels of AEDs, the Observed Serum 
Level (OSL)/ Average Therapeutic Level (ATL) ratio (132). The OSL is the serum level 
found for each AED prescribed for the patient. The ATL was assessed, by analyzing 
literature data (83, 98, 124, 137, 177, 197, 223). As is possible with PDD/DDD ratio’s, the 
OSL/ATL ratio’s of individual drugs can be added up calculate the total drug load of a 
patient using polytherapy. The ATLs of the standard AEDs can be found in paragraph 3.1.
2.2 Clinimetrics and the Composite Index of Impairments
Clinim etrics
Feinstein defines clinim etrics as the dom ain concerned w ith  indexes, ratings scales, and 
other expressions that are used to  describe and m easure symptom s, physical signs, and 
other distinctly clinical phenom ena in clinical m edicine (71). C linim etric indexes or rating 
scales will enable clinical data to  be described quantitatively, and for them  to  used as 
determ inants o f  prognosis, for evaluation o f  therapy and for clinical decision m aking. 
Classic exam ples o f  clinim etric indexes are the Apgar score and the G lasgow  Com a Scale, 
w hich are both used to  follow  clinical condition and prognosis.
F einste in ’s book gives a m anual for the developm ent o f  a clinim etric scale, such as the 
choice o f variables and the organization o f  the scale, bu t also for their evaluation 
(validation). There are three goals an index should fulfill: sensibility, consistency and 
accuracy. The sensibility o f  a scale is often judged  by its face and content validity. Face 
validity for a clinical instrum ent has been defined as the application o f  enlightened 
com m on sense, w hich is a m ixture o f  ordinary com m on sense plus a reasonable know ledge 
o f  pathophysiology and clinical reality (71). In assessing content validity, the com ponent 
parts are evaluated m ore thoroughly for om issions, inappropriate inclusions, w eighting o f 
com ponents and the use o f  an appropriate scale.
A  consistent or reliable clinim etric scale yields consistent results w hen m easurem ent is 
repeated. Input, instrum ent and inter- and intra-observer variability m ay threaten the 
consistency o f  a scale. W hen the instructions are clear and the scale is easy to  use, it will 
often have good consistency.
A ccuracy is usually assessed by com paring the observed m easurem ent and the result 
obtained w ith a standard reference system. Evaluating w hether a scale is accurate, m ay be 
difficult in absence o f  a definite standard (e.g. w hat is the gold standard o f  anxiety or pain 
??). W hen a gold standard exists, m easurem ents can be com pared to  it, w hich is called 
evaluation o f  criterion-related validity. W hen there is no gold standard, the so-called 
construct validity is tested w hich m eans that the effectivity o f  the index in describing an 
actual construct or condition is tested.
Feinstein has also discussed w hat a clinim etric scale for epilepsy should m easure: 
frequency and severity o f  ictal and interictal events, i.e. seizures and adverse effects (72). 
Furtherm ore, he suggests that consistency m ay be difficult to  test because o f  the 
paroxysm al character o f  the disorder, w hich m akes it necessary to  assem ble different
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patients and different clinicians at the same tim e and place. R egarding accuracy, there is 
no gold standard for the m easurem ent o f  epilepsy.
Feinstein urges to concentrate m ainly on the sensibility o f  an epilepsy index. How ever, 
there is quite a difference o f  opinion betw een experts w hich attributes to  include in such 
an index and how  to w eigh them . This m ay differ betw een patients as well, so patients 
should be offered the opportunity to  rate the im portance o f  each attribute. A n alternative 
approach m ight be to  let the patient give one global rating o f  im provem ent, for exam ple 
on a visual analogue scale, w hich corresponds to a quantification o f  the old-fashioned ‘how  
are you’-question. A fter this rating extra questions m ay be added to  determ ine w hat has 
im proved or deteriorated. This seem ingly sim ple ‘how  are you’-rating m ay bew ilder 
people, especially com ing from  Feinstein, the pioneer o f  clinimetrics. H e argues how ever 
that this has often been found to  be the m ost powerful index o f  effectiveness and that it has 
often been used as a gold standard.
Com posite Index o f  Im pairm ents
The Com posite Index o f  Im pairm ents (CII) consists o f  three subscales: the Seizure A ctivity 
Index (SA), the N eurotoxicity  scale (NTX ) and the System ic Toxicity scale (STX). The 
outcom es o f  all three subscales are dim ensionless units, enabling addition o f  the results 
to  a single com posite score. The subscales are described here and the CII is shown in full 
detail in A ppendix A.
Index of Seizures
The Seizure A ctivity index (SA) can be calculated by deducting points from  the Index o f 
Seizures (IS) w hen certain m odifying factors are present. The IS is a score w hich expresses 
seizure frequency in relationship to  the seizure type. In the IS, as in the V A  Seizure 
Frequency and Severity Rating, only the m ost frequently occurring seizure types are rated,
i.e. generalized tonic-clonic seizures and com plex and sim ple partial seizures. I f  a patient 
has m ore than one seizure type, the scores o f  these seizure types are added up to  arrive at 
the IS. The m ethod o f  scoring the Index o f Seizures for each o f  these three different seizure 
types is shown in tables 2.2a -2.2c The num ber o f  seizures are counted since the last visit 
(for partial seizures) or since starting the drug (for tonic-clonic seizures).
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Table 2.2a Scoring method for generalized tonic-clonic seizures
Generalized Tonic-Clonic Seizure IS Score
- Three or more seizures/12 months 20/seizure
- Two seizures/first 3 months 50
- Two seizures/6 months 45
- One seizure/first 3 months 40
- One seizure/6 months 40
- Two seizures/6-12 months 30
- One seizure/6-12 months 20
- Two seizures/12-24 months 20
- One seizure/12-24 months 10
- Seizure free >24 months 0
By looking at the scores given in table 2.2a, one can see what is deemed acceptable. Based 
on the severity of tonic-clonic seizures, one or two seizures in 6 months is considered 
almost unacceptable (40-45 points), except in the presence of modifying factors (see next 
page). One or two seizures in more than a year however, represents reasonable seizure 
control.
Table 2.2b Scoring method for complex partial seizures
Complex Partial Seizure IS score
Equal to or greater than 4 seizures/month 50 (+ 10 per extra seizure)
Three seizures/month 40
Two seizures/month 30
One seizure/month 20
One seizure in 1-3 months 15
Less than one seizure in 3 months 10
Seizure free 0
Table 2.2b shows that four complex partial seizures per month, in the absence of modifying 
factors, will render a score of 50 points. As partial seizures are difficult to control, less than 
a seizure per month represents fairly good seizure control (15 points). As is shown in table 
2 .2c on the next page, it takes over 12 simple partial seizures per month to reach a score 
of 50. Again, less than one seizure per month represents fairly good seizure control (13 
points).
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Table 2.2c Scoring method for simple partial seizures
Simple Partial Seizure IS score
Equal to or greater than 7/month 33 (+3 per extra seizure)
Six seizures/month 30
Five seizures/month 28
Four seizures/month 25
Three seizures/month 23
Two seizures/month 20
One seizure/month 15
One seizure in 1-3 months 13
Less than one seizure in 3 months 10
Seizure free > 1 year 0
Seizure Activity index (SA)
This index is a modification of the Index of Seizures. The modifiers are used per seizure
type and the modified scores per seizure type are added up to produce the Seizure Activity
score.
The modifiers are:
1. Presence of an aura, in the case of a generalized tonic-clonic or complex partial 
seizure. The patient is aware of the fact that a seizure is about to occur, in which 
case he can take precautions to prevent self-harm. When an aura is present, the 
seizure score is reduced by 20 percent.*
2. Precipitating factors provoking a seizure, which are avoidable, such as lack of 
sleep, use of alcohol, reduce the seizure score by 50 percent.
3. Restriction of seizures to the period of sleep or of awakening, reduces the seizure 
score by 40 percent.
4. Restriction of interference with function to less than 15 minutes reduces the seizure 
score by 50 percent **.
5. Clustering of seizures reduces the seizure score by 50 percent **.
* Only to be used with complex partial seizures and generalized tonic clonic seizures.
** Only to be used with partial seizures.
Neurotoxicity Index( NTX )
The NTX scores the incidence and severity of neurological adverse effects due to the anti-
epileptic m edication. W hen an adverse effect is present, the score o f  that effect is above 
zero and the severity is scored ‘relative to  the im portance o f  stopping the drug causing the 
problem ’ (45). This m eans that the physician assesses w hich o f  the given descriptions o f 
severity applies to  the patient w hich leads to  a given score. For exam ple, sleepiness only 
in the evenings scores 5 points w hile sleepiness during the day scores 10. In table 2.2d the 
range o f  possible scores w hen an adverse effects listed in the N T X  is present, is shown.
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Table 2.2d Range of Neurotoxicity scores per symptom
Neurotoxicity Scoring range
Diplopia 15-30
Nystagmus 5-10
Dysarthria 5-30
Ataxia/gait disturbance 5-50
Problems with rapid alternating movements 15
Tremor 10-50
Sedation 5-50
Affect and mood disturbances 5-50
Cognitive impairments 5-50
Dizziness 3-50
Headache 3-50
Systemic Toxicity Index(STX)
The STX scores the incidence and severity o f  the system ic adverse effects, as the N T X  
does for neurotoxicity. In table 2.2e the range o f  scores o f  the STX is present.
Table 2.2e Range of Systemic Toxicity scores per symptom______________________
Systemic toxicity Scoring range
Drug-related gastrointestinal problems 3-50
Hematopoietic system problems 50
Dermatologic problems 20-50
Loss of libido/ impotence 20-50
Hyponatremia 50
Elevated liver function tests 25-50
Weight gain 3-20
Changes in hair/hair loss 5-50
The planning com m ittee o f  the V A  scales, on w hich the CII is based, considered the 
appropriate w eighting o f  severity for each factor relative to  the need to  alter therapy. The 
point system w as review ed by a dozen neurologists w ho specialize in epilepsy (45). A  
difference o f approxim ately 10 points in the com posite score indicates a clinically 
im portant difference. A  com posite score > 50 denotes an unacceptable epilepsy control or
serious adverse effects, or a com bination o f seizures and adverse effects sufficiently serious 
to  discontinue the causative drug (see table 1.3) (45).
The reproducibility o f  the CII w as assessed for both individual scores o f  patients as for 
inter-rater agreem ent for the four ranges (266). The individual CII scores m ade o f  24 
patients by the investigator and by the treating clinician correlated well (r=0.90). N o 
system atic difference was seen betw een the scores obtained by both evaluators. The inter­
rater agreem ent for the four ranges o f the CII w as m oderate (k = 0 .5 2 ) ,  but the agreem ent 
on w hether the epilepsy control w as acceptable or unacceptable w as good (k = 0 .6 3 ) .
To assess the suitability o f  the index the hypothesis w as tested w hether an increased chance 
existed that the tim e until the next consultation for patients w ith a CII score <50 
(acceptable epilepsy control) w ould be > 3 m onths and that this tim e w ould be < 3 m onths 
for patients w ith a CII score >50 (unacceptable epilepsy control). The relation betw een the 
length o f  tim e until the next consultation and the CII score w as significant (W ilcoxon rank 
sum test p<0.01) and inverse (r=-0.66), and show ed the suitability o f  the C om posite Index 
o f  Im pairm ents as an indicator o f  clinical severity o f  epilepsy.
2.3 QOLIE-10
The QO LIE-10 questionnaire w as extracted from  the QOLIE-89. The ten-item  
questionnaire covers general and epilepsy-specific dom ains, grouped into three factors: 
epilepsy effects (m em ory, physical and m ental effects o f  m edication), m ental health 
(energy, depression, overall quality o f  life), and role functioning (seizure worry, work, 
driving, social lim its) (44). The QOLIE-10 is com pleted by the patient, for exam ple in the 
w aiting room. For each o f  the 10 questions the patient can choose betw een five answers, 
ranging from  very negative to very positive. The three QO LIE-10 subscales correlated well 
w ith their QO LIE-89 counterparts. Concerning construct validity, the Q O LIE-10 responses 
correlated well w ith the PO M S (Profile O f M ood States) which is used to  assess tension, 
anger, depression, vigor, fatigue and confusion. Correlations o f  system ic and neurotoxicity 
scores w ith the QO LIE-10 subscales w ere not high. Low  seizure frequency patients had 
better scores on the QO LIE-10 role functioning-subscale. The scale had good 
consistency/reliability and is show n in table 2 .3a (44).
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Table 2.3a The QOLIE-10 Questionnaire
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H ow m uçhoftteüm eduringtherast^w eeks
All of the 
time
Most of 
the time
Some of the 
time
A little of 
the time
None of 
the time
1. Have you had a lot of energy 
?
1 2 3 4 5
None of 
the time
A little of 
the time
Some of the 
time
Most of 
the time
All of the 
time
2. Have you felt down-hearted 
and blue ?
1 2 3 4 5
Not at all A little Somewhat A lot A great 
deal
3. Has your epilepsy or 
antiepileptic medication caused 
trouble with driving?
1 2 3 4 5
During the past 4 weeks, how much of the time have you been bothered by
Not at all 
bothersome
A little Somewhat A lot Extremely
bothered
1. Memory difficulties ? 1 2 3 4 5
2. Work limitations ? 1 2 3 4 5
3. Social limitations ? 1 2 3 4 5
4. Physical effects of 
antiepileptic medication ?
1 2 3 4 5
5. Mental effects of 
antiepileptic medication ?
1 2 3 4 5
Not at all 
fearful
Mildly
fearful
Moderately
fearful
Very
fearful
Extremely
fearful
9. How fearful are you 
of having a seizure 
during the next month ?
1 2 3 4 5
Very well; 
could hardly 
be better
Pretty good Good and 
parts about 
equal
Pretty bad Very bad; 
could hardly 
be worse
10. How has the 
quality of your life been 
during the past 4 weeks 
? That is, how have 
things been going for 
you ?
1 2 3 4 5
The QOLIE-10 may provide a useful screen for epilepsy-related QoL problems, with which
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patients can alert their physicians and the physician-patient interaction can be facilitated. 
The developers state that it is not a research tool, but that it can be a value-adding aspect 
to clinical practice (44).
2.4 Neuropsychological outcome measures
FePsy
The FePsy is a computer program which contains a range of computer-aided tests for 
neuropsychological assessment. Three of these tests were used in our comparative study 
of mono- and polytherapy described in chapter 6 : the tapping task, the binary choice task 
and the computerized visual searching task (CVST ):
- Tapping task: This task is an adaptation of the similar task in the Halstead-Reitan battery. 
The test person is instructed to tap the space bar with the index finger as fast as he or she 
can during 10 seconds. Tapping speed is measured for both hands. It provides a measure 
of motor speed.
- Binary choice task: In this task there are two stimuli: a red square on the left or a green 
square on the right of the screen which appear on the screen in random order. The patient 
is instructed to press a specific key with the left hand when the red square appears and to 
press another specific key with the right hand when the green stimulus appears. The patient 
is instructed to react as quickly as possible, but to make no mistakes. This is a measure of 
the reaction time that includes a decision component.
- Computerized Visual Searching Task (CVST): This task is an adaptation of Goldstein’s 
visual searching task. A centered grid pattern has to be compared to 24 surrounding 
patterns, only one of which is identical. The test consists of 24 trials (the 24 patterns 
change after 12 trials). The task deals with visual information processing.
Retesting usually leads to a learning or practice effect (7). For tests in which every item has 
the same difficulty level, a pool of items is used and there is a random selection of items 
each test. The learning effect does not occur through learning the sequence of items. In 
tasks such as the CVST, the profile time of each item is important. Here fixed retests must 
be made.
In the tapping task epilepsy patients achieve less taps than controls, and the difference 
between the dominant and the non-dominant hand is greater. In healthy controls the 18
year-olds perform  tw ice as fast 8 year-olds. In the binary choice task  the test scores are not 
different from  norm al controls. The reaction tim es do becom e low er as people becom e 
adults.. In epilepsy patients the decrease in average CV ST-tim e is m uch less from  11 years 
on. There is no difference betw een controls and patients in errors made. Probably the same 
problem -solving strategy is used and differences depend on slow er m ental speed (7).
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C hapter 3 D rug load and evaluation o f  adverse effects
Introduction
In the first two chapters it became clear that patients on AED polytherapy usually have 
higher drug loads than patients on AED monotherapy. It is quite conceivable that these 
drug load differences may be (partly) responsible for the reported differences in effects 
between mono- and polytherapy. In paragraph 3.1 a literature study is described in which 
this hypothesis is put to the test with respect to adverse effects. In paragraph 3.2 the broad 
relevance of drug load in clinical studies is discussed and theoretical arguments are given 
for the PDD/DDD method.
As was discussed in chapter 1, clinimetric evaluation has been introduced to measure the 
severity of adverse effects in AED trials. However, the danger of using these scales is that 
false-positive results may be introduced. To evaluate this, adverse effect data yielded by 
self-reporting and by clinimetric scales are compared in paragraph 3.3.
3.1 Polytherapy in epilepsy: a review of drug load and adverse effects
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Introduction
One of the main arguments against the use of AED polytherapy is that it is supposed to 
lead to more adverse effects (203). However, Lammers et al. found that the drug load may 
be more important than the number of drugs in determining the number of adverse effects 
(135). Drug load, i.e. the amount of drug exposure for a certain indication, can be 
expressed for dosages and serum levels, by the Prescribed Daily Dose/Defined Daily Dose 
(PDD/DDD) ratio and the Observed Serum Level/Average Therapeutic Level (OSL/ATL) 
ratio respectively (see chapters 1 & 2). In the present study a survey of the literature was 
performed using these ratio’s to evaluate the reporting of adverse effects in relationship to 
antiepileptic drug load. Only papers in which polytherapy was used in at least one of the 
treatment groups were selected.
Methods
The Medline program was used to screen the literature from 1974-1994, using the search 
commands: [epilepsy] AND [adverse OR side effects OR cognitive OR toxicity] AND 
[combination therapy OR add-on OR discontinuation]. Next, a further selection was made 
using the following requirements:
1. A multiple drug regimen in one of the treatment groups of a trial.
2. Mention of the dose or serum level of every prescribed antiepileptic drug per 
patient or mean dose respectively serum level and number of patients using each 
antiepileptic drug per treatment group.
3. Mention of incidence and specification of adverse effects per patient or treatment 
group.
Defined Daily Doses and Average Therapeutic Levels
For this study not the ATL but the average toxic level (AToxL) was used as this study 
focuses on adverse effects. The average toxic levels of the different AEDs were assessed 
from literature data (67, 142, 177, 197). The Defined Daily Doses, Average Therapeutic 
and Average Toxic Levels found are listed in table 3.1a.
36 Chapter 3
Table 3.1a DefinedDailyDose (DDD), A verage Therapeutic Level (A TL) and Average
Toxic Level (A ToxL) values for individual drugs
DDD (mg) ') ATL (mg/l) 2) AToxL(mg/l) 2)
Carbamazepine 1000 7 12
Phenytoin 300 15 20
Valproate 1500 70 120
Phenobarbital 100 30 40
Primidone 1250 12 15
Ethosuximide 1250 70 120
Clonazepam 8 - -
Clobazam 20 - -
Progabide 1800 2) - -
Vigabatrin 2000 - -
Flunarizine 30 2) - -
Felbamate 2700 2) 40 80
Clorazepate - 1 3) 5 3)
') Assigned by the WHO; 2) Assigned according to literature data; 3) Nordiazepam level
Statistical analysis was performed using Pearson's correlation coefficient and the z- 
transformation to test correlations between parameters. Dice were thrown to randomly 
select one observation per patient for statistical analysis in studies where drug load could 
be evaluated per patient.
Results
Screening ofthe literature
Through the Medline-search 661 papers were retrieved, of which 118 were trial reports 
with a multiple drug regimen in at least one of the treatment groups. Next, the above­
mentioned requirements were applied to select papers suitable for analysis. The bulk of 
papers was rejected for two reasons:
1. Eighty studies in which new drugs, multiple drug regimens or a reduction in the 
number of antiepileptic drugs in these regimens were evaluated, were rejected
because the authors did not provide data on doses or serum  levels o f  each 
individual drug or about the num ber o f  patients taking the drug; a few  
representative exam ples are cited in the reference list (8, 103, 131, 160, 170, 206).
2. Tw enty papers w ere rejected because adverse effects w ere not or inadequately 
m entioned (one fourth o f  the papers m entioned sub 1 suffered from  the same 
deficiency). Seizure control w as the only outcom e m easure in these cases; again 
ju s t a few  exam ples are cited (1, 131, 217).
Two papers w ere not suitable as differences in frequency o f  adm inistration w ere compared, 
e.g. a daily dose versus three doses per week; a third study w as unsuitable as it concerned 
a new  drug o f  w hich no inform ation about the average effective dose w as available. Fifteen 
papers m et the three requirem ents listed in the m ethods section. In these, drug toxicity  was 
evaluated by listing subjective com plaints, repeated neurological exam inations and/or 
neuropsychological testing. N o system atic com m ents w ere m ade in these papers regarding 
the severity o f  the adverse effects. W e pooled the selected papers into three groups: A, B 
and C.
Pool A Adverse effects and dose/serum levels reported per individual patient
In five papers the num ber and dose o f  all anti-epileptic drugs (but not serum  levels) and 
adverse effects w ere reported per patient (153, 183, 219, 248, 256).
The total antiepileptic drug-load in relation to  the num ber o f  adverse effects in individual 
patients is shown in figure 3.1a. A lthough the correlation coefficients vary betw een the 
trials, a w eak  positive association betw een these param eters does exist for the total group 
(correlation coefficient=0.41).
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Figure 3.1a Total drug load in relation to the number of adverse effects
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From the published data one measurement per patient was taken at random. The number 
of AEDs in relation to the number of adverse effects is shown in figure 3.1b. The 
correlation coefficient was 0.21 for these two parameters.
Figure 3.1b Number ofantiepileptic drugs in relation to the number ofadverse effects
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studies as in figure 3.1a. From the published data the same measurement per patient was taken as in figure 
3.1a. Numbers next to data-points indicate number of patients; for example, of the patients using 2 drugs, 
two were bothered by 3 adverse effects.
Pool B Adverse effects and dose/serum levels reported per treatment group
In seven papers tw o treatm ents w ere com pared and the num ber o f  adverse effects and the 
average dose or serum  level o f  every AED  w ere stated per treatm ent group (139, 154, 156, 
213, 218, 240, 267).
The m ean total antiepileptic drug-loads (expressed in PD D /D D D  or O SL/A ToxL ratio) 
w ith the respective num ber o f  adverse effects reported per treatm ent group are shown in 
table 3.1b. All o f  these studies used a cross-over design, except Schm idt (218). In all 
papers the num ber o f  adverse effects w as higher in the treatm ent group w ith a higher total 
antiepileptic drug-load and a higher num ber o f  A ED s (table 3.1b), except for the trial o f 
W ilensky et al. w here the num ber o f  AED s w as tw o in both treatm ent groups (267).
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Table 3.1b Trials where number ofadverse events were reported per treatment group
Treatment groups PDD/DDD ') No. of side effects
Loiseau et al. 
( n = 23 )
Vigabatrin versus 
placebo add-on
3.6 versus 2.1 18 versus 11
Loiseau et al. 
( n = 23 )
Lamotrigine versus 
placebo add-on
3.1 versus 2.2 50 versus 20
Tartara et al. 
( n = 21 )
Vigabatrin versus 
placebo add-on
3.5 versus 2.3 26 versus 9
Sander et al. 
( n = 18 )
Lamotrigine versus 
placebo add-on
3.3 versus 2.6 20 versus 14
Treatment groups OSL/AToxL ') No. of side effects
Leppik et al. 
(n = 56)
Felbamate versus 
placebo add-on
1.7 versus 1.4 133 versus 16
Wilensky et al. 
(n = 42)
Phenobarbital versus 
clorazepate both added 
to phenytoin
1.7 versus 1.5 22 versus 16
Schmidt
(n = 36)
Two-drug versus 
monotherapy
1.4 versus 0.9 41 versus 31
') The mean total antiepileptic drug-load (PDD/DDD) or OSL/AToxL per treatment group is listed.
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Pool C Drug toxicity evaluated by neuropsychological testing
In four papers neuropsychological testing had been used to detect drug-related changes in 
cognitive functioning and doses or serum levels had been adequately reported (66, 176, 
246, 267). The trial of Wilensky et al. is also used in group B (267). Different 
neuropsychological tests were applied by the various authors, which complicated a detailed 
comparison.
The mean total antiepileptic drug-load or OSL/AToxL ratio was calculated per treatment 
group (table 3.1c). The tests used have been categorized according to cognitive functions 
and the results of the various trials. Thus for example, decision making and visual scanning 
are categorized as components of mental speed. Intellectual achievement was tested by 
arithmetic in three trials.
Overall, patients in treatment groups with higher drug loads or higher OSL/AToxL ratio’s 
performed as well as, or worse, but not better, on neuropsychological tests than patients in 
treatment groups with a lower drug-load.
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Table 3.1c Trials where drug-related effects on cognitive functioning were measured. Trial designs, total drug-loads and conclusions on cognitive changes are shown. 
The changes o f the cognitive functions are those after switching from the first named treatment to the second (e.g. vigabatrin versus placebo - the condition while on 
placebo)___________________________________________________________________________________________________________________________________
Treatment groups *) PDD/DDD 2) Mental speed Short term 
memory
Attention/
concentr.
Visuo-motor
response
Intellect.
level
Motor
speed
McGuire et al. 
(n = 30)
Vigabatrin versus placebo add-on 3.0 versus 2.4 = - = = 1 = =
Treatment groups 1) OSL/AToxL2)
Duncan et al. (n=23) Before versus after removal of 
phenytoin from a multiple drug 
regimen
1.2 versus 0.9 = = Î - = Î
Duncan et al. (n=24) Before versus after removal of 
carbamazepine from a multiple drug 
regimen
0.9 versus 0.4 = = - Î
Duncan et al. (n=25) Before versus after removal of 
valproate from a multiple drug regimen
0.9 versus 0.6 = = = - = Î
Wilensky et al. 
(n = 42)
Phenobarbital versus clorazepate in 
combination with phenytoin
1.7 versus 1.5 - i Î - = =
Thompson and 
Trimble 
(n = 28)
High level versus low level multiple 
drug regimens
0.95 versus 0.63 Î Î - Î - =
1 ) Characterization of groups: In trials by Wilensky et al. (267), Duncan et al. (66) and Thompson and Trimble (246) a cross-over design was used. In the trial by McGuire et al. ( 176) a parallel 
design was applied
2) Total antiepileptic drug-load (in PDD/DDD) or OSL/AToxL is listed per treatment group
Discussion
Critique ofthe literature
M ethodology to  assess adverse effects and in particular m ethods o f  reporting about the 
incidence leave m uch to  be desired. Very few  o f  the papers collected in th is literature 
search satisfied the requirem ents for inclusion. Lack o f  inform ation about the exact 
dosages or serum  levels o f individual AEDS, or about the frequency o f  adverse effects, or 
both, w as particularly frequent.
The small num ber o f  papers selected w ould have been reduced even further i f  adequate 
quantification o f  the severity o f  adverse effects had been a requirem ent.
Relation between number of drugs, total drug-load and adverse effects 
Only group A  allowed com parison o f  toxicity in individual patients and could therefore be 
used to  estim ate the correlation coefficient betw een toxicity  and drug-load respectively 
num ber o f  drugs. The com parison o f  the papers presented in group A  points to a w eak 
relationship betw een adverse effects and total antiepileptic drug-load. A n inherent 
w eakness o f  our analysis is that D efined D aily D oses are established only for the m ain 
indication o f  a drug, i.e. seizure control, and not for toxicity. W hile correlations betw een 
serum  levels and toxicity have been published, unfortunately few  papers retrieved in this 
study contained inform ation about serum  levels. This is also to be regretted because the 
PD D /D D D  ratio does not account for possib le pharm acokinetic interactions. In group B 
and C it w as not possible to  disentangle the cause o f  higher toxicity, w hich m ight ju s t as 
w ell be due to  the higher drug-load as to  the use o f  m ultiple drugs or both.
The results from  group A  do show  that the correlation betw een incidence o f  adverse effects 
and drug load is slightly stronger than betw een adverse effects and num ber o f  antiepileptic 
drugs taken, although both are w eak and thus cannot be taken as proof. The inform ation 
presented does not as yet perm it any conclusions, how ever it does rem ove one o f  the 
objections to  study relative efficacy o f m ono- and polytherapy. That polytherapy m ay have 
its own m erits also has been advocated in hypertension and oncology therapy (63, 73, 81). 
N ot all results w ere in accordance w ith the hypothesis o f  an association betw een total drug­
load and num ber o f  adverse effects. One study in group C show ed that the elim ination o f 
phenytoin did have a beneficial effect on attention and concentration, w hereas w ithdraw ing 
valproate or carbam azepine did not (66). This is in agreem ent w ith reports that different
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anti-epileptic drugs often have different effects on cognitive functioning (4, 155). 
Phenytoin for example is reported to have a greater impact on motor speed and mental 
speed than carbamazepine (4).
The advantages of using methods to calculate total antiepileptic drug-load are illustrated 
by the paper by McGuire et al. (176). Here total drug loads in the vigabatrin add-on group 
and placebo control group were high. Adding vigabatrin only changed the drug load by 
20%. This means that, given the premises of this method, the patients in the placebo group 
were exposed to an only slightly less toxic total of drugs than the add-on group, from 
which the effect of vigabatrin on cognitive function had to be evaluated. This emphasizes 
the importance of reporting doses or serum levels of concomitant drugs, particularly in 
parallel studies.
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3.2 Theoretical background of the drug load concept 
Introduction
Nowadays combining drugs on pharmacological grounds is increasingly being used for 
other disorders than epilepsy, for example in hypertension treatment and cancer 
chemotherapy, etc. (81, 182, 192). The goal of using two or more drugs instead of one is 
to achieve greater efficacy with the same or less adverse effects or equal efficacy with less 
adverse effects (69, 74). In pharmacological terms this would signify supra-additive 
efficacy with additive or infra-additive toxicity and additive efficacy with infra-additive 
toxicity respectively. Consequently, numerous clinical trials are being undertaken to 
compare combination regimens with their individual constituents.
However the total drug load, i.e. the amount of drug exposure for a certain indication, is 
a neglected factor in many of these trials. When differences in effects are found in these 
trials, these are attributed to the pharmacodynamic properties of the therapeutic regimens, 
instead of to a possible difference in drug load between the groups. The drug loads of two 
regimens should however be equal before conclusions can be reached on differences of 
intrinsic efficacy or toxicity.
Many examples of neglecting drug load can be found in the literature. McKay et al. 
evaluated the effects of losartan 50 mg alone, hydrochlorothiazide 12,5 mg alone, a 
combination of losartan 50 mg and hydrochlorothiazide 6,25 mg and a combination of 
losartan 50 mg and hydrochlorothiazide 12,5 mg for essential hypertension, and concluded 
that the combination of losartan 50 mg and hydrochlorothiazide 12,5 mg produced an 
additive and safe reduction (165). However, for a clinically relevant evaluation they should 
have included a high-dose hydrochlorothiazide group and a high-dose losartan group, or 
should have used lower dosages of both drugs in the combination regimen, in order to 
compare regimens with a more equal drug load. This would have challenged the merits of 
the combination of losartan and hydrochlorothiazide. Similarly, studies by Faarvang et al. 
and by Nelson et al. on the possible advantages of combining anti-rheumatic drugs and of 
combining antidepressive drugs respectively, also did not include high dose monotherapy 
groups or lower dosages for the combinations (68, 188).
Another frequently encountered manner in which drug load is neglected, is the habit of not 
taking baseline medication into account. Onghena and Van Houdenhove reviewed 39
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placebo-controlled trials on antidepressant-induced analgesia for chronic non-malignant 
pain, and found that in these trials the use of other analgesics, ergotamine or anti-rheumatic 
drugs was permitted (190). For example in one of the reviewed papers, a study by Loldrup 
et al., patients were allowed to have up to 30 mg oxazepam and up to 3 g of paracetamol 
in addition to the study medication, without taking in-between group differences of 
oxazepam and paracetamol into account (157). Similarly, but in an anti-hypertension drug 
trial research, Avanzini et al. compared the effects of 4 different drug regimens, but started 
off one regimen with a considerably higher drug load than the others (11).
This problem is also of importance in add-on studies of antiepileptic drugs. The first trials 
to establish efficacy of a new antiepileptic drug are conducted by adding the new drug in 
comparison to adding placebo to existing insufficiently effective medication. This is 
necessary as it is unethical to give new antiepileptic drugs or placebo to newly diagnosed 
epilepsy patients, and thus the effects of the new compound are evaluated as if  only this 
drug is given. However, as was shown in paragraph 3.1, total drug loads of baseline 
medication of the active and the placebo group sometimes differ, and therefore it is unclear 
whether observed differences in toxicity are really due to the new antiepileptic drug or are 
drug load-related (54).
Although the concept of drug load is intuitively obvious, little has been published about 
a methodology to evaluate drug load in polytherapy. Such a methodology should be helpful 
in the planning and analysis of clinical trials and enable to determine the role of drug load 
as a prognostic factor. In experimental settings, fractions of drug exposure are already used 
in the isobologram method. This is the preferred method to detect synergy, zero interaction 
or antagonism (17). The dosages of a drug combination (da, db) are determined, which 
have the same effect as certain dosages of the drugs alone (Da and Db). The equation for 
the zero interaction line for two agents is: da/Da + d,/Db = 1 (17, 238). When the sum is less 
than one or more than one, the combination is judged to be supra-additive or infra-additive 
respectively. The interaction can thus be evaluated for the dosages used, irrespective of the 
nature of the dose-response curves of the individual drugs. This is illustrated in figure 3.2a.
Figure 3.2 Isobologram method
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gnitude. Next the two drugs are combined in order to reach that same effect. When (da,db) is on the zero 
interaction line (point P) the drugs are considered additive for that dose pair. Point Q represents infra­
additivity and point R supra-additivity
We have developed a method to assess drug load, analogous to the isobologram method.
Methodology
The Prescribed Daily Dose/Defined Daily Dose (PDD/DDD) ratio can be used to calculate
the drug load in treatm ent groups, w hen one uses the Prescribed D aily D ose as the average 
dose o f  a drug taken in a certain treatm ent group. The m ethod assum es that, thus 
norm alized, the drug loads o f  several drugs in one regim en can be added up. For exam ple, 
the D D D  o f  sodium  valproate is 1500 m g (265) and patients in group A  using 900 m g 
w ould have a drug load o f  900/1500 i.e. 0.6 PD D /D D D . The D D D  o f  carbam azepine is 
1000 m g (265) and patients in group B using 600 m g carbam azepine w ould have a drug 
load o f  600/1000, w hich is also 0.6 PD D /D D D . Patients in group C using 450 m g o f 
valproate and 300 m g o f  carbam azepine thus have an equal total drug load o f  0.6 
PD D /D D D , w hich m akes them  eligible for com parison w ith patients o f  group A  and B. So 
instead o f  com paring iso-effective drug fractions as is done in the isobologram  m ethod, we 
com pare the effects o f  equal drug fractions.
Results in epilepsy research
In paragraph 3.1 w e have applied the described m ethod o f  m easuring drug loads in a 
retrospective analysis o f  antiepileptic drug trials where m ultiple drug regim ens w ere used. 
In this review, toxicity w as w eakly but significantly correlated w ith drug load and not w ith 
the num ber o f antiepileptic drugs (54).
The PD D /D D D  ratio can also be used to  start both treatm ent groups o f  a clinical trial o ff 
w ith equal drug loads, as w as done in the trial described in chapter 6. This prevents bias, 
for exam ple w hen one treatm ent group w ould start w ith a low er drug load it m ay take 
longer to  get these patients into rem ission, although the drugs m ay be equally effective. 
A lternatively, in a treatm ent group w hich starts o ff  w ith a higher drug load, m ore patients 
m ay drop out because o f  adverse effects, w hile in fact the tw o regim ens m ay be equally 
toxic when equal drug loads are used. The PD D /D D D  ratio furtherm ore allows physicians 
participating in this trial to  adjust the dose in term s o f  PD D /D D D , thus keeping physicians, 
patient and investigator blinded.
Also, predicting outcom e o f  drug w ithdraw al after a reasonable sym ptom -free period may 
benefit from  the concept o f  drug load. Until now, the num ber o f  antiepileptic drugs has 
been deem ed an im portant factor in determ ining the risk o f  seizure recurrence (185). The 
total drug load o f  the antiepileptic drug regim en m ay very well prove to  be o f  m ore 
relevance in this respect.
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Discussion
The D D D -m ethodology w as originally developed to convert available volum e data from  
sales statistics or pharm acy inventory data into m edically m eaningful units, and the PD D 
w as introduced as the D D D  did not accurately reflect the drug exposure in selected 
populations. So, one m ay ask w hether it is justified  to  use the PD D /D D D  m ethodology for 
our purpose and i f  so, under w hat conditions ?
For exam ple, does the use o f  PD D /D D D  ra tio ’s assum e that the dose-effect curves are 
linear for the dose range under consideration ? It has been established that the isobologram  
m ethod can be used irrespective o f  the nature o f  the dose-effect curves o f  the individual 
drugs (17). In judging a com bination, one is only interested in how  the added drug fractions 
o f  a com bination needed to  reach a certain effect com pare w ith the full am ount o f  the 
individual drugs needed to  reach that same effect. It is actually because the same effect is 
used to  com pare the drugs w ith their com bination, that the dose-effect curves becom e 
irrelevant. The PD D /D D D  ratio actually turns the isobologram  m ethod around, as it is 
based on equal drug loads/fractions and then looks at differences in effects. N evertheless, 
the PD D /D D D  ratio does not rely on the nature o f the dose-effect curves either. One 
im portant point to  realize is that the isobologram  m ethod and the PD D /D D D  m ethod is that 
they only give inform ation about the effect or drug load under evaluation, and that the 
nature o f  the interaction m ay change w hen one looks at different m agnitudes o f  effect or 
drug load respectively. Also, the nature o f  the interaction m ay change w hen the proportion 
o f  the tw o drugs in the com bination is changed. H ow ever, w hen a com bination is found 
to  be infra-additive for a certain effect, th is will usually  still be the case w hen the drugs are 
given in different proportions (17).
In the isobologram  m ethod the doses o f  the individual drugs used in m onotherapy are 
equipotent. It is im portant that the D D D s o f  the different drugs under evaluation are also 
equipotent w hen using the PD D /D D D  ratio, w hich m ight not always be the case. D rugs 
m ay also have several indications, e.g. CBZ and V PA  being used as antidepressants. 
Furtherm ore, as is shown in chapter 2, the D D D ’s assigned by Oslo m ay differ from  the 
usual dosages, e.g. in the N etherlands. This m ay be due to  different dosages used for same 
indication, w hich can vary betw een countries bu t even betw een experts in the same 
hospital. D D D  values seem  to approxim ate the average prescribed dose better w hen it 
concerns drugs w hich are prescribed chronically instead o f  for one or tw o short periods
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(260).
Nevertheless, it seems safe to conclude that failing to evaluate drug load may complicate 
the evaluation of drug efficacy and toxicity, especially where combination therapy or fixed 
dosages are concerned. Not only should drug loads be determined in the retrospective 
analysis of clinical trials, but also should they be used to ensure equal drug loads at the 
start of treatment. In our field, antiepileptic drug treatment, neglecting drug load obscures 
the evaluation of new antiepileptic drugs and may have also been responsible for 
unfavorable reports about polytherapy, which now seem unjustified.
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3.3 Monitoring adverse effects in antiepileptic drug therapy: 
Wait and see or go for it? 
Introduction
Consensus on a detection strategy for AEs of antiepileptic drugs is lacking; clearly 
neurologists often follow different strategies (39). Unfortunately, these differences are 
reflected in the variability of reports about efficacy and tolerability of antiepileptic drugs. 
For example, in a large multi centre survey the frequency of AEs reported varied widely 
between centres from 6% to 79% of patients (39).
In the literature, a dichotomy can be found between papers in which the authors actively 
looked for AEs or only took notice of AEs if the patient proffers them.
Examples of rigorous assessment of AEs are papers of the Veteran Affairs group (173,174) 
and our own group which adopted the same technique (135). This method was developed 
by neurologists to be used in drug trials. The outcome was expressed in neurotoxicity and 
systemic toxicity scales (45). Comparing studies which made use of active inquiry about 
AEs, including our own database, and those which did not, we discovered that apparently 
the difference in approach does not equally affect the detection of all types of AEs.
To identify the effects of these different approaches more precisely, we only used papers 
that discussed either carbamazepine or valproate monotherapy .
Methods
The literature
A Medline search for papers from 1991-1995 on carbamazepine and valproate 
monotherapy trials was performed. Data of the seven papers identified 
(33,42,55,70,173,204,252), if  necessary, were translated to the V.A.-neurotoxicity and 
systemic toxicity scales in order to enhance comparability with the data of the trial by 
Mattson et al. (173) and of the Nijmegen database. For example, reports of "somnolence" 
were interpreted as "sedation" whereas "fatigue" and "depression" were classified in the 
"affect and mood disturbances" category.
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The database
Frequency of AEs associated with carbamazepine or valproate monotherapy were extracted 
from the database o f epilepsy patients o f the out-patient department o f a University 
neurology clinic, maintained by the Nijmegen Epilepsy Research group. The Neurotoxicity 
and the Systemic toxicity scales were used for detection o f AEs (45).
Results
The literature
The occurrence rates o f AEs during carbamazepine or valproate monotherapy are listed per 
trial in tables 3.3a and 3.3b. (33,42,55,70,173,204,252). Certain rates vary considerably 
among trials, which is exemplified by sedation in 42% of the patients in both 
carbamazepine and valproate groups in the trial by M attson et al. (173), respectively in 
41% for carbamazepine and 36% for valproate in the Nijmegen Database as opposed to 
11% to 22% in the carbamazepine group and 3% to 8% in the valproate group in the other 
trials.
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Table 3.3a Percentages of patients in selected papers with drug-induced adverse effects
while on carbamazepine monotherapy
Publication
# refers to reference list 
N between ()
204
(178)
252
(130)
33
(131)
55
(139)
173
(231)
NDB
(196)
Method* a + c a + c a c + d e + f e
Carbamazepine 
Mean Dose mg/day
516 450 600
median
? 722 762
Follow up (months) 36 36 ± 11 12 12-60 12-???
Diplopia - 4% - + 10% 7%
Nystagmus - - - - 30% 9%
Dysarthria - - - - - 5%
Gait 2% 4% 9% - 25% 6%
Rapid alternating movements - - - - -
Tremor 2% - - + 22% 11%
Sedation 11% 19% 22% 32% 42% 41%
Affect and mood disturbances 12% 17% 9% 24% 24% 6%
Cognitive impairments 2% 2% 3% - 18% 29%
Dizziness 7% 6% 17% 16% 29% 8%
Headache 6% 7% 25% 33% 20% 7%
Other neurotoxicity 2% - - - - -
Gastro-intestinal complaints 8% 4% 19% + 29% 3%
Haematopoietic disturbances - - - - - -
Dermatological reactions 10% 6% 19% - 11% 1%
Impotence - - - - 7% -
Hyponatremia - - - - - -
Abnormal liver function tests 2% - - - 4% -
Weight change 1% 6% - - 32% 8%
Hair loss/hirsutism 1% 2% - - 6% 11%
Other systemic toxicity 23% 24% 28% - - -
* Methods of detection of AEs: a = self-reporting; b = physical examination; c = laboratory investigations; d = adverse 
effect checklist; e = specific toxicity scales; f  = neuropsychological testing. Use of ‘e’ (specific toxicity scales) includes 
a,b,c and d. The "+" sign denotes "present", but no percentages given. NDB denotes the Nijmegen Epilepsy Research 
Group database.
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Table 3.3b Percentages of patients in selected papers with drug-induced adverse effects 
while on valproate monotherapy
Publication
# refers to reference list 
N between ()
204
(174)
252
(130)
70
(39)
42
(17)
173
(240)
NDB
(145)
Method* a + c a + c a+b+c d + f e+f e
Valproate 
Mean Dose mg/day
924 700 1082 688 2099 1127
Follow up (months) 36 36 ± 4 12 12-60 12-???
Diplopia - - 5% - 6% 4%
Nystagmus - - - - 26% 1%
Dysarthria - - - - - 5%
Gait - - - 12% 23% 6%
Rapid alternating movements - - - - - 3%
Tremor 5% - 3% 29% 45% 30%
Sedation 7% 8% 3% 18% 42% 36%
Affect and mood disturbances 11% 8% 15% 18% 25% 2%
Cognitive impairments 3% 5% - - 18% 28%
Dizziness 3% 1% 5% - 23% 11%
Headache 3% 5% 23% - 15% 10%
Other neurotoxicity 1% - - - - -
Gastro-intestinal complaints 7% 5% 10% - 33% 12%
Haematopoietic disturbances - - - - - -
Dermatological reactions 2% 3% - - 1% 1%
Impotence - - - - 10% -
Hyponatremia - - - - - -
Abnormal liver function tests 1% - - - 3% -
Weight change 12% 13% - 12% 43% 20%
Hair loss/hirsutism 3% 4% - 12% 12% 19%
Other systemic toxicity 25% 23% 5% - - -
* Methods of detection of AEs: a = self-reporting; b = physical examination; c = laboratory investigations; d = adverse 
effect checklist; e = specific toxicity scale; f  = neuropsychological testing. Use of ‘e’ (specific toxicity scales) includes 
a,b,c and d. The "+" sign denotes "present", but no percentages given. NDB denotes the Nijmegen Epilepsy Research 
Group database.
Cognitive impairments, sexual dysfunction, hair changes, weight changes, nystagmus, gait
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disturbances, and tremor were also found more often when an active approach was 
employed.
Discussion
Differences in detection strategy
The considerable methodological variability between trials results in large differences in 
the frequency o f certain AEs. This leaves the practising neurologist with uncertainty as it 
limits the information about AEs needed for assessing risks and benefits o f treatment.
To minimize false positive reports when actively looking for AEs necessitates a baseline 
measurement, as is required when using the V.A. scales (45). It is also important to 
determine what the exact complaint o f the patient is, e.g. drowsiness or fatigue and to take 
into account comments from family and other staff.
Nevertheless, differences found between active and passive approach might be partially 
explained by a num ber o f false-positive reports due to the explicit nature o f the scales. 
Complaints unrelated to either the antiepileptic drug use or to epilepsy may get included 
(172).
However, self-reporting may not always result in a correct representation o f AEs either. 
Höppener et al. reported that AEs due to carbamazepine use were not mentioned 
spontaneously, but had to be asked for especially in order to track them (111). Patients did 
not complain about their sleepiness, as they believed that it was related to their work or 
their epilepsy. After adjusting the dosage scheme all AEs disappeared. Salinsky et al. 
compared the results o f patients taking A ED ’s and several control groups on a 
patient-based sleepiness scale and an EEG-based wakefulness measure (212). They found 
that the subjective complaints o f AED users did not sufficiently reflect the considerable 
objective differences in drowsiness found.
Self-reporting o f cognitive functioning may be influenced by personality and mood factors. 
Patients with negative personality or mood complain more o f poor memory. The use of 
neuropsychological tests has furthermore revealed a much greater impact o f antiepileptic 
drug treatment on cognitive functioning than had been expected previously (249). These 
reports suggest that especially sedation and cognitive impairments may indeed be 
underdetected by self reporting, and that an active approach or an objective measurement 
is necessary here.
The lack of a standard physical examination also causes an under representation of certain 
AEs, such as nystagmus, gait disturbances, tremor, hair and weight changes. 
Correspondingly, in a large multi centre study of 509 patients at least 36% of AEs were not 
self-reported but were found only on examination (39).
Laboratory monitoring
Contrary to neurotoxicity monitoring, for systemic toxicity screening it is a tradition in 
medical practice to perform laboratory tests of all patients receiving antiepileptic drugs. 
However, many clinically non-significant abnormalities are detected (which lead to 
retesting) whereas life-threatening events may still occur the day after testing or even go 
undetected by testing. A more cost-effectieve approach would be to let patients who are 
not at risk contact the physician when certain symptoms occur and to do routine monitoring 
only in high-risk patients.
Dose dependency
The relationship of dose or serum level with AEs is a source of conflicting reports in the 
literature. Therapeutic ranges have been set for various antiepileptic drugs, however, AEs 
may also occur at supposedly subtoxic levels (133). This is an unresolved problem This 
also true in the field of neuropsychology (253). Therefore it seems important to be equally 
as attentive for AEs at serum levels in the therapeutic range as at levels in the toxic range. 
In tables 3.3 a and 3.3b it is shown that the researchers who did not actively probe for AEs 
used lower average doses of carbamazepine and valproate than the authors who used 
clinimetric scales. However, taking the lack of interindividual correlation between dose 
and AEs into account, it is reasonable to assume that the observed disparity in frequency 
of AEs reported is at least partly due to methodological differences in assessing AEs, and 
not solely to dosage.
Conclusions
Different approaches in detection strategies for AEs result in differences in the numbers 
found of certain AEs. We are of the opinion that baseline measurements and active 
checking are advisable for sedation, cognitive impairments, sexual dysfunction, hair 
changes, weight changes, nystagmus, tremor and gait. Routine laboratory monitoring is of
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doubtful value in patients who are not known to be at risk of idiosyncratic reactions.
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C hapter 4 R ation al polytherap y: can com binations be based on  
m echanism s of action ?
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Monotherapy has been the gold standard in epilepsy treatment for the last twenty years. 
However, seizure control is not achieved in up to one third of patients at maximally 
tolerated dosages of AED monotherapy, at which point polytherapy comes into the picture 
(171). In recent years, criteria have been proposed to aid in the selection of AED 
combinations for these difficult-to-treat patients (such as lack of pharmacokinetic 
interactions and relative lack of toxicity of individual drugs) (74). However, there is some 
controversy as well about one of the criteria for this ‘rational polytherapy’: should two 
drugs that work on the same neurotransmitter system or ion channel be combined, or 
should the drugs have totally different “targets” ? Both views have their supporters (74, 
91, 102, 126).
There have also been experts that claim that mechanistic polytherapy (i.e. polytherapy 
based on mechanisms of action) is not possible as we know too little about the chain of 
events leading to seizures and about mechanisms of action of AEDs and of their relative 
importance per drug (148, 163). In this chapter we will review the available polytherapy 
studies and try to discover whether, and if so how, AEDs may be combined based on their 
mechanisms of action.
4.1 Pathophysiology of seizures and mechanisms of action of antiepileptic 
drugs
Before we assess the feasibility of ‘mechanistic polytherapy’, the pathophysiology of 
seizures is summarized and the mechanisms of action of the current AEDs and the 
relevance of these mechanisms for their antiepileptic spectrum are briefly described.
Mechanisms underlying focal epilepsy
The current view on the mechanism of focal seizures will be summarized here. It should 
be noted that much is still unclear and that other mechanisms are involved in the 
development of intractable seizures (105, 147).
Cells in layers IV and V of the neocortex and pyramidal cells in the CA2 and CA3 regions 
of the hippocampus have the intrinsic potential to develop “bursts” (164). These bursts 
consist of a calcium-dependent membrane depolarization that evokes a train of sodium- 
dependent action potentials. In case of abnormal excitability, due to injury or an impaired 
balance between glutamate-mediated excitation and GABA-mediated inhibition, burst 
firing can be evoked and can synchronize. This means that a large group of neurons 
synchronously depolarizes, which is represented by an interictal spike in the EEG. This so- 
called paroxysmal depolarizing shift (PDS) and accompanying train of action potentials 
is normally followed by a large prolonged hyperpolarization, which is the correlate of the 
slow wave that usually follows EEG spike discharges (158). The spike wave discharge 
(SWD) in the EEG is the electrical correlate of this process of consecutive depolarization 
and hyperpolarization. The ‘epileptic’ neuron thus alternates between excitation and 
inhibition.
The excitatory PDS or giant excitatory post-synaptic potential (EPSP) appears to be 
generated by a combination of synaptic currents (mediated by glutamate) and voltage- 
dependent depolarizing currents, especially calcium and sodium currents (62). The 
inhibitory hyperpolarization or inhibitory post-synaptic potential (IPSP) that follows the 
PDS is also generated by synaptic events (GABA acting at both the GABAa and GABAb 
receptor) and intrinsic membrane currents (voltage- and calcium-dependent potassium 
currents, possibly chloride currents) (62).
The transition into a seizure is probably mediated by repetitive firing, in other words by
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repetition o f interictal discharges. Inhibitory synapses become less effective when 
repetitively activated and in contrast, excitatory synapses often show increased efficacy in 
those circumstances. Each PDS is then followed by a prolonged depolarization, until the 
neuron is tonically depolarized and fires synchronously with its neighbors to produce a 
seizure (62). This seizure activity may be propagated by specific anatomical routes, to 
result in a complex partial seizure or a secondary generalized seizure (150).
The cellular mechanisms discussed here are all potential targets for antiepileptic drugs 
against partial epilepsy. For example, drugs that block either glutamate receptors or drugs 
that block voltage-dependent sodium or calcium channels may decrease sustained 
repetitive firing. Similarly, drugs that enhance inhibition, especially y-aminobutyric acid 
(GABA)-mediated and potassium-mediated inhibition, can be effective in limiting burst 
firing and arrest o f the discharge (62, 164).
Antiepileptic drugs designed to limit seizure propagation through the common propagation 
pathways may have a broader anticonvulsant spectrum than therapies that only target the 
site involved in seizure initiation (150). The amygdala and piriform cortex may form a gate 
for forebrain recruitment and partial generalization o f kindled seizures, while the substantia 
nigra may be responsible for brainstem gating recruitment and thus full generalization (via 
the superior colliculus) (150).
M echanisms underlying generalized seizures
The origin o f seizures in primary generalized epilepsy differs from focal epilepsy. Neurons 
within the nucleus reticularis thalami (NRT) and thalamocortical relay cells are believed 
to be responsible for the mechanism underlying generalized absence epilepsy. The NRT 
is composed of GABAergic cells that project heavily to one another and to almost all 
thalamocortical relay nuclei (232). Thalamocortical relay cells normally discharge to 
cortical neurons continuously (so-called tonic firing). These neurons may produce low 
threshold calcium currents (LTCC), through the T-type calcium channel, however at 
resting membrane potential this channel is inactivated (159). The LTCC represents a key 
membrane property in burst firing excitation and is associated with the oscillatory activity 
in relay cells during synchronized sleep and during absence seizures (232). It is triggered 
by a late GABAB-mediated IPSP (i.e. hyperpolarization) from the NRT, which gives rise 
to a rebound burst o f action potentials (158, 232). GABAA-mediated inhibition in the NRT
diminishes its GABAergic output to thalamocortical relay cells.
In absence epilepsy a generalized cortical synchronization of SWDs appears on the 
electroencephalogram (EEG) with the typical 3 Hz-frequency. Drugs which block the T- 
type of calcium channel, such as ESM and trimethadione are prescribed to patients with 
absences. Drugs that enhance GABAa inhibition in the nucleus reticularis thalami and/or 
reduce GABAB-mediated inhibitory input into thalamocortical relay neurons, may also be 
efficacious in absence epilepsy.
Mechanism of action of AEDs
The present knowledge about the mechanisms of action of antiepileptic drugs is 
incomplete. Not only are the mechanisms of action of the antiepileptic effect not 
completely known, there is even less knowledge about the mechanism of action of the 
adverse effects. However, there are two major target categories for AEDs:
- Altered intrinsic membrane properties: these usually include abnormal ionic conductances 
(calcium, sodium, potassium).
- Altered synaptic function: manifested as an increase in excitatory transmission or 
insufficient inhibitory transmission.
The current knowledge about the effects of the presently available AEDs on these 
processes is summarized here.
Sodium channels
The voltage-gated sodium channel is involved in generation and propagation of sodium- 
dependent action potentials, and delaying its reactivation significantly reduces the 
frequency of sustained repetitive firing (75). Phenytoin (PHT) and carbamazepine (CBZ) 
are believed to bind to the sodium channel in its inactive state after a depolarization and 
to slow its recovery from inactivation (224, 269). These drugs do not reduce the amplitude 
or duration of single action potentials, but reduce the ability of neurons to fire ‘trains’ of 
action potentials at high frequency (163). The effect of CBZ and PHT on sustained 
repetitive firing has three properties: 1) voltage dependency: it increases after 
depolarization and decreases after hyperpolarization; 2) use-dependency: the first action 
potential in the ‘train’ is unaffected, but with successive action potentials the heights of 
these potentials are reduced until there is failure of firing; 3) time-dependency: the
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reduction in action potential properties lasts several hundreds o f milliseconds after the first 
action potential train (162). The use dependency o f these effects ensures that normal 
physiological action remains undisturbed.
The significance o f valproate’s (VP A) effects on sodium channels is uncertain: the 
spontaneous firing o f neurons is usually inhibited only by high doses or concentrations of 
VPA, but in the substantia nigra pars reticulata (SNR) o f rats a reduction in the firing rate 
was already found at low dosages. This inhibitory effect on SNR neurons might however 
also be due to the selective increase in GABA turnover induced by VPA in the substantia 
nigra o f rats (149). In cultured hippocampal neurons VPA did slow the recovery from 
inactivation, but in the rat hippocampal slice VPA had no effects on the bursting behavior 
o f neurons (2, 149). There are other experts that claim that V PA ’s sodium channel blocking 
is it main mechanism o f action (163, 179).
Barbiturates and benzodiazepines (BZDs) do reduce sustained repetitive firing by blocking 
sodium channels, but only at high drug concentrations, which may explain part o f their 
efficacy in status epilepticus (261). Blocking sodium channels (directly or indirectly) is 
deemed to be relevant for the efficacy o f several o f the new AEDs: felbamate (FBM), 
gabapentin (GBP; only after prolonged administration), lamotrigine (LTG), oxcarbazepine 
(OXC) and topiramate (TPM).
The drugs that limit sustained repetitive firing through effects on sodium channels do not 
share efficacy for all seizure types and often have different adverse effects. This may be 
caused by other mechanisms o f action that these drugs have (see below), but another 
possibility is that the drugs vary in their selectivity for the various a  subunits at Na+ 
channels; preferential actions on particular subunit types could produce markedly different 
effects on seizures as well as unique adverse effects (179). Furthermore, AEDs could affect 
the slow or the fast inactivation o f sodium channels and differences may exist in voltage, 
use and/or time dependency.
Calcium channels
Many o f the available antiepileptic drugs have effects on voltage-dependent calcium 
channels. The best characterized calcium channels are the L-type, T-type, N-type and P- 
type channels. Depolarization o f a neuron causes Ca2+ to enter the cell through these pre- 
synaptic calcium channels (207). This causes a release o f excitatory neurotransmitters,
which results in a further Ca2+ influx through excitatory amino acid-operated and voltage- 
dependent post-synaptic channels. This large Ca2+ influx is thought to trigger burst firing 
(207). The calcium channels have different voltage ranges for, and rates of, activation and 
inactivation (159, 164). P-type channels appear most significant for glutamate release; N- 
and P-type channels control monoamine release (179). Contrastingly, T-type calcium 
currents are activated by hyperpolarization.
Phenytoin, barbiturates and BZDs all have been demonstrated to inhibit calcium influx 
during depolarization and to block presynaptic release of neurotransmitter, but only at 
supratherapeutic concentrations (164). Ethosuximide (ESM) and trimethadione (TRM) 
reduce T-type currents in thalamic relay neurons at therapeutic concentrations, whereas 
VPA did not (41). The efficacy against absence seizures of ESM and TRM is often 
explained by this mechanism. VPA does block T-type currents in afferent neurons (120) 
CBZ blocks veratrine-stimulated calcium-flux, which is in agreement with its sodium 
channel blocking properties (162). Of the new antiepileptic drugs, LTG, OXC and FBM 
all reduce high-threshold voltage-sensitive calcium currents, but the clinical relevance of 
these effects are uncertain (262). GBP binds with high affinity to a novel a2ô regulatory 
subunit of a voltage-sensitive calcium channel. It has been suggested that GBP may modify 
monoamine neurotransmitter release through its interaction with this subunit (262).
So far, non-T-type calcium channel blockers such as flunarizine and nifedipine have not 
proven to be very effective antiepileptic drugs in clinical practice. In the future, calcium 
channel blockers may possibly be employed as anti-epileptogenic or neuroprotective 
agents, considering their role in glutamate release and second-messenger systems (234).
Glutamate
Excitation in the nervous system is produced primarily by glutamate and possibly also by 
aspartate. Glutamate binds to three different ligand-gated ion channel (ionotropic) 
receptors: the A/-methyl-D-aspartate (NMDA), the a-amino-3-hydroxic-5-methylisoxazole- 
4-propionic acid (AMPA) and the kainate receptor (99). When glutamate is released into 
the synaptic cleft and interacts with these postsynaptic receptors, this causes membrane 
depolarization and increases the chance that the postsynaptic cell will initiate an action 
potential (99).
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Activation o f AMPA receptors appears to mediate most o f the excitatory 
neurotransmission in the CNS (99). The giant EPSP, which is represented by the interictal 
spike in the EEG, is normally also only AMPA-mediated. However when the 
depolarizations are o f sufficient amplitude and duration (such as during the onset o f a 
seizure) NM DA receptors are activated (158). These then reinforce the persistent envelope 
of depolarization that underlies a tonic-clonic discharge. Thus glutamate-mediated synaptic 
transmission accounts for the synchronization o f epileptiform activity.
The NM DA receptor is also involved in the hippocampus, where epileptiform bursts can 
produce long-lasting hyperexcitability. The induction o f these plastic changes requires 
NMDA-receptor activation which then enhances NM DA and non-NMDA receptor 
mechanisms (222). NM DA receptor density and utilization is increased in temporal lobe 
epilepsy (271).
M uch work has been done on glutamate receptor antagonists. Theoretically, NMDA 
receptor antagonists are more interesting than AMPA receptor antagonists, as AMPA is 
constantly involved in normal brain function (158). NM DA receptor antagonists initially 
looked very promising in animal epilepsy models. However, clinical trials and recent 
animal data demonstrated problems with NMDA-antagonists. No efficacy could be found 
for partial seizures and there were marked adverse effects. This was surprising as 
tolerability in healthy volunteers was fine, although perhaps cognitive adverse effects were 
to be expected as NM DA is also involved in synaptic plasticity and learning (32). 
Furthermore, it has been shown in experiments that limbic epileptogenesis enhances the 
adverse effects o f N M DA receptor antagonists, leading to motor impairment, 
proconvulsant effects and psychotomimetic effects (110). Perhaps NMDA-antagonists in 
low dosages in combination therapy can be o f use (46). AMPA or kainate antagonists are 
in the process o f evaluation.
Another potential indication o f glutamate receptor antagonists is as neuroprotective/anti- 
epileptogenic agents. Although NM DA receptor antagonists had no efficacy in fully 
kindled rats (and can even have seizure exacerbating effects), activation o f NMDA 
receptors is a prerequisite for epileptogenesis in the kindling model (150). Administration 
o f (the NM DA receptor-associated) glycine site antagonists and administration o f AMPA 
antagonists does increase the focal seizure threshold in kindled rats (150).
A drug such as LTG which reduces glutamate release by blockade o f sodium channels is
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very different from receptor antagonists and is not associated with ‘NMDA-tolerability 
problems’. Part of the antiepileptic effect of LTG has been attributed to inhibition of 
glutamate release. However, other sodium channel blocking drugs such as CBZ and OXC 
also have this effect, and it is questionable whether the magnitude of inhibited glutamate 
release by any of these drugs is clinically significant (257).
Felbamate modulates glutamate receptor function through its action on glycine (a co­
agonist with glutamate at the NMDA-receptor) and its anticonvulsant action is reversed by 
glycine agonists (262). The binding of FBM has been reported to have a striking 
resemblance to the binding of AMPA, however it does not modulate AMPA-dependent 
action potentials (215). Topiramate reduces kainate-evoked inward currents, and thus 
decreases neuronal excitability (261). Some work is now also being done on metabotropic 
glutamate receptors and epilepsy (32).
GABA
GABA is synthesized in GABAergic nerve terminals through decarboxylation of glutamate 
by glutamic acid decarboxylase (GAD) and is degraded to succinic semialdehyde by 
GABA-transaminase (GABA-T) in nerve terminals and glial cells. Succinic semialdehyde 
can either be oxidated to succinate or reduced to gamma-hydroxybutyrate (GHB).
It is a fallacy that in most brain regions, augmentation of GABA will be anti-convulsant 
(85). GABA does appear to constrain the seizure activity of the amygdala, an area which 
is believed to believed to be critical for the initial propagation of focal seizure activity 
(150). Another region where stimulation of GABA receptors and elevation of GABA 
seems to be anticonvulsant against a broad spectrum of seizures, is the SNR (85). The SNR 
appears to indirectly control various distinct epileptogenic circuits via the superior 
colliculus, including those circuits responsible for generating limbic seizures, 
thalamocortical seizures and brain stem-generated tonic convulsions (58, 85). In the 
kindling model, GABA synthesis and receptor density were decreased only in the amygdala 
and the substantia nigra (150). It is important to note that nerve terminal GABA levels, and 
not so much the GABA in metabolic pools, are clinically relevant (85, 150).
GABAa
The GABAa receptor forms a gated postsynaptic Cl- channel, which is activated by binding
at least two molecules of GABA. Compounds that potentiate chloride influx through the 
GABAA-receptor, have long been known to have anticonvulsant effects. Barbiturates and 
BZDs both have their own allosterically coupled GABAa binding sites. Barbiturates cause 
the chloride channel to stay open longer, whereas BZDs cause the chloride channel to open 
more frequently (164).
Recent studies on the GABAa receptor subunits have established that receptors formed 
from a1ß1 subunits are sensitive only to barbiturates, whereas the transient expression of 
y2, a2 and ß1 subunits results in both BZD and barbiturate sensitivity (261). The genes 
coding for these different subunits are differentially expressed in various regions of the 
brain, suggesting that the receptor may vary from region to region, possibly introducing 
functional variations in synaptic inhibition and drug action. CBZ and PHT also potentiate 
the GABA-mediated current when the a2ß1y2 receptor subtype is expressed, but the 
potentiation is smaller than the potentiation by barbiturates and benzodiazepines (97). 
However, the concentrations of PHT and CBZ needed to reach this effect are far below the 
normal brain concentrations of CBZ and PHT, so the authors of this last paper consider it 
likely that the interaction of these drugs with certain GABAa receptors contributes to their 
antiepileptic activity.
The effects of VPA seem more complex. Animal and human experiments have produced 
evidence that CNS GABA levels increase significantly at commonly used VPA dosages 
and especially in the clinically important nerve terminals (85, 149). Regional brain studies 
in VPA-treated rats have shown marked differences in increased GABA levels. For 
example, GABA levels are increased more in the substantia nigra, which is thought to have 
a critical role in seizure propagation. The onset of VPA’s effect on presynaptic GABA 
levels in brain regions (notably the SNR) is very rapid, and the time course of 
anti convulsive and antinociceptive activity correlated with that of the nerve terminal 
alterations in SNR GABA levels (149). Valproate probably inhibits GABA-transaminase 
in nerve terminals and increases GABA synthesis by activating glutamic acid 
decarboxylase (GAD), the latter especially in the substantia nigra (149). This results in 
increased GABA release into the synaptic cleft. Toxic doses of VPA decrease GAD 
activity, resulting in decreased synaptic GABA release (149). The special effects of VPA 
in the SNR could be explained by the uneven distribution and regional heterogeneity of 
enzymes involved in GABA synthesis and degradation (150). VPA does not exert effects
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at the postsynaptic GABAa receptor complex. However, in vivo VPA has been shown to 
increase BZD-binding, which is probably due to increased GABA levels. Benzodiazepine- 
antagonists do not reduce the anticonvulsant potency of VPA, but there is some evidence 
of cross-tolerance (87).
Vigabatrin (VGB) binds to GABA-T and irreversibly inactivates it, thereby increasing 
brain GABA levels (261). Tiagabine (TGB) blocks the re-uptake in the presynaptic nerve 
terminal and thus increases synaptic GABA levels. Felbamate only enhances GABA- 
evoked chloride currents at supratherapeutic concentrations. Gabapentin has been shown 
to increase GABA levels in some brain regions and a potentiation of GABA-mediated 
inhibitory currents has been observed in cultured hippocampal neurons (179, 261). 
Topiramate increases the opening and bursting frequency of the GABAa receptor channel, 
similar to the effect of the BZDs, but probably via a novel binding site. Interestingly, VGB, 
GBP and TGB differ considerably in their efficacy in several epilepsy models, which has 
yet to be explained (51).
There is some evidence that GABAa is also involved in generalized absence epilepsy 
(113). Activation of GABAa receptors in the NRT appears to suppress the generation of 
absence seizures in the lethargic (lh/lh) mouse absence model. Vigabatrin injected into 
thalamocortical relay nuclei resulted in an exacerbation of absence seizures while injection 
of VGB into the NRT resulted in inhibition of SWDs (232). Therefore, if  NRT neurons are 
inhibited, SWDs decrease and if NRT inhibitory input into thalamocortical relay nuclei is 
increased, SWDs increase (232). Benzodiazepines have been shown to enhance GABAa 
mediated inhibition within the NRT and thereby suppress GABAB-mediated inhibition in 
relay neurons (232). In the pentylenetetrazole model (Ptz-model: an animal model used for 
myoclonic and/or absence seizures), mice who had developed tolerance to BZDs were also 
tolerant to VPA (87). Barbiturates, PHT, CBZ, VGB and TGB exacerbate absence seizures 
in humans (148).
GABAB
GABAb receptors are often located presynaptically on axon terminals and one major 
function of these receptors is believed to be inhibition of neurotransmitter release (24). 
GABAb receptor antagonists may affect the release of GABA and glutamate, but some may 
just inhibit the release of one of the two. This suggests that the GABAb receptors mediating
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GABA and those mediating glutamate release are probably pharmacologically distinct (24).
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One of the defining features of generalized absence epilepsy is their potentiation by 
increased GABAergic brain activity. Baclofen, a GABAb agonist is much more effective 
than the GABAa agonists in potentiating the synchronous rhythmic SWDs in experimental 
absence seizures (233). The role of GABAB is further supported by the finding that GABAB 
antagonists significantly reduce or block rhythmic SWD.
Other mechanisms of action
There are also other mechanisms of action which have been associated with the effects of 
certain AEDs. Valproate inhibits formation of y-hydroxybutyrate (GHB) by inhibiting 
aldehyde reductase, which is the enzyme that enhances the transformation of succinic 
semialdehyde into GHB. This effect of VPA may be important because GHB produces 
absence-like episodes in animals and is used as an absence epilepsy model (149). 
L-dopamine and d.l.-amphetamine have been shown to potentiate the efficacy of PHT and 
PB in the MES, while apomorphine had no effect (125). There is some evidence suggesting 
that release of dopamine in the striatum leads to inhibition of SNR neurons, which may 
lead to seizure control (for example in absence epilepsy) (58). This mechanism may 
contribute to the anticonvulsant mechanisms of some of the present AEDs.
Topiramate inhibits certain carbonic anhydrase isoforms (261). This effect probably does 
not contribute to the efficacy of TPM, but may be responsible for some of the adverse 
effects.
Does mechanism of action predict anticonvulsant spectrum ?
The clinically relevant mechanisms of action of the currently available drugs are 
summarized in table 4.1a.
Table 4.1a Mechanisms of action of presently licensed antiepileptic drugs____________
AED Na+
channel
blockade
T-type Ca2+ 
channel 
blockade
non-T-type 
Ca2+ channel 
blockade
GABA 
mimetic drugs
anti-glutamate
action
PHT +++ + +
PB/PRM * ++ + ++ ++
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AED Na+
channel
blockade
T-type Ca2+ 
channel 
blockade
non-T-type 
Ca2+ channel 
blockade
GABA 
mimetic drugs
anti-glutamate
action
cbz +++ + +
OXC +++ + +
VPA ++ + ++ +
ESM +++
CLZP** + + +++
LTG +++ +
VGB +++
tgb +++
gbp + ++ +
fbm + + + ++
TPM ++ ++ ++
Adapted from (149, 163, 179, 232, 262).
* PB is the major active metabolite of PRM. It is uncertain to which extent primidone itself contributes to 
efficacy and to toxicity.
** representative of 1-4 benzodiazepines.
+++: well-documented action believed to account for a major part of the drug’s anticonvulsant effect.
++: effect probably of clinical significance
+: effect only tentatively characterized or seen only at supratherapeutic concentrations
As can be seen in table 4.1a, almost all AEDs have multiple mechanisms o f action, which 
complicates classifying them according to their mechanism o f action and anticonvulsant 
spectrum. It must be emphasized that it is still controversial as to how much each separate 
mechanism o f action contributes to the overall anticonvulsant effects o f these different 
drugs. This is true not only for the newer AEDs, but also for some o f the older drugs, such 
as valproate. Furthermore, it is important to highlight that most o f the drugs shown in table 
1 have additional pharmacological actions, but these are presently not considered to be 
essential for anticonvulsant activity. Nevertheless, a possible classification o f mechanisms 
o f action to explain anticonvulsant spectra o f the various AEDs is:
1) Drugs that decrease sustained repetitive firing:
these drugs may be efficacious against partial and generalized tonic-clonic seizures. Many 
o f the conventional AEDs do this by delaying the recovery from inactivation o f sodium 
channels. Sustained repetitive firing may also be decreased by glutamate receptor
antagonists (blocking either the a-amino-3-hydroxic-5-methylisoxazole-4-propionic acid 
(AMPA) or the A/-methyl-D-aspartate (NMDA) subtype of the glutamate receptor) and by 
drugs that block voltage-dependent calcium channels.
2) Drugs that increase GABAergic neurotransmission:
these drugs may be efficacious against all seizure types, dependent on their site of action 
and on whether they target GABAa or GABAB receptors. As was mentioned before, it is 
a fallacy that in most brain regions augmentation of GABA will be anticonvulsant (85) A 
fine example is absence epilepsy, in which GABAa mediated inhibition in the nucleus 
reticularis thalami (NRT) blocks seizures, whereas GABAa mediated inhibition in 
thalamocortical relay neurons enhances seizures (232). Thus it seems that the 
anticonvulsant spectrum of a drug that enhances GABA-mediated inhibition is determined 
by the regions in which it has this effect and by the receptors (GABAa or GABAB) on 
which it acts;
3) Drugs which block the T-type calcium channel in thalamocortical relay cells: 
these are efficacious against generalized absence seizures.
Although being quite useful, this classification still has some unresolved issues: For 
example, LTG is reported to block absence seizures but it does not enhance GABAergic 
neurotransmission nor does it block the T-type calcium channel (21). Another example are 
the main mechanisms of action of carbamazepine (CBZ) and phenytoin (PHT) which are 
often thought to be the same (i.e. slowing the recovery of the sodium channel from its 
inactive state). However, patients not responding to CBZ may benefit from PHT and vice 
versa (102). Also, in the amygdala kindling model, animals not responding to PHT may 
respond to CBZ (147). Experimental data suggest that PHT produces a more frequency- 
dependent block than CBZ (224). It is also possible that they bind to different types of the 
a-subunit of the sodium channel or to different sites of the GABAa/BZD receptor, which 
may have different regional distributions, and consequently lead to differences in efficacy 
and tolerability (163). Furthermore, it is quite possible that a combination of the 
mechanisms of action of a drug, in some critical proportion, might be what determines the 
antiepileptic potency of a drug (199).
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Now that we have briefly covered the pathophysiology o f epileptic seizures and the 
mechanisms o f action o f the presently available AEDs, we can proceed with our literature 
review. In this review the available studies on AED polytherapy are reviewed to determine 
whether drugs can be selected for combination therapy based on their mechanisms of 
action and if  so, which combinations lead to increased effectiveness. Consequently we also 
needed to evaluate the merits o f the various designs and methods o f analysis used in these 
studies.
Methods
The PubMed program o f the National Library o f M edicine was used to screen the literature 
for every combination of the drugs listed in table 1, using the search command: 
[combination] AND [seizures] AND [name drug 1] AND [name drug 2]. Additional papers 
reporting on AED combinations were identified by checking the cited references o f review 
papers and the cited references of the retrieved research papers. Only those papers 
reporting on combinations o f two drugs were eligible for inclusion in this study.
Results
Animal data
Twenty-one papers satisfied the criteria described above, o f which 13 were retrieved by 
Medline search. O f the drugs listed in table 1, 30 different two-drug combinations have 
been evaluated in animals. However, it is difficult to compare these data because o f the 
various epilepsy models employed and because the methods to evaluate drug interaction 
were often different. The most important animal models will be briefly discussed now: 
The maximal electroshock model (MES): a 50 or 60 Hz alternating current is administered 
for 0.2 sec through corneal or auricular electrodes. Abolition o f the hind-limb tonic 
extensor component following stimulation is taken as the endpoint for this test, signifying 
the ability to prevent spreading o f seizure activity through neural tissue. This model was 
thought to represent partial seizures and generalized tonic-clonic seizures, but because of 
the lack o f efficacy of VGB in this model it is now only acknowledged as a model for 
generalized tonic-clonic seizures (GTCS).
The pentylenetetrazol test (Ptz): Ptz impairs GABAergic neurotransmission. A convulsive 
dose of Ptz is injected subcutaneously and the animals are then watched for 30 minutes for 
the presence of an episode of clonic spasm persisting for at least 5 seconds. Absence of 
such an episode is suggestive of raising seizure threshold. This model is used for 
myoclonic and/or absence seizures. A problem is that phenobarbital (PB) is efficacious in 
this model, although it is not efficacious against absence seizures (261). 
Amygdala-kindling: repeated electrical stimulations in the amygdala induce the progressive 
development of seizures, evolving through well-defined stages. Once the enhanced 
sensitivity has developed, as evidenced by seizures resembling secondary generalized 
seizures, the animal is said to be fully kindled. If kindling stimulations are continued 
thereafter, spontaneous seizures may develop, demonstrating that kindling has resulted in 
epileptogenesis (149). This model is used to test the efficacy of a drug in limiting focal 
seizures from the amygdala and is considered useful as a model for complex partial 
seizures. If the electrical stimulations are continued during AED treatment, the seizures 
may become refractory to all anticonvulsants, resembling the development of intractable 
temporal lobe epilepsy (147).
Some of the papers found were not eligible as they were not in English, French, German 
or Dutch. The collected animal data are summarized in table 4.2a (29, 37, 48, 50, 56, 140, 
168, 184, 196, 221, 237, 259),
(30, 93, 94, 187, 208, 214, 215, 225, 235). The term ‘non-protective dose’ signifies that 
the drug in question is efficacious in the model studied, but is administered at a dose which 
does not offer full protection. The term ‘non-efficacious’ means that the drug is not 
efficacious in the animal model studied at maximally tolerated dosages. In almost all of the 
studies listed, the ED50 and TD50 were defined as the dose at which 50% of the animals had 
reached the desired endpoint or had reached a certain level of toxicity respectively (in some 
studies the EC50 and TC50 were determined; i.e. the plasma or brain concentrations at 50% 
of the animals had reached the desired endpoint or had reached a certain level of toxicity 
respectively).
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Table 4.2a Polytherapy studies in animal models ofepilepsy
AEDs first author 
(ref. nr.)
animal model experimental design method of analysis efficacy toxicity
p h t /p b Weaver
(259)
mice MES1 EDx PB + 
(ED50 - EDx) PHT *
estimated and observed 
ED50 compared
supra-additive additive
Leppik
(140)
rats MES EDx drug PB + 
(ED50 - ED,) PHT
estimated and observed 
ED50 compared
additive no info
Masuda
(168)
mice + 
rabbits
MES doses given 
alone and together
isobologram method supra-additive no info
Picker
(196)
rats effects on 
behavior
low doses added 
together
estimated and observed 
effects compared
no info effect combi = 
drugs alone
Bourgeois
(29)
mice MES drugs tested alone 
and together
FEC method ** additive infra­
additive
Stringer
(237)
rats MDA2 non-efficacious PHT 
added to PB
MDA duration and time to 
onset
effect PB Î no info
p h t /c b z Schmutz
(221)
mice + 
rats
MES drugs tested alone 
and together
summation of effects 
method
effect combi 
>drugs alone
effect combi = 
drugs alone
Morris
(184)
mice MES drugs tested alone 
and together
FEC method additive additive
PHT/VPA Chez (37) mice MES drugs tested alone 
and together
FEC method supra-additive additive
D. Paschoa 
(56)
rats CS3 non-protective VPA 
added to PHT
stimulus is increased until 
response occurs
efficacy PHT 
Î
no info
p h t /c z p Czuczwar
(50)
mice Ptz4/
bicuc5
non-efficacious PHT 
added to CZP
re-evaluation o f the 
effects o f CZP
ED50 CZP 1 no info
Czuczwar
(48)
mice MES drugs tested alone 
and together
visual comparison of data effect combi 
>drugs alone
no info
p b /p r m Bourgeois
(29)
mice MES drugs tested alone 
and together
FEC method supra-additive infra­
additive
p b /v p a Picker
(196)
rats effects on 
behaviour
low doses added 
together
estimated and observed 
effects compared
no info effect combi = 
drugs alone
Bourgeois
(29)
mice MES drugs tested alone 
and together
FEC method additive additive
c b z /v p a Schmutz
(221)
mice + 
rats
MES drugs tested alone 
and together
summation of effects 
method
effect combi 
>drugs alone
effect combi = 
drugs alone
Bourgeois
(29)
mice MES drugs tested alone 
and together
FEC method additive infra­
additive
v p a /e s m Bourgeois
(29)
mice Ptz drugs tested alone 
and together
FEC method additive infra­
additive
Musolino
(187)
rats Ptz low-dose drug added 
to the other
comparison of regression 
lines
effect combi 
>drugs alone
no info
Roks
(208)
rats no
epilepsy
drugs tested alone 
and together
isobologram method no info infra­
additive
* EDx PB + (ED50 - EDx) PHT; for example: ED20 PB + (ED50 - ED20) PHT; ** FEC method: fractional effective
concentration method; 1) MES: maximal electroshock seizures; model for generalized tonic-clonic seizures; 2) MDA: 
maximal dentate activation; model for complex partial seizures; 3) CS: cortical stimulation: model for partial seizures; 
4) Ptz: pentylenetetrazol; model for myoclonic and/or absence seizures; 5) bicuculline: GABAa receptor antagonist; 
model used for partial seizures. For AED abbreviations see table 4.1a.
Table 4.2a Polytherapy studies in animal models ofepilepsy(continued)
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AEDs first author 
(ref. nr.)
animal model experimental
design
method of analysis efficacy toxicity
v p a /c z p Bourgeois
(30)
mice Ptz low dose CZP added 
to VPA
re-evaluation o f VPA’s 
ED50 and TD50
ED50 VPA I TD50 VPA I
e s m /c z p Bourgeois
(30)
mice Ptz low dose CZP added 
to ESM
re-evaluation of ESM’s 
ED50 and TD50
ED50 ESM I TD50 ESM I
LTG/PHT De Sarro 
(214)
mice DBA6 non-protective dose 
of LTG added to PHT
re-evaluation of PHT’s 
ED50 and TD50
ED50 PHT I TD50 PHT I
l t g /p b De Sarro 
(214)
mice DBA non-protective dose 
of LTG added to PB
re-evaluation of PB’s 
ED50 and TD50
e d 50 p b  I t d 50 p b  I
l t g /c b z De Sarro 
(214)
mice DBA non-protective dose 
of LTG added to CBZ
re-evaluation CBZ’s 
ED50 and TD50
e d 50 c b z  I t d 50 c b z  I
l t g /v p a De Sarro 
(214)
mice DBA non-protective dose 
of LTG added to VPA
re-evaluation of VPA’s 
ED50 and TD50
ED50 VPA I TD50 VPA I
l t g /d z p De Sarro 
(214)
mice DBA non-protective dose 
of LTG added to DZP
re-evaluation of DZP’s 
ED50 and TD50
ED50 DZP I TD50 DZP I
l t g /t p m Stephen
(235)
mice Ptz non-efficacious drugs 
given together
evaluation of seizure 
control
efficacious
combination
no info
g b p /p h t De Sarro 
(215)
mice DBA non-protective dose 
of GBP added to PHT
re-evaluation of PHT’s 
ED50 and TD50
ED50 PHT I TD50 PHT I
g b p /p b De Sarro 
(215)
mice DBA non-protective dose 
of GBP added to PB
re-evaluation of PB’s 
ED50 and TD50
e d 50 p b  I t d 50 p b  I
g b p /c b z De Sarro 
(215)
mice DBA non-protective dose 
of GBP added to CBZ
re-evaluation of CBZ’s 
ED50 and TD50
e d 50 c b z  I t d 50 c b z  I
g b p /v p a De Sarro 
(215)
mice DBA non-protective dose 
of GBP added to VPA
re-evaluation of VPA’s 
ED50 and TD50
ED50 VPA I TD50 VPA I
g b p /d z p De Sarro 
(215)
mice DBA non-protective dose 
of GBP added to DZP
re-evaluation of DZP’s 
ED50 and TD50
ED50 DZP I TD50 DZP I
g b p /f b m De Sarro 
(215)
mice DBA non-protective dose 
of GBP added to FBM
re-evaluation of FBM’s 
ED50 and TD50
e d 50 f b m  I t d 50 f b m  I
g b p /l t g De Sarro 
(215)
mice DBA non-protective dose 
of GBP added to LTG
re-evaluation of LTG’s 
ED50 and TD50
ED50 LTG I TD50 LTG I
f b m /p b Gordon
(94)
mice MES non-protective dose 
of PB added to FBM
re-evaluation of FBM’s 
ED50 and TD50
e d 50 f b m  I t d 50 f b m  I
f b m /c b z Gordon
(94)
mice MES non-protective dose 
of CBZ added to FBM
re-evaluation of FBM’s 
ED50 and TD50
e d 50 f b m  I t d 50 f b m
f b m /v p a Gordon
(94)
mice MES non-protective dose 
of VPA added to FBM
re-evaluation of FBM’s 
ED50 and TD50
e d 50 f b m  I t d 50 f b m  I
f b m /d z p Gordon
(93)
mice m e s /
Ptz
non-protective dose 
of FBM added to DZP
re-evaluation of DZP’s
ED50
e d 50 f b m  I no info
t p m /p h t Shank
(225)
mice MES drugs tested alone 
and together
isobologram method additive no info
t p m /p b Shank
(225)
mice MES drugs tested alone 
and together
isobologram method supra­
additive ***
no info
t p m /c b z Shank
(225)
mice MES drugs tested alone 
and together
isobologram method supra­
additive ***
no info
*** Some of the ratio’s of this combination were synergistic. 6) DBA/2 mice: genetically epilepsy prone rats.
Comments
A few conflicting results between the studies are immediately apparent from table 4.2a. For 
example, the PB/FHT combination which was reported to be synergistic for efficacy in 
three papers, whereas it was reported to have additive efficacy in two other papers. 
Furthermore, not all of the methods used to evaluate interactions have the same merit. In 
fact, most studies did not employ the isobologram method, which is considered to be the 
optimal method to detect supra-additivity (synergy), additivity (zero interaction) or infra­
additivity (antagonism) (17, 238). The method used by Weaver et al and Leppik et al. and 
the Fractional Effective Concentration (FEC) method as used in most of Bourgeois’ 
experiments and in some other studies are quantitative methods similar to the isobologram 
method (29, 37, 140, 184, 259). Recently, a sound statistical basis for the isobologram 
method was published by Roks et al. (208). Thus in table 4.2a, the results of studies using 
isobologram or similar methods are defined in terms of infra-additivity, additivity and 
supra-additivity (these terms are reserved for these methods). A combination may offer 
advantages when the balance between efficacy and toxicity, i.e. the therapeutic index (the 
TC50/EC50; T.I.) is improved. This was the case for the combinations FHT/PB (29, 259), 
PHT/VPA (37), PB/PRM (29), CBZ/VPA (29) and VPA/ESM (29). However, due to the 
low T.I. of PB, combinations with this drug still had a lower T.I. than the other constituents 
of these combinations (i.e. PHT and PRM). A number of other studies using the 
isobologram method only studied either efficacy or toxicity, and therefore the T.I.’s of 
these combinations could not be determined (140, 168, 208, 225).
There is another study design which, although not using the isobologram method, is also 
informative: the study of Stephen et al. showed that two drugs (i.e. LTG and TPM) which 
have no efficacy in the Ptz test at maximal dosages, protected against Ptz-induced seizures 
when they were given in combination (235). However, no information was given 
concerning the toxicity of the combination.
In the bulk of the studies listed in table 4.2a a different design was used, in which both 
drugs are efficacious in the employed animal model. In this design drug B is titrated to its 
ED50 in the presence of a non-protective dose of drug A, and potentiation of anticonvulsant 
effect is claimed when the ED50 of drug B proves to be reduced compared to its ED50 in 
monotherapy. If, however, we use the ‘sham combination test’ of Berenbaum (in which 
drug A and B are the same drug) for this study design, the addition of a non-protective dose
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of drug A will lead to a reduced ED 50 o f drug B and to the conclusion that drug A 
potentiates the anticonvulsant effect o f drug B. This is impossible, as drug A and B are the 
same drug (17). Furthermore, if  one examines the therapeutic index, it will also be elevated 
in the sham combination test, which is equally impossible. Demonstrating that there is no 
interaction between two anticonvulsants is indeed possible by using this method as was 
shown by Borowicz et al. (26).
One study used response surface modeling to evaluate interactions between CBZ, FBM and 
PHT (86). This study is not listed in table 4.2a, because o f the complexity o f the data 
presented. In his review, Berenbaum also discusses this model (17).
Human data
Of the drugs listed in table 1, 12 different two-drug combinations have been evaluated in 
epilepsy patients. In most o f these studies, patients were diagnosed to have difficult-to-treat 
epilepsy and had already tried many AEDs, in monotherapy and in combination therapy 
(10, 34, 36, 52, 84, 100, 102, 104, 112, 186, 191, 211, 239, 241, 258), (181, 209, 230, 
235). O f these 19 papers, 12 were retrieved by the M edline search. The main outcome 
measure in the selected studies was seizure frequency. The studies had open, uncontrolled 
and non-randomized designs and some were (partly) retrospective. The effects on 
tolerability were mostly described very briefly or not reported on at all. The data o f these 
studies are summarized in table 4.2b. Dosages and serum levels are listed when available, 
as these may have some relevance for estimating intractability. Serum levels are not 
included in Table 4.2a, as intractability was not considered an issue in animal studies. 
Case reports about a certain combination are not listed if  there are larger studies reporting 
about that combination. Interesting studies on combinations o f VPA+LTG, VPA+VGB, 
LTG+VGB, LTG+TPM and TGB+VGB were not eligible for inclusion because patients 
in those studies also took other drugs in addition to the combination (9, 76, 77, 128, 138, 
198, 216, 236, 251).
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Table 4.2b. Polytherapy studies in epilepsy patients
Drugs first author 
(ref. nr.)
number of 
patients
seizure type study design efficacy adverse effects
PHT/PB Gruber (100) 24 generalized tonic-clonic 
and partial seizures
patients were given placebo, 50 mg PB monotherapy, 50 mg PHT 
monotherapy or 25 mg PB + 25 mg PHT in a crossover design
the combination was equally 
efficacious as the two drugs alone
no info
Painter
(191)
59 neonatal seizures 29 patients not completely controlled by one o f the two drugs at serum 
levels in the therapeutic range were given PB + PHT
9 of 29 (31%) had complete control of 
seizures
no overt clinical 
toxicity
Cereghino
(36)
41 generalized tonic-clonic 
and partial seizures
patients were given PHT 300 mg dd, PB 300 mg dd and CBZ 1200 
mg dd in the following combinations: PHT+PB; PHT+CBZ; 
PB+CBZ; PHT+PB+CBZ in a cross-over study
of the three 2-drug combinations, 
PB + PHT was most efficacious
PB+PHT : no 
patients 
withdrew
PHT/CBZ Hakkarainen
(102)
100 adult-onset seizures 33 patients not controlled by either drug were given PHT/ CBZ 5/33 seizure free 
with PHT/CBZ
no info
Cereghino
(36)
41 generalized tonic-clonic 
and partial seizures
patients were given PHT 300 mg dd, PB 300 mg dd and CBZ 1200 
mg dd in the following combinations: PHT+PB; PHT+CBZ; 
PB+CBZ; PHT+PB+CBZ in a cross-over study
of the three 2-drug combinations, 
CBZ + PHT was least efficacious
CBZ+PHT : 
3 patients 
withdrew
PHT/LTG Brodie (34) 92 all seizure types patients were not controlled by PHT were given PHT + LTG 
(average add-on dose 359 mg dd)
38% of patients > 50% seizure 
reduction; 13 of 16 pts. completed LTG 
monotherapy phase
13% withdrew 
due to toxicity
CBZ/VPA Armour (10) 18 generalized tonic-clonic 
and partial seizures
intractable patients not controlled by maximal VPA monotherapy were 
given VPA+CBZ
12 improved with CBZ/VPA 
combination
no info
Dean (52) 100 partial seizures (+/- 
secondary generalization)
patients were not controlled by maximal CBZ 
monotherapy were given VPA + CBZ
17% o f patients were seizure-free; 
another 39% had a > 50% reduction
no info
Fröscher
(84)
54 generalized tonic-clonic 
and partial seizures
difficult-to-treat patients were given VPA+CBZ at therapeutic serum 
levels
GTCS*: 76% > 50% reduction; partial 
seiz.: 29% > 50% reduction
adverse effects 
in 50%
Harden (104) 18 partial seizures (+/- 
secondary generalization)
patients not controlled by maximal CBZ 
monotherapy were given VPA + CBZ
3 patients > 50% seizure reduction some toxicity
Walker (258) 43 complex partial seizures + 
secondary generalization
patients were first given VPA monotherapy; if  not controlled CBZ 
monotherapy; still not controlled CBZ+VPA
17 patients not controlled by either 
drug alone: 12> 50% reduction (6 
seizure free) on VPA + CBZ
no new or 
additive 
toxicity
Efficacy mostly described by average percentage seizure reduction and/or by percentage seizure free patients; pts.= patients; GTCS = generalized tonic-clonic seizures
Table 4.2b. Polytherapy studies in epilepsy patients (continued)
Drugs first author 
(ref. nr.)
number of 
patients
seizure type study design effi
c b z /c l z p Tatzer (241) 34 West (24) or Lennox 
Gastaut Syndrome (10)
patients were given CBZ + either CLZP or 
nitrazepam (NZP) all at their usual dose range
IS: 14 > 50% seizure re 
free);myoclonic-astatic
Hosada (112) 28 partial seizures children with seizures refractory to maximal 
CBZ monotherapy were given CBZ + CLZP
23 of 28 patients st 
12 months after the
c b z /l t g Brodie (34) 129 all seizure types patients not controlled by CBZ were given CBZ + 
LTG (average add-on dose 347 mg dd)
41% of patients > 50% s 
pts. completed LTG
c b z /v g b Murri (186) 40 partial seizures (+/- 
secondary generalization)
patients not controlled by maximal 
CBZ monotherapy were given CBZ + VGB 
(average add-on dose 2,75 g dd)
overall 70% sei 
7 patients
Tanganelli
(239)
14 partial seizures (+/- 
secondary generalization)
patients not controlled by maximal CBZ 
monotherapy nor by maximal VGB 
monotherapy were given CBZ + VGB
8 of 14 > 75% seizur 
5 were se
v p a /e s m Rowan (211) 5 absence seizures all patients refractory to maximal VPA and two also 
to ESM; all were given VPA + ESM
all five becam
v p a /c z p Mireles (181) 55 mixed retrospective review of patients with 
intractable epilepsy who had received 
VPA (average serum level 56.6 mg/l) + CZP 
(average serum level 22.6 ng/l) combination
seizure control improv 
absences, 8/9 with myoc 
CPS: 3/14 with prim. GT 
and in 3/14 wit
Rosenberry
(209)
12 absence and/or myoclonic 
seizures
patients were not controlled by either VPA 
or CZP alone and were given combination
6 of 8 patients remai 
experienced a mark
v p a /l t g Brodie (34) 115 all seizure types patients not controlled by VPA were given VPA + 
LTG (average add-on dose 96 mg dd)
64% of patients > 50% s 
pts. completed LTG
v p a /f b m Siegel (230) 13 Lennox-Gastaut Syndrome Patients on VPA alone at therapeutic serum levels 
received add-on 
FBM or placebo in a cross-over study
40% fewer drop attack 
seizures on FBM (VP
l t g /t p m Stephen (235) 2 mixed seizure types 
(partial/generalized)
Patients receiving maximal LTG monotherapy were 
given TPM as add-on medication
Both patient
IS = infantile spasms; pts. = patients; CPS = complex partial seizures; GTCS = generalized tonic-clonic seizures
Comments
There is no straightforward methodology for the investigation of AED pharmacodynamic 
interactions in the clinical setting (200). In humans the isobologram method cannot be used, 
as it is impossible to titrate to exactly the same effect in all treatment groups. Gruber et al. 
used an approach somewhat similar to the isobologram method by giving patients either 50 
mg of PHT, 50 mg PB or a combination of 25 mg of PHT plus 25 mg of PB (100). All three 
regimens were found to have equal efficacy in this study, however it is somewhat surprising 
that 50 mg of PHT was as efficacious as 50 mg of PB.
A study design similar to that in the animal experiment of Stephen et al. (235) has been used 
by various investigators. In these studies patients, who did not respond to drug A given 
alone nor to drug B given alone at maximal dosages, were given the combination of drug 
A and B (often adding the first drug to the drug the patient was taking at the time). When 
the combination of A and B resulted in improved seizure control in a considerable number 
of these patients and pharmacokinetic interactions have been ruled out, this was considered 
to be suggestive of either improved efficacy or improved tolerability. Using this design, 
Hakkarainen, Walker et al. and Tanganelli et al. respectively observed that the combinations 
of CBZ/VPA and CBZ/VGB had added value, whereas CBZ/FHT did not (102, 239, 258). 
Other studies, in which patients had received only one of the drugs prior to receiving the 
combination (similar to add-on drug trials for new AEDs), offer less convincing evidence 
regarding effectiveness of combination therapy. Using this design one cannot exclude the 
possibility that the added drug is solely responsible for the improved effectiveness. 
Another approach which does have merit, is the one used by Brodie et al. and by Cereghino 
et al. (34, 36). In these studies the investigational AED was used in several two-drug 
combinations. If seizure control brought about by one combination exceeded the control 
brought about by any other combination and pharmacokinetic interactions had been ruled 
out, this was considered to be suggestive of a positive pharmacodynamic interaction. 
Indeed, this was observed to be the case for the combinations PB/FHT and VPA/LTG.
Discussion
Based on those animal and human studies that had one of the preferred designs (i.e. studies 
that used isobolographic analysis or similar methods, studies in which both of the drugs 
combined were non-efficacious in the animal model or patients studied and studies in which
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combinations were compared to other combinations), a number of combinations appear to 
be associated with increased effectiveness. These potentially advantageous combinations 
are listed in table 4.2c (29, 34, 36, 37, 48, 168, 225, 235, 239, 258, 259). The clinically 
significant mechanisms (marked with three or two asterisks in table 4.1a) of the drugs 
involved are also shown.
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Table 4.2c Potentially advantageous AED combinations and clinically relevant 
mechanisms ofaction ofthe drugs involved
Combinations Mechanisms of action Seizure type Animal
studies
Human
studies
PHT/PB Na+/GABA, Na+, glutamate generalized tonic-clonic and 
partial seizures
96, 168, 
201,259
36
PHT/VPA Na+/GABA, Na+ generalized tonic-clonic seizures 37
CBZ/VPA Na+/GABA, Na+ generalized tonic-clonic and 
partial seizures
29 258
CBZ/VGB Na+/GABA partial seizures 
(+/- secondary generalization)
239
VPA/ESM GABA, Na+/
T-type calcium channel
absence seizures 29
VPA/LTG GABA, Na+/Na+ generalized tonic-clonic and 
partial seizures
34
Only mechanisms of action with three or two “+” in Table 1 are shown. Some of the combinations listed 
only had increased effectiveness in animal experiments; some only in clinical studies and some in both. 
Slashes divide the two drugs in column 1 and the mechanisms of action of the respective drugs in column 2.
Other interesting combinations are PHT/CZP, PB/TPM, CBZ/TPM, LTG/TPM, although 
toxicity was not reported in the studies of these combinations (48, 225, 235). Table 4.2c 
shows combinations with improved effectiveness, whether this was accomplished by actual 
synergy between drugs or increased tolerability. It is unknown whether the mechanisms 
responsible for the anti-convulsant effects of these drugs also cause their adverse effects. 
As is shown in table 2, Bourgeois did observe additivity for efficacy and infra-additivity for 
toxicity for several combinations, which suggests that increased effectiveness is often due 
to improved tolerability (29).
Further insight on this may be forthcoming from experimental animal studies involving 
candidate AEDs. Czuczwar et al. reported that AMPA/kainate antagonists and NMDA- 
antagonists reduced each other’s ED50 in an electroconvulsion model (47). However, in 
some of these combinations adverse effects were also potentiated. The same group also
reported that some NMDA-antagonists and some non-competitive AMPA/kainate 
antagonists reduced the ED50's of CBZ, PHT and VPA in the maximal electroshock-induced 
convulsions without exacerbating adverse effects (46). Löscher et al. found that NMDA 
antagonists, which only exhibited weak efficacy in kindled rats, potentiated the efficacy of 
the competitive AMPA-antagonist 2,3-dihydroxy-6-nitro-sulfamoylbenzo(F)quinoxaline 
(NBQX) without potentiating its toxicity (151).
Klitgaard et al. reported that combining a glutamate-receptor antagoni st (AMPA or NMDA) 
and a drug that enhances GABAergic inhibition did not result in a supra-additive effect 
against audiogenic seizures in DBA/2 mice, whereas combining two glutamate antagonists 
or combining two GABAergic drugs did (126). Increased efficacy of two GABAergic drugs 
has also been found in vitro (205); these authors constructed a molecular model that could 
describe and explain the synergy between two GABAergic drugs at a molecular level, 
giving a rational for the observed synergy in the in vivo setting. Löscher’s group also found 
that NMDA receptor antagonists combined with GABA-enhancing drugs did not result in 
increasing effectiveness in kindled rats (150). However, Czuczwar’s group did find 
increased effectiveness for these combinations in the electroconvulsive threshold test and 
also reported that LY 300164, an AMPA/kainate receptor antagonist, interacts with 
clonazepam in the MES and in amygdala-kindled rats (25, 49).
The latter group has also reported that some calcium channel blockers may decrease the 
ED50 of some of the standard AEDs against electroconvulsions and in the Ptz model (46). 
Although these data have been corroborated by other groups (207), clinical add-on trials 
of calcium channel blockers have not been very successful.
Based on the data described and on our present knowledge of AED mechanisms of action, 
the following mechanistic combinations may be useful in patients with generalized tonic- 
clonic seizures and partial seizures:
1. combining a sodium channel blocker with a drug enhancing GABAergic inhibition 2. 
combining two drugs that both enhance GABAergic inhibition 
3. combining an AMPA antagonist with a NMDA antagonist
The case of combining two sodium channel blockers seems less promising: CBZ and PHT 
do not act synergistically, and LTG interacts more efficaciously with VPA than with CBZ 
or PHT. It may be argued, however, that the success of combining VPA with LTG, or for 
that matter PB with PHT, is based on the fact that these drugs all possess sodium channel
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blocking properties. On the other hand, questions have been raised whether sodium channel 
blocking really contributes to VPA’s or PB’s clinical efficacy (149, 262).
Furthermore it is important to keep in mind that improved effectiveness, i.e. an improved 
balance between efficacy and tolerability, is the goal of combination therapy. For example, 
combinations of drugs that enhance GABAergic inhibition may enhance efficacy, but some 
of them also produce supra-additive hypnotic effects (57, 109). Also, idiosyncratic 
reactions may increase simply because two drugs are used instead of one, but also because 
of metabolic interactions.
Instead of looking at cellular mechanisms, AEDs have also been categorized according to 
their ability to increase seizure threshold (as evidenced by efficacy in the Ptz model) and 
to prevent seizure spread (as evidenced by efficacy in the MES test) (151). It is uncertain 
whether one should combine two drugs that raise seizure threshold, two drugs that inhibit 
seizure spreading or that one should combine one of each category (158). Given the 
efficacy of the AEDs in these two models (148), the combinations listed in table 4 do not 
help in distinguishing these options.
It is also interesting to consider the regional effects of AEDs. Increasing GABAergic neuro­
transmission in the substantia nigra pars reticulata (SNR) for example, is a remarkably 
effective means of suppressing seizure propagation in a wide range of convulsive and non­
convulsive animal epilepsy models (85, 150). Benzodiazepines, VPA and PB have been 
shown to inhibit firing in the SNR, whereas PHT and CBZ were ineffective in this respect 
(150). Perhaps this could be another area worth exploring for rational polytherapy.
It is very apparent that our knowledge of the mechanisms of action of the presently licensed 
AEDs is far from complete, and consequently we cannot fully explain their anticonvulsant 
spectra. Furthermore, Macdonald concludes that until the basic mechanisms of seizures are 
fully understood, there will only be a theoretical basis for rational polypharmacy (163). This 
will be discussed further in chapter 7.
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C h a p ter  5 A E D  co m b in a tio n  th era p y  in an im als
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As was discussed in chapter 4, there are a number o f animal models for epilepsy. In 
Nijmegen, the Department o f Comparative and Physiological Psychology o f the Catholic 
University has worked extensively with the WAG/Rij rat as a model for human absence 
epilepsy. The WAG/Rij rat shares behavioral, electro-encephalographic and anticonvulsant 
profiles with human absence epilepsy (161, 193).
In this chapter the research which was done in collaboration with the Department of 
Comparative and Physiological Psychology (Dr. C.M. van Rijn) is described. The first 
paragraph concerns a study which was focused on the neurotoxic effects o f valproate (VPA) 
and ethosuximide (ESM), alone and in combination, in W istar rats and on the design and 
analysis o f polytherapy studies in animals. In the second study, described in paragraph 5.2, 
the effect o f VPA and ESM, alone and in combination, on the number o f spike-wave 
discharges in WAG/Rij rats was assessed.
5.1 Neurotoxicity of the combination of valproate and ethosuximide in Wistar rats
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Introduction
Bourgeois has studied the possible advantages o f many antiepileptic drug combinations in 
mice (29). Anti-convulsant effect was studied by observing whether clonic seizures elicited 
by maximal electroshock or pentylenetetrazole (depending on the drugs to be studied) were 
suppressed and neurotoxicity was evaluated by use o f the rotarod test (absence of 
neurotoxicity being defined as the ability to stay on a rotating horizontal rod for at least 10 
minutes). Results were presented as a therapeutic index, which in these studies was a ratio 
o f the TC50 (concentration with toxic action in 50% of the animals) and the EC50 
(concentration with therapeutic action in 50% of the animals). As was discussed in chapter 
four, Bourgeois found two drug pairings to have advantages when used in combination: 
valproate plus carbamazepine and valproate plus ethosuximide. In both cases the anti­
convulsant effect was purely additive but due to an infra-additive neurotoxicity the 
combination had a better efficacy versus toxicity ratio than the single drugs. However, 
neurotoxicity was only evaluated by use o f the rotarod test, measuring motor coordination 
and praxis, while for example, sedative effects were not assessed.
In the present study we will focus on the combination o f valproate and ethosuximide and 
on a more extensive evaluation o f neurotoxic effects; the grip strength meter, the accelerod 
(an accelerating version o f the rotarod), and video observation were used to assess 
neurotoxicity. Dose-effect curves o f valproate and ethosuximide in mono- and polytherapy 
were determined in order to assess drug interaction with respect to strength, ataxia, and 
sedation. Also, a novel approach for the statistical analysis o f drug interactions is presented.
Methods
Animals
Male adult Wistar rats, weighing between 224 and 320 grams, were used for this 
experiment. They were housed in identical plastic cages and had free access to food and 
water except during the motor experiments. They were kept on a reversed light dark cycle 
(dark between 9.00 en 21.00 hours).
Drugs
Valproate (Albic Inc. Maassluis, The Netherlands) and ethosuximide (Sigma chemical co., 
The Netherlands), dissolved in 0.9% sodium chloride, were administered intraperitoneally 
alternating left and right to prevent adhesions.
Experiment
The animals were divided in four groups of eight rats, one group receiving valproate, one 
group receiving ethosuximide, one group receiving the drug combination and one saline 
control group. Every rat received six dosages including a zero dosage of the drug it was 
randomly assigned to, with an interval of 7 days. This interval was chosen on basis of the 
half-life of elimination of valproate (146) and ethosuximide (12), being respectively 4.6 and 
22 hours. The sequence of the six different doses was assigned to an individual rat 
according to an adapted Latin square. This design was chosen to correct for follow up 
effects. All injections were blinded for the investigator. The dose of valproate ranged from 
zero to 560 mg/kg and of ethosuximide from zero to 360 mg/kg, based on pilot experiments. 
For the drug combination a fixed weight ratio of 2/3 valproate with 1/3 ethosuximide was 
given, the doses ranged from zero to 360 mg/kg valproate with 180 mg/kg ethosuximide. 
The ratio of valproate and ethosuximide were based on their TD50 (in this case the amount 
of drug causing 50% of the maximum effect) found in the aforementioned pilot 
experiments. After weighing and injection, the rats were evaluated using the three 
aforementioned tests in a fixed sequence.
First, the grip strength of the fore-paws was determined (130). The grip strength apparatus 
consists of a push-pull strain gauge attached to a T-bar. To measure the grip strength the 
animal is placed with its fore-paws on the T-bar and is than gently pulled backwards until 
its grip is broken. The strength is measured in grams. Before the experiment the animals
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were trained for three days. The grip strength test took place between 40 and 60 minutes 
after injection. The average of three trials was taken in the further analysis of the data. 
Next, the animals were placed on an accelerating rotarod (119). The rod started at 15% of 
maximum speed (50 rev/min) and accelerated 0.2% per second. The time a rat managed to 
stay on the rod was scored and the longer one of two runs was taken for further analysis. 
Before the experiment, the animals were trained for three days and had to be able to stay on 
the accelerod for at least one minute to participate in the experiment. Each test day, before 
injection, the animals were tested on the accelerod and grip strength. These test results were 
used to correct for possible time effects. The test took place between 80 and 100 minutes 
after injection.
The third test was a behavioral analysis. The animals were observed for 25 minutes by video 
camera between 100 and 125 minutes after injection. The animals were in observation cages 
of 30 by 30 by 50 cm and a minimum of light was used to keep them in an active state. The 
videotapes were observed with help of “The Observer” computer program (Noldus 
Information Technology Inc. Wageningen The Netherlands). The behavior was categorized 
into four classes, namely: 1. active behavior being all movements automatic behavior not 
included, thus locomotion, sniffing and rearing; 2. passive behavior being the absence of 
any movement; 3. grooming and 4. automatic behavior, being eating and drinking.
Data analysis
The data of all three tests were analyzed by non-linear regression analysis using the program 
Graphpad Prism 2.0.
The data were fitted to the sigmoid Emax model:
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equation 1 :
E  drug E  min +
1 +
d o s e
T D 5 0
Hill
Edrug is the measured effect of the drug at a certain dose. E drug starts at Emin and goes to Emax 
with a sigmoid shape. The TD50 and Hill factor (Hill) were calculated for the three drugs 
(VPA, ESM, and VPA+ESM  according to its total weight).
N ext the theoretical additive curve was generated for the drug combination using the 
sigmoid Emax model for a mix o f two compounds according to equation 2*:
1 +
(  A )  * d o s e  +  (1 -  A )  * d o s e
T D  50, valproate TD50
Hillcombination
with equation 3:
(  A )  * H illvalproate + _ (1 A )  * H ille thosux
H i l l ,
TD 50 , valproate 0, ethosux
combination
( A ) (1 -  A )
T D 50, valproate T D 50 , ethosux
+  -
max
Ecombination is the calculated additive effect o f the combination o f drug at a certain dose. 
Ecombination starts at Emin and goes to Emax with a sigmoid shape. A is the fraction o f valproate 
in the combination. The H illcombination is the weighted mean o f the Hills o f the single 
compounds. Next, the sigmoid Emax model o f equation 1 was fitted to the generated 
additive data yielding an expected additive TD50 and an expected additive Hill. Confidence 
intervals (CI’s) o f the expected additive parameters are calculated from the CI’s o f the 
measured single compound curves using
* After publication o f the paper, we found out that equation 2 is correct for calculating the 
theoretical additive TD50, but only approaches the rest of the curve. The correct equation 
will be used when the paper in paragraph 5.2 is submitted. equation 4:
Expected CI= [(A x % CIvalproate + (1-A) x % CIethosuximide) x expected TD50]
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The experimental parameter estimates o f the drug combination were compared to the 
theoretical additive parameter estimates using the 95% confidence intervals. The curves of 
valproate and o f ethosuximide were normalized using their TD50s. The curve o f the 
experimental combination was normalized using the TD50 o f the theoretical additive 
combination.
The TD50 parameter estimates obtained by the sigmoid Emax model were plotted in an 
isobologram to visualize the type o f interaction (17, 238).
Results:
Baseline measurements
To obtain baseline values and to correct for time effects, the grip strength and the accelerod 
performance were measured each test day before injection. A group x day analysis of 
variance was performed on these data. A group difference was present (F(3,144) = 6.51, P 
< 0.001 for the grip strength and F(3,144) = 7.11, P < 0.001 for the accelerod). A day 
difference was present for the grip strength only (F(5,144) = 2.39, P< 0.05). No group x 
time interaction was present, indicating that the changes over time are the same for all 
groups.
For the grip strength the group means varied from 970 grams (S.E.M. 30 g) in the drug 
combination group to 1160 g (S.E.M. 30 g) in the saline control group. For the accelerod 
performance the group means varied from 110 seconds (S.E.M. 11 s) in the ethosuximide 
group to 171 s (S.E.M. 6 s) in the valproate group. An increase o f grip strength was found 
over the test days, from 980 g (S.E.M. 30 g) on test day 1 to 1130 g (S.E.M. 50 g) on test 
day 6. Because o f this time effect, we used the percentage post-injection performance of 
pre-injection performance as the measure for drug effects for the grip strength and the 
accelerod performance. In this way, every rat functioned as its own control.
Grip strength
The overall mean pre-injection grip strength was 1060 g (S.E.M. 20 g). Both compounds 
as well as the combination negatively influenced grip strength performance in a dose- 
dependent fashion. Equation 1, the sigmoid Emax model, was fitted to the data, yielding the
TC50 and the Hill. With these parameter values of the single drugs the theoretical additive 
curve for the drug combination was calculated using equation 2. The grip strength data 
(table 5.1a) show that the experimental dose needed to get 50% toxicity in the combination 
experiment is lower than the theoretical additive dose, suggesting supra-additivity in 
toxicity.
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Table 5.1a. Side effects quantified by grip strength
VPA ESM V PA /ESM T heoretical TD50
TD50 (mg/kg) 883 385 345/173 411/206
95 % CI 509 - 1534 270 - 550 323/161 - 370/185 254/127 - 672/336
PDD/TD50 1 1 0.39/0.45 0.47/0.53
Norm. TD50 1 1 0.84 1
Hill -1.1 -2.1 -1.7
95% CI -1.7 - -0.4 -3.6 - -0.6 -1.9 - -1.4
Parameter estimates of fitting the sigmoid Emax curve to the data. The TD50 is the dose at which 50% toxic effect is 
achieved. All weight values are normalized using the TD50 values. The experimental combination uses the TD50 of the 
individual drugs as norm. A normalized TD50 of the experimentally determined combination below 1 points to supra- 
additivity whereas more than 1 indicates infra-additivity. If the 95% confidence intervals of the normalized TD50 of the 
experimental combination do not overlap with the intervals of the theoretical additive ones than the interaction is assumed 
to be statistically significant. Hill is a measure for the steepness of the curve.
However, the 95% confidence intervals of the experimental TD50 and the theoretical TD50 
overlap to a great extent, as is shown in the inset of figure 5.1a.
Therefore, the finding of supra-additivity proved not to be statistically significant (table
5.1a).
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Figure 5.1a Normalized dose-response curves and isobologram for the effect on grip 
strength performance
Grip s treng th  o fth e  fo re  paws
Dose response graphs for the
change in grip s t r e n g t h
performance in rats following injection of valproate (open circles), ethosuximide (open squares) or of the 
combination of both (closed circles), after fitting the sigmoid Emax model to the data. All weight values are 
normalized using the TD50 values. The experimental combination value uses TD50s of the individual drugs 
as norm. The normalized drug doses (dose/ED50) are plotted on the abscissas and the grip strength data on 
the ordinate. The solid lines show the theoretical additive dose response curves as derived from equation 2, 
and the broken lines show the experimentally measured dose response curves. While fitting the curves to the 
data, the tops of the curves were fixed at 100 % and the bottoms were fixed at 0 %. The inset shows the TD50s 
plotted in an isobologram with the TD50 of valproate on the abscissa, and the TD50 of ethosuximide on the 
ordinate. The straight line that connects the two plotted TD50s of the pure single drugs is the “zero interaction 
line” (131), with the dotted lines marking their 95% confidence intervals (CI’s). Indicated with an * is the 
theoretical additive TD50 which would be obtained with the used ration. The closed circles indicate the 
experimental TD50s with their 95 % CI’s. If experimentally determined data points lie on the zero interaction 
line then the drug effects are additive (no interaction). If the points lie below this line then there is supra- 
additivity and if they lie above this line then there is infra-additivity. If the 95% CI of the experimentally 
determined combination do not overlap with the intervals of the zero interaction line than the interaction is 
assumed to be statistically significant.
Accelerod performance
The pre-experiment training required that every animal could stay on the accelerod for 60 
seconds. The overall mean pre-injection accelerod performance was 140 s (S.E.M. 5 s). 
Both compounds as well as the combination negatively influenced accelerod performance 
in a dose dependent way. Equation 1, the sigmoid Emax model, was fitted to the data, 
yielding the TD50 and the Hill. W ith these parameter values o f the single drugs the 
theoretical additive curve for the drug combination was calculated using equation 2. The 
accelerod data (table 5.1b) show that the experimental dose needed to get 50% toxicity in
the combination experiment is higher than the theoretical additive TD50, suggesting infra­
additivity in toxicity.
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Table 5.1b. Adverse effects quantified by the accelerod
VPA ESM VPA/ESM Theoretical TD50
TD50 (mg/kg) 482 338 379/190 281/141
95% CI 431 - 540 184 - 620 249/125 - 579/289 219/109 - 382/191
PDD/TD50 1 1 0.79/0.56 0.58/0.42
Norm. TD50 1 1 1.35 1
Hill -6.8 -2.7 -3.3
95% CI -12.0 - -1.5 -7.5 - 2.1 -8.7 - 2.1
For details, see legend to table 5.1a.
However, the 95% confidence intervals o f the experimental TD50 and the theoretical TD50 
do overlap, as is shown in the inset o f figure 5.1b. Therefore, the finding o f infra-additivity 
is not statistically significant (table 5.1b).
Figure 5.1b Normalized dose-response curves and isobologram for the effect on 
accelerod performance
( open 
ethosux
imide (open squares
) or the combin
ation (closed sqaures), after fitting the sigmoid Emax model to the data. While fitting the curves to the data, 
the tops of the curves were fixed at 100 % and the bottoms were fixed at 0 %. For additional details, see 
legend to figure 5.1a.
Observation of behavior
Both compounds caused, in a dose-dependent way, the animals to be less active and more 
passive than the control animals. Grooming and automatic behavior was not influenced in 
a dose-dependent way and no further inference was performed on these data. Equation 1, 
the sigmoid Emax model, was fitted to the data, yielding the TD50 and the Hill. With these 
parameter values o f the single drugs the theoretical additive curve for the drug combination 
was calculated using equation 2. The experimental TD50s o f the drug combination are higher 
than the theoretical additive ones for both the passive behavior and the active behavior 
(tables 5.1c and 5.1d).
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Table 5.1c. Adverse effects quantified by observation of active behavior
VPA ESM VPA/ESM Theoretical TD50
TD50 (mg/kg) 493 346 471/235 288/144
95% CI 376 - 648 261 - 459 415/208 - 534/267 219/109 - 379/190
PDD/TD50 1 1 0.95/0.68 0.58/0.42
Norm. TD50 1 1 1.63 1
Hill -2.8 -1.8 -2.4
95% CI -5.1 - -0.4 -2.8 - -0.8 -2.9 - -1.8
For details, see legend to table 5.1a.
Table 5.1d. Adverse effects quantified by observation of passive behavior
VPA ESM VPA/ESM Theoretical TD50
TD50 (mg/kg) 418 300 451/226 247/123
95% CI 356 - 490 254 - 353 373/187 - 545/273 210/105 - 289/145
PDD/TD50 1 1 1.08/0.75 0.59/0.41
Norm. TD50 1 1 1.83 1
Hill 3.1 2 2.1
95% CI 1.3 - 4.9 1.2 - 2.7 1.4 - 2.8
For details, see legend to table 5.1a.
In both cases the 95% confidence intervals o f the experimentally measured TD50 and the 
theoretical TD50 do not overlap, as the insets o f figures 5.1c and 5.1d show.
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Figure 5.1c Normalized dose-response curves and isobologram for the effect on
b ehavior
Active behavior in a 1500  s. observation period 
(second) (% o f baseline)
While fitting the curves to the
data, the tops of the curves were fixed at specific baseline values of active behavior: for valproate 950 s (SEM 
31 s), for ethosuximide 1061 s (SEM 30 s) and for the combination 1076 s (SEM 36 s). The bottoms of the 
curve were fixed at 0 s. For additional details, see legend to figure 5.1a.
Figure 5.1d Normalized dose-response curves and isobologram forthe effect on passive 
behavior
Faee'we behavior in a 1 5 0 0  s. observation period 
(second) (% change)
While fitting the — 0U curves to
the data, the bottoms of
the curves were fixed at specific baseline values of passive behavior: for valproate 238 s (SEM 28 s), for 
ethosuximide 112 s (SEM 22s) and for the combination 177 s (SEM 19 s). The tops were fixed at 1500 s. For 
additional details, see legend to figure 5.1a.
Thus, statistically significant infra-additivity was found for these effects o f combination
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therapy.
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Discussion
Various methods have been used for the analysis o f drug interactions. In an extensive 
review Berenbaum lists the most commonly used approaches, such as the isobologram 
method, the summation o f effects-method, the multiplication o f surviving fractions-method, 
the method o f calculating the effect o f a zero-interactive combination from the law o f mass 
action and the very popular “no method approach” (i.e. authors claiming to have 
demonstrated supra-additivity or synergy without specifying their methods ) (17). In his 
review, Berenbaum argues that the isobologram method, which was created by Fraser (79) 
and further developed by Loewe (152), is the most valid method. He claims that the greatest 
advantage o f this method compared to others, is that interactions can be analyzed 
“irrespective o f their mechanism o f action or o f the nature o f their dose-response 
relationships” (17).
In this experiment we used the isobologram method to evaluate the interaction o f valproate 
and ethosuximide on adverse effects. Loss o f strength, as measured by the grip strength 
meter, and loss o f coordination, as measured by the accelerod, combined in an additive way. 
However, accelerod performance only became significantly affected at the maximal dose 
permitted (in contrast to the other adverse tests).
Observation o f behavior shows significantly more active and less passive behavior in 
polytherapy compared to monotherapy, indicating infra-additivity. These two measurements 
are not totally complementary, because grooming and automatic behavior were other 
behavioral variables (the latter two were not included in the analysis). The fact that the 
behavioral studies show significant infra-additivity in toxicity is an important finding when 
translated to humans, as sedation is the most frequently reported side effect o f antiepileptic 
drug therapy (39). Furthermore, our experiments may reflect clinical experience that adverse 
effects become apparent earlier in spontaneous behavior than in elicited behavior, as is also 
exemplified by the accelerod results.
How these results may be explained is uncertain. The mechanisms behind most adverse 
effects o f antiepileptic drugs are unknown. Löscher et al. have shown that functional 
tolerance for V PA ’s adverse effects develops relatively fast in kindled rats, whereas VPA 
is efficacious during chronic treatment o f these animals (247). In that study VPA levels
were higher in the substantia nigra and the striatum than in other regions, and remained high 
throughout the study duration of 6 weeks (247). One may suggest that, as tolerance develops 
for VPA’s adverse effects but not for its anticonvulsant effect, these effects must be 
mediated by different mechanisms or at different locations. A study by Liljequist and Engel 
in Sprague-Dawley rats suggests that VPA ‘s effects may be mediated through differentiated 
mechanisms at the GABA-BZD-complex (248). The anti-conflict effects of VPA were 
blocked by the benzodiazepine receptor antagonist Ro 15-1788 and by picrotoxin, but not 
by another benzodiazepine receptor antagonist, Ro 5-3663, nor by bicuculline. Valproate’s 
effects on locomotor activity were blocked only by a small dose of Ro 15-1788 and its 
effect on rotarod performance were only blocked by Ro 5-3663. The doses needed to 
produce impairment of locomotor activity and rotarod performance were equal to the doses 
used to produce toxicity in our study, and higher than needed for VPA’s anticonvulsant 
effects (239).
As for the adverse effects of ESM, Lin-Michell et al. showed that administration of a high 
dose of ESM significantly increased neurotoxicity and brain GABA levels in mice (145). 
As GABA levels decreased during chronic administration of this toxic dose, tolerance for 
the neurotoxic effects developed. Thus ESM’s adverse effects may be GABA-mediated. 
Lin-Michell et al. furthermore showed that co-administration of ethosuximide with 
progabide, a GABAa agonist led to additive neurotoxic effects, as measured by the rotarod 
(145).
The infra-additivity of sedation in our experiment suggests that the two drugs cause sedation 
by different mechanisms. Therefore, although both VPA’s and ESM’s adverse effects may 
be GABA-mediated, it is quite possible that the exact mechanisms by which they influence 
spontaneous behavior do differ, which would explain our finding.
A criticism may be that we did not measure serum levels, let alone brain levels, during this 
experiment. However, the rats were used repeatedly and the schedule of the experiment did 
not permit time for drawing of blood and recovery to allow serum level sampling. As this 
combination is used relatively often in clinical practice, there have been some studies on 
pharmacokinetic interactions between the two drugs. Bourgeois et al. reported that ESM 
brain levels were higher when VPA was co-administered, and they suggested that this was 
due to enzyme inhibition (27). However, the overall evidence does not suggest major 
pharmacokinetic changes when the two drugs are given in combination (22).
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Both Berenbaum and Tallarida advise to analyze drug interactions with the isobologram 
method (17, 238). The problem with this method is that it only visualizes the interaction and 
that no statistical inference is given. Bourgeois used a method to quantify the difference 
between mono- and polytherapy, namely the fractional effective concentration (FEC). The 
FEC is the ratio between the concentration o f a drug in combination with another drug and 
the concentration at which the drug alone achieves the same effect. W hen the two FEC 
values o f the two drugs are added the FEC index is obtained. An additive interaction exists 
if  the FEC index is between 0.7 and 1.3. If the FEC index is below 0.7, there is supra- 
additivity, and an FEC index over 1.3 indicates infra-additivity. This method quantifies the 
isobologram method but still does not use statistics to prove interaction because the border 
values are arbitrary and do not take into account the variance o f the measurements.
The expected regression curve o f the combination therapy is calculated by entering the TD50 
of both compounds and the ratio which was applied in the experiment into equation 2. Thus 
we create points with variance that can be compared to actually measured points using 
statistical evidence by 95% CI which is analogous to statistical testing with a p value of
0.05. W oolverton and Balster used linear regression by using only the linear portions o f the 
dose-effect curves and they also determined 95% confidence intervals (270). In our study 
non-linear regression was used, which enables us not only possible to say something about 
the middle o f the curve, but also about the extremes o f the curve, where for example the 
TD10 is located. In future experiments therapeutic effects will also be measured, and this 
might enable us to calculate the TD 10/ED90 ratio. The TD50/E D 50 ratio and the TD10/ED90 
ratio are not necessarily equal and the latter ratio may be o f more relevance as it approaches 
the goals set in clinical practice better.
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5.2 Monotherapy versus polytherapy in the WAG/Rij model of epilepsy
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Introduction
The methodology described in paragraph 5.1 provides a statistical basis for the isobologram 
method (208). Furthermore, three tests for neurotoxicity were evaluated. In the present study 
efficacy and toxicity o f the same therapeutic regimens as used in paragraph 5.1 will be 
evaluated in the WAG/Rij rats, a model o f human absence epilepsy. The WAG/Rij strain 
is an inbred genetic rat strain that spontaneously develops spike-wave discharges (SWDs) 
in the first 12 months o f its life, which can be visualized by EEG. The SWDs resemble the 
spike-wave discharges seen in human absence epilepsy (161). During drug efficacy studies 
in these rats the number o f SWDs, and not the clinical phenom ena that accompany the 
SWDs, are taken as outcome measure. The WAG/Rij rat also shares its pharmacological 
profile with human absence epilepsy (193).
Methods
Animals
Male adult WAG/Rij rats, approximately 9 months o f age and weighing between 300 and 
342 grams, were used for this experiment. They were housed in identical plastic cages and 
had free access to food and water during the experiments. They were kept on a reversed 
light dark cycle (dark between 9.00 en 21.00 hours).
A tripolar EEG-electrode (Plastic Products Company, The Netherlands) was placed on the 
surface o f the cortex: one in the frontal region (coordinates with skull surface flat and 
bregma zero-zero: A2.0 L3.5) and a second one in the parietal region (A6.0 L4.0). The 
ground electrode was placed over the cerebellum. Following surgery, subjects were allowed 
to recover for at least two weeks before the start o f the experiment.
Drugs
Valproate (Albic Inc. Maassluis, The Netherlands) and ethosuximide (Sigma chemical co., 
The Netherlands), dissolved in 0.9% sodium chloride, were administered intraperitoneally 
alternating left and right to prevent adhesions.
Experiment
The 16 animals were divided in four groups of four rats, which received every therapeutic 
regimen for one week during the 8 week experiment. Groups 1 and 2 were used in weeks
1, 3, 5 and 7. Groups 3 and 4 were used during weeks 2,4, 6 and 8. The experiment schedule 
is shown in table 5.2a.
98 Chapter 5
Table 5.2a Week schedule ofthe experiment
Group 1 Group 2 Group 3 Group 4
Week 1 VPA ESM
Week 2 VPA + ESM control
Week 3 ESM VPA + ESM
Week 4 control VPA
Week 5 VPA + ESM control
Week 6 VPA ESM
Week 7 control VPA
Week 8 ESM VPA + ESM
During treatment weeks each rat received their assigned treatment in ascending dosages. For 
example, during the valproate week the rats received the zero-dose the first day, 100 mg/kg 
the second day, 140 mg/kg the third day, 200 mg/kg the fourth day and 280 mg/kg the fifth 
day. In the ethosuximide week the dosages given were 0 mg/kg, 14.3 mg/kg, 20 mg/kg, 28.6 
mg/kg and 40 mg/kg. In the polytherapy group the dosages of VPA/ESM were 0/0 mg/kg, 
50/7.14 mg/kg, 70/10 mg/kg, 100/14.3 mg/kg and 140/20 mg/kg respectively. During the 
control week the animals received a saline injection each day. The ratio of valproate and 
ethosuximide were based on their ED50 (in this case the amount of drug causing 50% of 
maximum effect) found in a pilot experiment.
On each test day, the animals were placed in observation cages of 30 by 30 by 50 cm and 
a minimum of light was used to keep them in an active state. Baseline EEG was recorded 
for two hours. After drug injection, another four hours of EEG were recorded.
For each rat, the number and mean duration of spike-wave discharges before and after 
injection were measured on all its test days, according to criteria reported elsewhere (161). 
Briefly, trains of spike-waves with a spike (peak) amplitude of at least twice the background 
EEG and a duration of at least 1 second were assigned as spike-wave discharges.
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Serum levels
To control for pharmacokinetic interactions, a separate experiment was carried out. Animals 
in group I received 28.6 mg/kg ESM  and animals in group II received 200 mg/kg VPA. 
Blood was collected from the tail o f animals 40 minutes after drug administration and serum 
levels were determined by gas chromatography.
One week later all animals received both 28.6 mg/kg ESM  and 200 mg/kg VPA. Blood was 
collected from the tail o f animals 40 minutes after drug administration; in group I ESM 
serum levels were analyzed and group II VPA serum levels were analyzed.
Data analysis:
EEG data were analyzed by non-linear regression analysis using the program Graphpad 
Prism 2.0. The data were fitted to the sigmoid Emax model and the ED 50 ‘s and H ill’s with 
their respective confidence intervals calculated for the different treatment regimens. The 
theoretical additive curve was generated for the drug combination using the sigmoid Emax 
model for a mix o f two compounds according to the equations used in paragraph 5.1 (208). 
The experimental parameter estimates o f the drug combination were compared to the 
theoretical additive parameter estimates using the 95% confidence intervals. The curves of 
valproate and o f ethosuximide were normalized using their ED 50s. The curve o f the 
experimental combination was normalized using the ED 50 o f the theoretical additive 
combination and the ED50 parameter estimates obtained by the sigmoid Emax model were 
plotted in an isobologram to visualize the type o f interaction (17, 238).
Results
All rats showed spontaneously occurring spike-wave discharges in their cortical EEG and 
were used throughout the experiment. Every test day the EEG was recorded two hours pre­
injection and a group x day analysis o f variance was performed on these data: there were 
no significant group or day effects.
The pre-injection number o f spike wave discharges per hour averaged at 18, with a standard 
deviation o f 8. In the first 15 minutes post-injection the number o f spike waves was very 
variable: it averaged at 17 SWD/hour and the standard deviation was also 17. As efficacy 
seemed to decline after 75 minutes at lower dosages it was decided to take the 15 to 75
minute post-injection interval as the time frame to assess efficacy from. As the baseline 
number o f SWDs per hour varied, the number o f SWD/hour post-injection was divided the 
number of SWD/hour pre-injection and thus the animals served as their own controls. These 
percentage data were used for further analysis.
Efficacy
Both compounds as well as the combination reduced the number o f SWDs in a dose 
dependent way. The sigmoid Emax model, was fitted to the data, yielding the ED50 and the 
Hill o f the various regimens (table 5.2b). W ith these parameter values o f the single drugs 
the theoretical ED50 for the drug combination was calculated using the isobologram method. 
The experimental dose needed to get 50% efficacy in the combination experiment is higher 
than the theoretical additive ED 50, suggesting infra-additivity for efficacy. As the confidence 
intervals overlap, this finding is not statistically significant.
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Table 5.2b Efficacy ofvalproate and ethosuximide, alone and in combination.
VPA ESM VPA/ESM theoretical additive ED50
ED50 (mg/kg) 174.5 23.2 114.1/16.3 84.3/12.0
95% CI 136.6 - 223.0 20.44 - 26.34 100.2/14.3 -130.0/18.6 74.0/10.5 - 100.9/14.4
dose/ED50 1 1 0.65/0.70 0.48/0.52
Norm. ED50 1 1 1.35 1
Hill -3.4 -2.4 -3.7
95 % CI -6.4 - -0,4 -3.4 - -1.5 -5.5 - -1.8
Parameter estimates of fitting the sigmoid Emax curve to the data. The ED50 is the dose at which the number 
of SWDs per hour is reduced by 50%. All weight values are normalized using the ED50 values. The 
experimental combination value uses the theoretical additive ED50 as norm. A normalized ED50 (Norm. ED50) 
of the experimentally determined combination below 1 points to supra-additivity whereas more than 1 
indicates infra-additivity. If the 95% confidence intervals of the normalized ED50 of the experimental 
combination do not overlap with the intervals of the theoretical additive ones than the interaction is assumed 
to be statistically significant. Hill is a measure for the steepness of the curve.
The normalized dose response curves o f the drugs are shown in figure 5.2.a.
Figure 5.2a Normalized dose-response curves for ethosuximide, valproate and their 
combination
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Dose response graphs for the change of spike wave discharges (SWD)in rats following injection of valproate 
(open circles), ethosuximide (open squares) or of the combination of both (closed circles), after fitting the 
sigmoid Emax model to the data. All weight values are normalized using the ED50 values. The experimental 
combination value uses the ED50s of the individual drugs as norm. The normalized drug doses (dose/ED50) 
are plotted on the abscissas and the SWD data on the ordinate. ED50 values (table 5.2b) were obtained by 
fitting the sigmoid Emax model (equation 1) to the data.
The isobologram visualizes that the confidence intervals o f the theoretical additive ED 50 and 
the experimental ED50 o f the combination, do overlap, as is shown in figure 5.2b
Figure 5.2b Isobologram for a 50% reduction in spike wave discharges of WA G/Rij rats 
by a combination of ethosuximide and valproate
-3  1 .0  1 .35
dose (mg/kg)
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Analysis o f variance did not show any significant differences in serum levels o f ESM  or
2 Ô .6  m g / k g  2 0 0  m g / k g
VPA in the presence of the other drug.
Discussion
Our results indicate that the efficacy of the VPA/ESM  combination tended to be infra­
additive, although this did not reach statistical significance. In two previous studies the 
efficacy o f this combination was studied in the pentylenetetrazole (Ptz) model, a model 
which represents absence and myoclonic seizures (197, 250). Bourgeois et al. found the 
combination to have an additive “anti-Ptz” effect, while M usolino et al. found a supra­
additive interaction. The isobologram method was used in the former study, but not in the
latter one. Rowan et. al. described five patients with refractory absence seizures who 
became seizure-free only after receiving this combination (217).
A first explanation for the differences in results may be offered by the differences in animal 
model and species. Although the WAG/Rij rat and the Ptz model are both considered to be 
models for human absence epilepsy, the models do differ in doses needed for their effects 
and there are some differences in their pharmacological profiles (145, 239). There are also 
pharmacokinetic issues to consider: during treatment weeks animals were used for five 
consecutive days and some drug accumulation may be suspected. However, no day effects 
were found. We can not shed more light on these differences either by looking at the 
mechanism of action of the two drugs, as it is uncertain by which mechanism VPA blocks 
absence seizures. Coulter et al. have shown that ESM reduces the low-threshold (T-type) 
calcium current of thalamic neurons at clinically relevant concentrations and this 
mechanism is generally accepted to be responsible for ESM’s anti-absence effect (162). 
Valproate was shown not to have this effect, but it does block T-type calcium currents in 
afferent neurons (162, 163). Löscher has contended that VPA‘s effect of enhancing nerve 
terminal GABA in the substantia nigra may explain its efficacy in a variety of epilepsy 
types, including absence epilepsy (157). Another explanation for VPA’s anti-absence effect 
could be its inhibition of the formation of y-hydroxybutyrate, a GABA-metabolite which 
has been shown to produce absence-like effects in several species (157).
However, when the results of the studies of both our studies are taken together, they are 
quite similar to the findings of other researchers. Bourgeois et al. found that efficacy was 
additive in Ptz-treated mice, but that toxicity was infra-additive (250). Rowan et al. were 
not able to control absence seizures with VPA at maximal dosages, and the addition of ESM 
to VPA resulted in seizure freedom in five patients (217). The VPA dosage was not reduced 
in these patients, bit apparently it was possible to add ethosuximide without producing 
unacceptable adverse effects (in one patient the VPA dose was reduced, but this had to be 
reversed because of renewed seizures). In accordance with these data additivity for efficacy 
was found in the present study (although marginal), and infra-additivity for toxicity in the 
study described in paragraph 5.1. When toxicity is reduced without reducing efficacy, it 
enables the physician to use higher drug loads than was possible in monotherapy, in an 
attempt to increase seizure control. In conclusion, the studies described in this chapter do 
suggest possible advantages of the use of the valproate-ethosuximide combination.
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C hapter 6 C om bination therapy in epilepsy patients
In this chapter a clinical trial is described, in which the combination o f carbamazepine and 
valproate was compared to carbamazepine monotherapy. As this trial was aimed at 
evaluating the effectiveness of polytherapy for adult patients with newly diagnosed epilepsy, 
a different combination o f AEDs was used than the one in the previous chapter. The 
majority o f patients with adult-onset epilepsy have symptomatic or cryptogenic partial 
epilepsy, and they are usually prescribed either carbamazepine or valproate in the 
Netherlands.
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6.1 Double-blind randomized trial comparing carbamazepine plus valproate 
against an equal drug load of carbamazepine in untreated adult epilepsy 
patients 
Introduction
Reynolds and Shorvon showed in 1979 that when the number of antiepileptic drugs (AEDs) 
was reduced to one in selected patients using polytherapy, these patients had fewer adverse 
effects and sometimes even better seizure control (229). This finding was confirmed by 
other researchers; a few representative examples are cited in the reference list (1, 218, 245). 
In 1995 however, Devinsky suggested that these studies had not been optimally designed: 
small groups of patients who were doing poorly with polytherapy were switched to 
monotherapy; selection was not randomized and factors such as changes in blood levels 
were often not controlled (59). He claimed that if  a small group of patients doing poorly on 
monotherapy were converted to low-dose polytherapy, the outcome of such a study would 
likely support polytherapy over monotherapy. Indeed, such a study was published two years 
later: a selected group of patients did much better after the switch from monotherapy to low- 
dose polytherapy (23).
The aim of the present study is to compare monotherapy to combination therapy in a multi­
center double-blind clinical trial of adult-onset epilepsy patients, with patients starting off 
on equal drug loads. The combination of carbamazepine (CBZ) and valproate (VPA) was 
selected because this combination was found to be effective in patients who had an 
unsatisfactory response to monotherapy in a number of open non-randomized studies (10, 
52, 84, 104, 258). The planned time frame and expected inclusion rate in the present trial 
did not allow for two monotherapy groups. Choosing between CBZ and VPA for 
monotherapy, CBZ was selected based on the largest trial comparing CBZ and VPA to 
date, in which CBZ was more efficacious against complex partial seizures than VPA whilst 
being equally efficacious against generalized tonic-clonic seizures, and in which the 
incidence of sedation (42% each), change in affect or mood (24% CBZ vs 25% VPA) and 
cognitive disturbance (18% each) were similar (173). Our main hypothesis is that the 
combination of low doses of CBZ and VPA will have less neurotoxic adverse effects than 
CBZ monotherapy, as measured with the Composite Index of Impairments (CII).
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Methods
Population: The trial was initiated in July 1995. The inclusion criteria were: adult patients 
with untreated generalized tonic-clonic, complex partial and/or simple partial seizures; an 
accurate history including adequate neuro-physiological data for a firm diagnosis; well- 
defined types of seizures according to the International Classification of Epileptic Seizures 
(40); age 18 years and older. Criteria for exclusion were: not satisfying the inclusion 
criteria; inability to give informed consent (e.g. language or cultural barrier); absence 
seizures; juvenile myoclonic epilepsy; acute or progressive neurological disorders; alcohol 
or other substance abuse; psychiatric diseases; mental retardation.
Procedure of the trial: Neurologists of 17 hospitals in the vicinity of Nijmegen and of the 
Nijmegen University Hospital, identified eligible patients who needed AED treatment. 
When the patient had given written consent, after being adequately informed, the clinician 
alerted the principal investigator (C.L.P.D.). The principal investigator then interviewed and 
tested patients in their own hospital, using the clinimetric and neuropsychological methods 
described below. Subsequently patients started with their trial medication. There was 
general agreement between the participating neurologists that patients would start on a 
maintenance dose of 0.4 PDD/DDD; neurologists were allowed to deviate from this in 
individual cases. The dose was titrated from 0.1 PDD/DDD in the first week and 0.2 
PDD/DDD in the second week to 0.4 PDD/DDD (table 6.1a).
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Table 6.1a Dosage titration schedule for monotherapy and polytherapy groups
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Morning Evening
Monotherapy 1st week 
0.1 PDD/DDD
- 1 CBZ 100 mg verum
2nd week 
0.2 PDD/DDD
1 CBZ 100 mg verum 
1 VPA 150 mg placebo
1 CBZ 100 mg verum 
1 VPA 150 mg placebo
from 3rd week 
onwards 
0.4 PDD/DDD
2 CBZ 100 mg verum 
1 VPA 150 mg placebo
2 CBZ 100 mg verum 
1 VPA 150 mg placebo
Polytherapy 1st week 
0.1 PDD/DDD
- 1 CBZ 100 mg verum
2nd week 
0.2 PDD/DDD
1 CBZ 100 mg verum 
1 VPA 150 mg placebo
1 CBZ 100 mg placebo 
1 VPA 150 mg verum
from 3rd week 
onwards 
0.4 PDD/DDD
1 CBZ 100 mg verum 
1 CBZ 100 mg placebo 
1 VPA 150 mg verum
1 CBZ 100 mg verum 
1 CBZ 100 mg placebo 
1 VPA 150 mg verum
DDD carbamazepine 1000mg; DDD valproate 1500 mg
During the trial the neurologist could change the dosage, in terms o f PDD/DDD fractions, 
when clinically necessary. Patients participating in the trial had scheduled evaluation points 
after 2 and after 12 months. Between these scheduled evaluation points patients were 
interviewed and examined by the principal investigator at irregular intervals, depending on 
seizure frequency and AED toxicity. During the year o f their participation in the study the 
patients were seen at least four times by the principal investigator. The procedures followed 
were in accordance with the ethical standards of the medical ethical committees of all the 
hospitals involved and with the Helsinki Declaration o f 1975.
Assignment and Blinding procedure: Random numbers were linked to monotherapy or 
polytherapy by an unblinded observer at the SEIN (Stichting Epilepsie Instellingen 
Nederland), an epilepsy center in Heemstede, the Netherlands. Each patient included 
received the next available number from one onwards. The principal investigator, treating 
neurologists and patients were blinded to the randomization code. An envelope containing 
the code was kept in the patient’s medical file for emergencies. Sanofi (Paris, France)
supplied enteric-coated VPA and placebo-VPA 150 mg tablets. Katwijk Farma (Katwijk, 
the Netherlands) supplied CBZ and placebo CBZ 100 mg tablets. The drugs were packaged 
in strips of plastic dispensed by an Automatic Tablet Counter (Baxter) at the SEIN and were 
placed in randomly numbered paper bags; the paper bags and plastic strips were marked 
with the dose in PDD/DDD fractions but not whether the dose contained one or two active 
drugs. The principal investigator was told by the unblinded observer which numbered paper 
bag to dispense to which patient.
Outcome measures: the following outcome measures were used: seizure diaries, the 
Composite Index of Impairments (CII), Q0LIE-10 and FePsy (7, 44, 266). These methods 
have been discussed in detail in chapters one and two.
Therapeutic drug monitoring: Serum levels were collected at the first control visit and after 
each change in drug load. Samples were analyzed by the laboratory of the SEIN using high 
pressure liquid chromatography (carbamazepine) and gas chromatography (valproate). The 
results were reported to the physician and the principal investigator in terms of the observed 
serum level divided by the average therapeutic level (OSL/ATL ratio) (thus leaving the 
blinding procedure intact) (133). Laboratory tests such as liver function and hematological 
tests were done at the first control visit and after every dose change.
Statistics: Sample size calculation was based on the NTX scores, as differences between the 
two treatments were expected especially in neurotoxic effects. With 55 patients in each 
treatment group, the study had a power of 80% and a significance level of 0.05 to show a 
difference of 10 points in NTX-score between treatments.
Wilcoxon tests and paired t-tests were used to compare outcome measures. Three analyses 
were performed: an analysis of patients completing the trial; a ‘per protocol’ analysis oftrial 
completers and treatment failures; an ‘intention-to-treat’ analysis of all patients that had 
completed one follow-up visit. The Kaplan-Meier method was used to compare retention 
time between treatments in the ‘per protocol’ and the ‘intention-to-treat’ groups. Analysis 
of variance was used to analyze changes in the FePsy test results.
Results
Descriptions of the study groups
The 130 enrolled patients were either patients with newly-diagnosed epilepsy or known 
epilepsy patients not on AEDs for the past two years, who had suffered a relapse. Of these
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130, five patients were excluded from the analysis: in the monotherapy group two patients 
elected not to participate after the baseline visit. Another two patients did start their 
allocated treatment, but their neurologists were forced to break the code due to pre-existing 
cardiologic conditions before the first follow-up visit. In the polytherapy group one patient 
died of brain metastasis before the first follow-up visit and should not have been 
randomized. Thus, 125 patients were included in the intention-to-treat analysis; figure 6.1a 
is a flow diagram presenting the progress of the trial through its various stages.
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Figure 6.1a Flow diagram ofthe progress ofthe trial
Reasons for not receiving treatment, treatment failure or protocol violation are given in the text.
In the monotherapy group there were nine protocol violators: three non-compliant patients;
two patients with juvenile myoclonic epilepsy; two patients with alcohol abuse; two patients
that left the trial for other medical conditions (hepatitis B infection and meningeoma). Of
the non-compliant patients, one was later lost to follow-up, one restarted carbamazepine
treatment after seizure recurrence and one was started on valproate monotherapy after
seizure recurrence.
In the polytherapy group there were six protocol violators: two patients got pregnant (did 
not use oral contraceptives or other birth control despite warnings about possible teratogenic 
effects; both have delivered healthy babies); one patient with atypical absence seizures; one 
patient with dizzy spells who turned out to have obstructive sleep-apnea syndrome; one 
patient with brief episodes of altered consciousness who later was found not to have 
epilepsy; one patient who was transferred to a nursing home and was given carbamazepine
monotherapy by the resident physician. Four polytherapy patients were lost to follow-up; 
one of these patients died of a lung carcinoma. The demographic characteristics of the 125 
patients included in the analysis are summarized in table 6.1b.
112 Chapter 6
Table 6.1b Baseline characteristics of study participants
Monotherapy Polytherapy
Total 59 66
Sex: - male 
- female
35 (59%) 
24 (41%)
40 (61%) 
26 (39%)
Age at onset of epilepsy: - mean
- median
41
37
38
35
Previous brain injury 28 (47%) 30 (45%)
Lesions on brain imaging 16 (27%) 21 (32%)
Education: - Elementary/Prevocational
- Junior general secondary/ Senior secondary vocational
- Senior general secondary/ Higher professional
- Pre-university/University
27 (46%) 
20 (34%) 
9 (15%) 
3 (5%)
39 (59%) 
15 (23%) 
9 (14%) 
3 (4%)
Seizure types: - generalized tonic clonic seizures
- complex partial seizures
- simple partial seizures
50 (85%) 
11 (19%) 
6 (10%)
47 (71%) 
20 (30%) 
8 (12%)
There were no statistical differences in the demographic characteristics between the 
treatment groups. In the monotherapy and polytherapy groups respectively 6 and 4 patients 
had taken AEDs in the past.
Clinimetric scores
The seizure activity (SA), neurotoxicity (NTX), systemic toxicity (STX), Composite Index 
of Impairments (CII) and QOLIE-10 scores did not show significant differences between 
the two treatment groups after two or twelve months of treatment in any of the three 
analyses. The polytherapy group did have a higher baseline CII, but the CII scores of the 
study groups were almost equal after twelve months. The SA, NTX, STX, CII and QOLIE- 
10 scores at baseline, 2 and 12 months are shown in table 6.1c for patients that completed 
the trial.
Table 6.1c Average clinimetric scores per treatment group ofpatients that completed 
the trial (in parentheses data the median data are shown)
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Monotherapy
(n=37)
Polytherapy
(n=47)
Monotherapy
(n=37)
Polytherapy
(n=47)
baseline SA 43.6 (40) 54.7 (40) baseline CII 56.1 (53) 65.7 (54)
2 month SA 19 (0) 3.1 (0) 2 month CII 22.4 (20) 22.4 (20)
12 month SA 0.8 (0) 4.0 (0) 12 month CII 13.4 (10) 13.6 (10)
baseline NTX 11.5 (10) 10.3 (10) baseline QOLIE 17.2 (17) 16.9 (17)
2 month NTX 18.2 (15) 15.0 (13) 2 month 
QOLIE
17.9 (17) 18.1 (17)
12 month NTX 9.2 (5) 6.8 (5) 12 month 
QOLIE
15.8 (15) 15.9 (15)
baseline STX 0.9 (0) 0.7 (0)
2 month STX 2.4 (0) 4.5 (0)
12 month STX 3.4 (0) 4.3 ()
The average median clinimetric score are given in parenthesis
The changes compared to baseline of the overall QOLIE-10 score did not show significant 
differences between treatment arms. At baseline the answer to Question-1 of the QOLIE 
(‘Have you had a lot of energy ?’) differed significantly in favor of the monotherapy group, 
but this was not the case at follow-up visits. The answer to Question-10 (‘How has the 
quality of your life been during the past 4 weeks; that is, how have things been going for 
you ?’) was also more favorable for the monotherapy group at baseline, but this did not 
reach significance. When the 2 month-measurement for this question was compared to the 
baseline visit, there was an improvement which was significantly greater in the polytherapy 
group, the scores now being about equal in both groups. There were no other significant 
differences in the individual QOLIE-10 questions or overall QOLIE-10 score between the 
mono- and polytherapy groups in any of the analyses.
Efficacy
In both treatment arms seizure frequencies were reduced successfully, without statistical 
differences between the two treatments in any of the three analyses (analysis of patients that 
completed the trial, ‘per protocol’ analysis and intention-to-treat analysis). In both treatment 
groups the percentage of seizure free patients was much higher in patients with generalized 
tonic-clonic seizures than in patients with partial seizures. In table 6.1d the seizure 
frequencies and numbers of seizure free patients are shown per seizure type for the group 
which completed the study (n= 84). Seizure free patients are patients who did not have any
seizures for at least three months on the dose they were using at the end of the trial.
In the polytherapy group there was one patient in which the dose was elevated to 1.6 
PDD/DDD (= 800 mg carbamazepine plus 1200 mg of valproate). At this dose the patient 
still had 2 complex partial seizures per month (baseline frequency 12/month). The highest 
drug load given in the monotherapy group was 0.8 PDD/DDD (800 mg/day), which was 
used by two patients. Both patients became seizure free at this drug load.
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Table 6.1d Seizure frequencyandpercentage of responders (patients that completed the 
trial)
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Group
(number of patients)
Baseline seizure 
frequency 
(per month)
12 months seizure 
frequency 
(per month)
% seizure free 
at
12 months
Mono GTCS (33) 0.4 0.003 94%
Poly GTCS (34) 1.6 0.01 85%
Mono CPS (5) 4.6 0.01 80%
Poly CPS (14) 6.2 0.47 50%
Mono SPS (5) 5.4 0.02 40%
Poly SPS (4) 13.4 0.58 50%
Mono overall (37) 1.7 0.02 86%
Poly overall (47) 3.9 0.21 74%
Seizure frequencies per month. GTCS: generalized tonic-clonic seizures; CPS: complex partial seizures; SPS: 
simple partial seizures
Table 6.1e shows the distribution of dosages in PDD/DDD ratio’s for both treatment groups 
at the end of the trial.
Table 6.1e Distribution ofdosages of patients that completed the trial
Group 0,4 0,6 0,8 1,2 1,6
(number of patients) PDD/DDD PDD/DDD PDD/DDD PDD/DDD PDD/DDD
Monotherapy (n=37) 28 8 1 - -
Polytherapy (n=47) 37 5 3 1 1
Adverse effects
Individual adverse effects were actively sought after by use of the NTX and STX scales. In 
table 6.1f the frequency and clinimetric score of each adverse effect at baseline and at two 
months are shown for patients that completed the trial.
Table 6.1f Frequency ofadverse effects at baseline, two months and 12 months for the 
two treatment arms
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Adverse effect Mono 
baseline % 
(n=37)
Mono 2 mth 
toxicity % 
(n=37)
Mono 12 mth 
toxicity % 
(n=37)
Poly baseline 
% 
(n=47)
Poly 2 mth 
toxicity % 
(n=47)
Poly 12 mth 
toxicity % 
(n=47)
Diplopia 0% 3% 0% 2% 2% 0%
Nystagmus 0% 0% 0% 0% 0% 0%
Dysarthria 8% 5% 3% 6% 2% 0%
Gait 8% 22% 0% 11% 11% 2%
Rapid
alternating
movements
3% 3% 0% 0% 0% 0%
Tremor 0% 0% 0% 2% 2% 2%
Sedation 16% 57% 41%* 21% 53% 15%*
Affect and mood 
disturbances
35% 43% 38% 32% 45% 16%
Cognitive
impairments
46% 51% 32% 32% 43% 26%
Dizziness 8% 24% 5% 19% 21% 2%
Headache 30% 14%* 11% 30% 32%* 2%
Other
neurotoxicity
0% 3% 0% 0% 0% 1%
Gastro-intestinal
complaints
14% 11% 13% 6% 15% 5%
Hematopoietic
disturbances
0% 0% 0% 0% 0% 0%
Skin reactions 0% 5% 0% 0% 4% 0%
Impotence 0% 0% 3% 0% 2% 0%
Hyponatremia 0% 0% 0% 0% 0% 0%
Abnormal liver 
function tests
0% 0% 0% 0% 0% 0%
Weight change 0% 3% 0%* 0% 11% 10%*
Hair loss/ 
hirsutism
0% 11% 11% 4% 2% 8%
Other systemic 
toxicity
0% 5% 0% 0% 6% 3%
The frequencies per adverse effect, at baseline, 2 months and 12 months as measured with the Composite 
Index of Impairments. Frequencies that differ significantly are marked with asterisks
In all three analyses statistically significant differences were found in frequency or average 
severity of separate adverse effects (not corrected for multiple comparisons): in the 
monotherapy group the proportion of sedated patients and the clinimetric score for sedation 
(absolute score and score relative to baseline) were significantly higher after 12 months. In
the polytherapy group the number of patients with headache was higher at two months but 
this difference had disappeared at twelve months (the headache severity score did not differ 
between treatments at any time). After twelve months the frequency and the severity score 
of weight change were significantly higher in the polytherapy group.
In the monotherapy and polytherapy groups 13 and 9 patients respectively withdrew because 
of adverse effects. In table 6.1g the adverse effects leading to withdrawal are shown. Most 
treatment failures were due to two or more adverse effects and therefore there are more than 
22 adverse effects shown.
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Table 6.1g Adverse effects leading to treatment failure
ataxia sedation affect/
mood
disturbance
memory
impairmt
dizziness headache gastro­
intestinal
complaints
rash weight
gain
Monotherapy 
(13 patients)
2 5 5 5 2 1 2 4 0
Polytherapy 
(9 patients)
1 4 6 4 0 2 2 1 1
There was a higher number of rash-related treatment failures in the monotherapy group, 
although this did not reach statistical significance. The overall higher frequency of rash 
observed in the monotherapy group is not reflected in table 6.1e, which only concerns 
patients who completed the trial.
Retention time
The Kaplan-Meier graph of the time to withdrawal (figure 6.1b) suggests that patients on 
monotherapy were more likely to withdraw before patients on polytherapy, especially in the 
first two months. However, this did not reach statistical significance (Mantel-Haenszel test 
p=0.16). The hazard ratio was 1.83 and its 95% confidence intervals was 0.79-4.26.
Figure 6.1b Survival curve for patients staying on treatment
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Patients often had better performances on the tests after the baseline visit, as is shown in 
table 6.1h. The repeated measures analysis of variance of the test results did not show 
significant differences between the treatment groups in any of the three analyses. There 
were a few individual patients that performed worse after treatment start, but this was 
without significant difference between treatments.
Table 6.1h FePsy data for the intention-to-treat group
BASELINE 2 MONTHS 12 MONTHS
Monotherapy tapping 
dominant hand
63 62 62
Monotherapy tapping 
non-dominant hand
57 56 59
Monotherapy BCH reaction 
time
533 485 458
Monotherapy CVST 12 11.8 10.7
Polytherapy tapping 
dominant hand
60 61 59
Polytherapy tapping 
non-dominant hand
56 57 54
Polytherapy BCH 487 464 433
Polytherapy CVST 13.8 13.1 11.1
Dosages/serum levels
The average serum levels and drug loads (expressed in PDD/DDD and OSL/ATL) at two
months, twelve months and at time of treatment failure are shown in table 6.1i.
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Table 6.1i Average serum levels and drug loads
Group Mono 
2 months 
(n=47)
Poly 
2 months 
(n=61)
Mono 
12 months 
(n=37)
Poly 
12 months 
(n=47)
Mono
treatment
failures
(n=7*)
Poly
treatment
failures
(n=8*)
PDD/DDD 0.4 0.4 0.45 0.49 0.4 0.44
CBZ (mg/l) 5.4 3.4 5.5 3.4 5.8 3.7
CBZ-E (mg/l) 0.57 0.33 0.49 0.33 0.69 0.33
VPA (mg/l) - 20 - 21 - 20
OSL/ATL 0.77 0.77 0.79 0.79 0.83 0.81
CBZ-E = carbamazepine epoxide; * = in some cases of treatment failure, no serum level sampling was 
performed
Serum level sampling times depended on the appointments between the principal 
investigator and patients, and thus were not standardized. The average sampling times were 
4.08 hours ± 2.27 and 4.10 hours ± 2.27 for mono- and polytherapy respectively.
Discussion
We did not find a clinically significant difference in NTX scores between monotherapy and 
polytherapy, which the study was powered to do. It is important to note that the study was 
not designed to show differences in efficacy, and differences in efficacy were not expected 
to be found as they are almost never found in clinical trials of newly-diagosed epilepsy 
patients. One can however also look at effectiveness, which is a measure expressing both 
efficacy and toxicity. The Commission on Antiepileptic Drugs of the International League 
Against Epilepsy considers retention time to be the most clinically relevant endpoint of 
AED trials, as it is a measure for effectiveness (115). In our study the difference in 
retention time did not reach statistical significance, but chances of withdrawal from 
treatment tended to be lower for the polytherapy group. The results of this trial suggest that 
low doses of two drugs may be as efficacious but less toxic than a full dose of a single drug 
(i.e. at equal drug loads). This is remarkable, as polytherapy has been reputed to cause 
increased toxicity. The pharmacological explanation for the lesser toxicity of polytherapy 
may be that dose-related adverse effects of both drugs are not caused by the same
mechanism of action, and thus may be milder because of the lower dosages and serum 
levels of the individual drugs (69).
It is unknown whether the mechanisms of action held responsible for the anticonvulsant 
effects of these AEDs, are also the mechanisms by which their adverse effects are caused. 
For VPA, there is even uncertainty which is its main anti-convulsant mechanism of action: 
its GABA effects or its sodium channel blocking properties (2, 149, 179, 261). A study by 
Liljequist and Engel suggests that VPA ‘s adverse effects are mediated through 
differentiated mechanisms at the GABA-benzodiazepine-ionophore complex, as was 
already discussed in chapter 5 (144). The anticonvulsant effects of CBZ are thought to be 
mediated mainly through its sodium channel-blocking properties, but CBZ has also been 
shown to have GABAergic and anti-glutamatergic effects (97, 257). The mechanism behind 
CBZ’s adverse effects is unknown. Thus it is reasonably clear that CBZ and VPA’s anti­
convulsant mechanisms of action have some differences, but also some overlap. As for their 
adverse effects, the results of our clinical trial suggest that there is a sufficient difference 
in the mechanisms of the two drugs to result in infra-additive toxicity.
Actually, in most open trials of specific AED combination therapy high doses of two drugs 
are added together to achieve increased efficacy where one drug is not sufficient at 
maximally tolerated dosages. The increased efficacy of the combinations in these studies 
is usually accomplished because of a higher total drug load, which indicates that the adverse 
effects of these combinations are infra-additive (i.e. actually less than when the adverse 
effects were the result of the same drug load of a single drug).
In this context it is interesting that the efficacy measures did not show any statistical 
differences between the monotherapy and the polytherapy regimens. Unfortunately, the 
number of patients with complex partial seizures and the seizure frequencies these patients 
had differed between the two tretament groups. There were a few patients in the polytherapy 
group who proved difficult to treat, and although continuing treatment at twelve months, 
still had frequent seizures. The reason that these patients did continue their treatment is that 
the treatment did have some success, and particularly after dose changes. If the proportion 
of patients with complex partial seizures had been higher in both groups, it would have been 
possible to get a better impression about possible diiferences in efficacy for this seizure
type.
Nevertheless, despite higher baseline seizure frequencies, polytherapy reduced seizure
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frequency successfully for all seizure types, which is remarkable at a drug load of about
0.50. One could argue however that the actual drug loads are higher because the the DDDs 
for CBZ and VPA are rather high, being set at 1000 and 1500 mg respectively. This is 
corroborated by the fact that the OSL/ATL data indicate that the overall drug load expressed 
in serum levels is 0.8 instead of 0.5. In terms of serum levels, the relative proportion of 
CBZ in polytherapy was higher than VPA’s, which may be explained by CBZ’s induction 
of VPA’s metabolism (143). Moreover, valproate has been shown to inhibit CBZ 
metabolism, thus prolonging its elimination half life (166). Either way, one has to assume 
that for most polytherapy patients a low drug load of one of the drugs was sufficient or that 
the two drugs both contributed to the efficacy of the combination. The latter would be in 
agreement with animal experiments in which some AED combinations, such as the 
combination of valproate and carbamazepine, were shown to have additive efficacy (but 
infra-additive adverse effects) compared to the individual drugs (29).
Although there were no differences in overall NTX scores, significant differences were 
found for individual adverse effects. At the last visit significantly more monotherapy 
patients complained of sedation, one of the most important adverse effects of AEDs (39). 
More polytherapy patients appear to have developed tolerance for this adverse effect. 
Unfortunately, mechanisms of tolerance are still ill-understood. Significant differences were 
also found for weight gain (after twelve months) and for headache (only after two months). 
Weight gain is a well-known adverse effect of valproate, which has been associated with 
impaired oxidation of fatty acids (64).
Regarding systemic toxicity, the overall clinimetric score (STX) did not show significant 
differences between the groups. Valproate inhibits the epoxide hydrolase enzyme, and thus 
moderately increases the epoxide-to-CBZ ratio which probably does not enhance adverse 
effects in general, but may increase the chance of hypersensitivity reactions (226, 242, 
247). However, in this trial the number of patients with serious skin reactions and the 
absolute epoxide were higher in the monotherapy group (table 6.1h), and thus low-dose 
polytherapy may actually reduce the frequency of idiosyncratic drug reactions. It is also 
possible that the higher CBZ titration rate in the monotherapy group is partly responsible 
for the higher number of rashes. As far as hepatotoxicity is concerned, only one patient in 
the polytherapy group developed both a rash and elevated liver enzymes. No significant 
differences were found using the quality of life scale.
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Using three tests of the FePsy battery, we were not able to find significant differences in 
neuropsychological functioning. Most patients did better when they were medication than 
at the baseline visit, which should be interpreted as training effects (W. Alpherts, personal 
communication). Most of the patients could be rendered seizure free easily, and therefore 
one may deem them to have “light” forms of epilepsy. Consequently, the dosages they took 
were low and this may all be responsible for the lack of deterioration in the tests results. 
Due to the unfavorable reputation that polytherapy has, which now seems unjustified, 
epileptology is lagging behind other disciplines in their knowledge of the merits of drug 
combinations. When two drugs or three drugs have failed as monotherapy, neurologists 
have no information as to which combinations they should prescribe. The only available 
data come from open trials in which some potentially advantageous combinations have been 
identified (34, 239, 258). More double-blind trials like the present one are needed to make 
an evidence-based choice when a monotherapy drug fails (even a first monotherapy drug). 
Using the concept of drug load could give some insight whether the increased effectiveness 
of a combination is due to an improvement in efficacy or tolerability: in case of improved 
efficacy, drug loads will be more or less equal between groups; in case of improved 
tolerability, it will be possible to increase the drug load in that treatment group more than 
in other treatment groups and thus achieve better efficacy.
In conclusion, the results of this study do not provide evidence that monotherapy is superior 
to polytherapy with antiepileptic drugs. In the case of carbamazepine and valproate, as 
shown by this study, improved effectiveness may be attained through improved tolerability. 
Both pharmacological and clinical studies of AED combinations are needed to develop 
evidence-based treatment algorithms.
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The following neurologists contributed patients for inclusion in the trial: Rijnstate 
Ziekenhuis Arnhem: dr. H.F.H Tacken
Maasziekenhuis Boxmeer: H.J. Friedericy, Mrs. Dr. A.M.H.G. van der Heyden-Montfroy 
St. Carolus Ziekenhuis ‘S Hertogenbosch: F.J.A. Cleven 
St. Deventer Ziekenhuizen: J.B.M. ten Holter
Stichting de Gelderse Vallei, Ede: P.H.P. Jansen, dr. M.G. Smits, dr. A.J.M. Vos 
Elkerliek Ziekenhuis Helmond: J.J.M. Hagemans
Sint Antonius Ziekenhuis Nieuwegein: Dr. S.T.F.M. Frequin, H.P. Siegers 
Sint Anna Ziekenhuis Oss: H.J. Mennema, dr. P.R. Schiphof 
St. Joseph Ziekenhuis Veghel: P.Th.M. van der Ham 
St. Joseph Ziekenhuis Veldhoven: J.A.P. Hiel, dr. B.J. van Kasteren 
Ziekenhuis Velp: dr. D.J. Lankamp, mrs. dr. M.B.M. Ruijs 
St. Elisabeth Ziekenhuis Venray: P.H.M. Pop, J.H.A. Wiezer 
Streekziekenhuis Koningin Beatrix Winterswijk: J.P. de Ruiter 
Streekziekenhuis Zevenaar: A. van der Steen, A.H.M. Hageman
Het nieuwe Spittaal Zutphen: K. van Baak, mrs. J.C. van Hemert-van der Poel, H.J.D. de 
Zwart
UMC Nijmegen: neurologists and residents of the neurology outpatient department
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Chapter 7 Discussion
In the preface the aims of this thesis were defined. These were:
1. To investigate whether drug load, rather than the number of antiepileptic drugs, is 
responsible for adverse effects.
2. To evaluate whether polytherapy is a good alternative for monotherapy when 
prescribed at equal drug loads.
3. To assess the possibility of selecting AED combinations by mechanisms of action.
4. To determine the best methodologies to evaluate polytherapy with antiepileptic 
drugs.
In this chapter we examine whether these aims have been achieved and if not, what remains
to be done. In the last paragraph the clinical relevance of the findings of this thesis is
discussed.
7.1 Is drug load, rather than the number of antiepileptic drugs, responsible for 
adverse effects ?
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One should not expect that either drug load or the number of AEDs will explain all the 
differences in adverse effects between patients using polytherapy and patients using 
monotherapy. There are well-recognized differences in mechanisms of actions and in 
adverse effect profiles between the standard AEDs. For example, GABAergic drugs such 
as benzodiazepines and barbiturates are well-known for their sedative effects and sodium 
channel blockers such as PHT and CBZ are known to cause ataxia when given in high 
dosages (122, 250). Furthermore, as Hönack and Löscher have shown that kindled rats are 
more susceptible to motor impairment induced by AEDs than non-kindled rats, the 
susceptibility of patients for AED-induced adverse effects may vary because of differences 
in the type and severity of their epilepsy (110). As patients that use polytherapy will 
generally have a more severe epilepsy, they may be more susceptible to the deleterious 
effects of AEDs. Nevertheless, polytherapy with AEDs is thought to be one of the factors 
that may increase adverse effects (203).
As was discussed in the preface and chapter 1, the Nijmegen Epilepsy Research Group had 
already performed a couple of studies on the relationship between adverse effects and drug 
load in epilepsy patients prior to this thesis (133, 135). The first study showed that 
polytherapy does not lead to more toxicity than monotherapy, when patients with equal total 
drug loads are compared (135). However, when the correlation between adverse effects and 
drug load (expressed by the PDD/DDD ratio and the OSL/ATL ratio) was evaluated in the 
second study, it was only marginal in both monotherapy and polytherapy patients (133). 
These studies did have the drawbacks that baseline values were not available and that most 
of the patients studied had been epilepsy patients for many years, and thus already had been 
using AEDs for a very long period. Nevertheless, another interesting result of these studies 
was that polytherapy patients had much higher average drug loads than monotherapy 
patients (133, 135). This was to be expected, as polytherapy is mostly used in difficult-to- 
treat patients, but it does support the assumption that drug load may just as well be the 
cause of higher toxicity in polytherapy patients.
In paragraph 3.1 published research papers were analyzed to evaluate whether drug load or 
the number of drugs determines toxicity in AED polytherapy. In those studies in which
medication was specified for each individual patient, the number of adverse effects was 
correlated more strongly with drug load than with number of AEDs. However, the 
correlation between number of adverse effects and drug load again only amounted to 0.41, 
which explains about 17% of the variance in number of adverse effects. In the other papers 
studied, where medication use could only be compared per group, drug load was 
consistently higher in patient groups which had more adverse effects.
In the animal experiment described in paragraph 5.1, both valproate and ethosuximide 
influenced the toxicity measures (grip-strength, accelerod and behavior) in a dose- 
dependent fashion. When these drugs were administered together toxicity as measured by 
the rotarod and the grip strength meter combined in an additive manner, whilst the negative 
effects on spontaneous behavior were infra-additive. Thus two AEDs produced less, instead 
of more, sedation than one AED.
In the double-blind clinical trial described in chapter 6, the PDD/DDD method was used 
to start patients off on the same drug load. This ensured us that drug load was not a factor 
in possible differences in efficacy and toxicity between the treatment groups at the start of 
the trial. However, the aim of that study was not to determine possible relationships 
between PDD/DDD, OSL/ATL and adverse effects, but to compare efficacy and adverse 
effects between mono- and polytherapy with AEDs. This meant that the drug load could be 
changed whenever clinically necessary, but that most patients remained at their initial daily 
drug load of 0.4.
As was shown in chapter 6, overall neurotoxicity and systemic toxicity did not differ 
between mono- and polytherapy. Only a few specific adverse effects did differ significantly, 
such as sedation, headache and rash, at selected points in time. It was in fact again 
polytherapy that tended to be tolerated better as less patients withdrew due to adverse 
effects, although this did not reach statistical significance.
Polytherapy has also been implicated in the occurrence of idiosyncratic drug reactions, such 
as serious skin reactions and hepatotoxicity. Regarding the CBZ-VPA combination, VPA 
has been found to increase CBZ epoxide levels, and these epoxides may be involved in the 
pathophysiology of rashes and the other dermatologic reactions (121, 226). However, 
epoxide levels in the polytherapy group stayed well below the epoxide levels in the 
monotherapy group (where the CBZ dose was twice as high) and a higher high number of 
serious skin reactions was found in the monotherapy group. Thus drug load (and/or a higher
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CBZ titration rate) proved to be more important than the number of drugs.
Generally speaking, it is more difficult to establish a relationship between drug load and 
adverse effects in humans than in animals, as the relationship between dose and effect 
varies considerably between individuals. For example, most patients that completed the trial 
still used the starting maintenance dose of 0.4 PDD/DDD, but the majority of patients who 
were withdrawn from treatment because of adverse effects, were also on that drug load. In 
animals, especially when using one genetic strain of animals, dose-effect studies can be 
readily constructed as these animals share (roughly) the same susceptibility for efficacy and 
adverse effects. Furthermore, animals in these studies receive the whole range of dosages, 
whereas in patients dosages are adjusted only when this is considered to be safe and 
clinically necessary.
Although we have not been able to answer question number 1 unequivocally, the studies 
described in paragraph 3.1 and in chapters 5 and 6 did show that drug load may be an 
important factor in determining the toxicity of an AED regimen. Moreover, these studies 
demonstrated the importance of taking drug load into account in the design and analysis 
of clinical trials. This will be commented upon further in paragraph 7.4.
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7.2 Is low-dose polytherapy a good alternative for monotherapy ?
In the studies described in chapters 5 and 6 this question was evaluated for two AED 
combinations (VPA-ESM in rats and VPA-CBZ for epilepsy patients). The results were 
quite similar for these two combinations, but there were some differences as well. The 
valproate-ethosuximide combination appeared to be infra-additive for efficacy, but this did 
not reach statistical significance. Combining two drugs with different mechanisms of action 
apparently is no guarantee for additive anticonvulsant effects. As for adverse effects, the 
combination proved to be infra-additive for sedation and additive for grip-strength and 
rotarod performance (although it is important to note that the VPA:ESM proportion given 
in the polytherapy experiments differed between the two studies in chapter five). In the 
clinical trial, the combination of CBZ and VPA did look slightly less efficacious than 
carbamazepine monotherapy, but there was a strong suggestion that the effectiveness of the 
combination may actually be higher because of less adverse effect-related treatment failures. 
Can some sense be made out of these results when one looks at the theoretical dose 
response curve of a single drug ? In the simplest circumstance, agonist occupancy of the 
receptor obeys the law of mass action, and the relationship between agonist concentration 
and response is reflected by a rectangular hyperbola (31, 210). At low doses the effect of 
the drug increases proportionally with the dose, but at higher doses the incremental response 
diminishes. This may be explained by receptor binding: as the number of unoccupied 
receptors decreases the drug concentration needed to occupy a “free” receptor increases. In 
the physiological situation there are thought to be “spare” receptors, i.e. not all the receptors 
have to be occupied for the maximal effect to take place. This is more efficient as a lower 
drug concentration is needed for a maximal effect. Also, addition of an irreversible 
antagonist will not automatically diminish the maximal effect. The maximal effect is not 
only dependent on occupancy of receptors, as later steps in the receptor-effect pathway can 
become the limiting factor.
This illustrates what to expect from combination therapy tin theory: when two drugs are 
combined that act at the same receptor, it is improbable that this can really improve the 
effect (partly because these drugs will compete for receptor binding (163)). When drug B 
is added to drug A which acts at a different receptor of the same molecular target, drug B 
might change the receptor affinity for drug A (e.g. barbiturates enhance benzodiazepine 
receptor affinity by an allosteric mechanism) or enhance its post-receptor effects, and thus
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the combination may be supra-additive. If two drugs are combined which modify the same 
neurobiological process, but act at different molecular targets (e.g. “presynaptic” vigabatrin 
and “postsynaptic” phenobarbital), this might either lead to increased GABAergic inhibition 
and/or the possibility to administer each drug at non-toxic dosages, provided that the 
adverse effects do not share the final common pathway (163).
Finally, when we combine two drugs which act on different neurobiological processes and 
act at different molecular targets, one might expect that low doses of the two drugs will 
produce a supra-additive effect. However, this does not seem to apply to the combinations 
tested in our studies (assuming that they really have different mechanisms of action), which 
might be explained by a limiting final common pathway. It could also be that the two 
processes are not suited for combination. For example, GABA-mediated membrane 
hyperpolarization theoretically could decrease the actions of sodium channel blockers, as 
actions of the latter drugs are voltage dependent (163). Nevertheless, Fagan’s theoretical 
argument for combination therapy, which was discussed in paragraph 1.1, seems to hold 
true (69). If two drugs are combined at dosages with 50% effect, the toxicity of such a 
combination may be minimal. In other words, the therapeutic window of the combination 
may be enhanced.
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7.3 Assessing the possibility of selection of AED combinations based on 
mechanisms of action
Many experts in the field of AED therapy have suggested that selected AED combinations 
may improve effectiveness, i.e. increase efficacy and/or increase tolerability. Ferrendelli has 
defined criteria to assist the clinician in the rational selection of AED polypharmacy, which 
are listed in table 7.3a (74).
Table 7.3a Principles of rational AED combinations
Selection criteria for rational AED combinations
1. Drugs with different mechanisms of action
2. Drugs with good efficacy
3. Drugs with low potential for toxicity (including idiosyncratic toxicity)
4. Drugs with low potential for drug interactions
5. Drugs with high therapeutic indexes
Ferrendelli obviously belongs to the experts that claim that efficacy can be increased by 
combining two drugs that have different mechanisms of action (criterion one) (74, 102). 
Other expert epileptologists recommend combining drugs which act at the same target to 
increase efficacy (91, 126). As was discussed in the previous paragraph, theoretically both 
strategies could work. However, most of the presently available AEDs have multiple 
mechanisms of action and the relative contributions of single mechanisms of action to the 
efficacy of the AEDs are not known. Almost all of the available AEDs block voltage- 
dependent sodium channels or increase GABAergic neurotransmission, and many of them 
do both. In paragraph 4.2 it was found that it is difficult to apply either strategy, but that 
advantageous combinations may seemingly consist out of two drugs acting at the same 
target but also out of two drugs acting at different targets. When the adverse effects of two 
AEDs are not additive, this will enable the clinician to administer two drugs at high, but 
non-toxic dosages. In other words, it may be possible to give higher drug loads in 
combination therapy than in monotherapy. As was argued in chapter 4, this strategy is 
probably responsible for the increased effectiveness of most of the combinations which 
proved to be useful in the clinical studies described in that chapter. As it is not known 
whether the mechanisms of action responsible for anticonvulsant efficacy are also involved
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in the pathophysiology of adverse effects, drugs acting at the same target for their 
anticonvulsant effect may also be combined in an attempt to achieve increased tolerability. 
The studies discussed in chapter 4, do not provide more insight concerning this aspect: for 
example, the PHT/PB combination (Na+/GABA, Na+, glutamate) was infra-additive for 
toxicity in mice, but the PHT/CBZ combination (Na+/Na+) and the CBZ/PB (Na+/GABA, 
Na+, glutamate) were both additive (29).
Contrary to criterion one, criteria two to five can be evaluated quite easily for each of the 
currently marketed AEDs. When we for take criterion four for example, it has become 
possible to determine a drug’s metabolic pathways and its enzyme-inducing or inhibiting 
effects of cytochrome P450 isoforms (169). This will allow researchers and clinicians to 
predict interactions and anticipate the necessity of dose adjustments (169). Enzyme- 
inducing or inhibiting effects may be beneficial, when a toxic metabolite is metabolized 
faster or when its formation is reduced respectively. When stiripentol is given to patients 
using CBZ, this inhibits the transformation of the CBZ parent drug into its metabolites, and 
these patients tolerate higher carbamazepine levels (169). Likewise, danazol inhibits the 
formation of CBZ-epoxide, which makes CBZ levels exceeding 20 mg/l tolerable (82). In 
chapter 4, it was described that drug interactions may also increase the incidence of 
idiosyncratic reactions. In this respect pharmacovigilance is very important, which could 
lead to dosing recommendations for certain combinations.
With regard to therapeutic indexes (criterion five), the combination of PB + PHT did 
display infra-additive toxicity in animals, but because of the low therapeutic index of 
phenobarbital the combination still had a lower therapeutic index (TC50/EC50) than 
phenytoin alone (29). This confirms the point made by Ferrendelli, that drugs with high 
therapeutic indexes generally are more suitable for combination therapy (74).
The criteria listed in table 7.3a do offer some assistance in selecting AED combinations, but 
they do not identify the combinations which are really advantageous in clinical practice. It 
may be that two drugs, although both block the sodium channel and both have an average 
therapeutic index, may interact differently with other drugs (e.g. CBZ and PHT). Therefore 
we still need a thorough testing procedure of AED combinations.
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7.4 Which are the best methodologies to evaluate polytherapy with antiepileptic
drugs ?
Now that we have established that selected AED combinations may offer some advantages 
over their individual constituents, the question arises which way we should proceed ? This 
question raises many issues to consider:
A. Which combinations should be tested ?
B. Which study subjects should be chosen (i.e which animal models and which 
patients) ?
C. Which outcome measures should be used ?
D. What are the best study designs to evaluate AED combination therapy ?
In this last paragraph of this chapter, an attempt will be made to address these issues.
B. Which combinations ?
As was discussed in paragraphs 4.2 and 7.3 mechanisms of action and the criteria defined 
by Ferrendelli may be of some assistance to select possible combinations. However, the 
most appropriate selection criterion seems to be clinical practicality or necessity. For 
example, in absence epilepsy combinations between valproate, ethosuximide and 
lamotrigine are of interest. Patients with juvenile myoclonic epilepsy may benefit from a 
combination of VPA with drugs such as PB, LTG and TPM (74). For symptomatic 
generalized epilepsies combinations of VPA, LTG, TPM and a benzodiazepine may be 
evaluated. In patients with partial epilepsy, combinations of a conventional AED with either 
LTG, TPM, levetiracetam (LEV) or TGB or combinations of these new drugs should be 
investigated. Case reports of successful combinations can be helpful in selecting these 
combinations.
C. Which study subjects ?
Löscher has underlined the importance of selecting appropriate models for testing of 
theoretically promising combinations (150). A problem of current animal studies is that 
most concentrate on the MES model, and some on the Ptz model. Polytherapy is usually 
only used in refractory epilepsy and it is questionable whether these models really predict 
efficacy in such patients (147). Therefore, Löscher urges to use other models, such as the 
amygdala kindling model in which the ‘epilepsy’ really becomes intractable (147). He has
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proposed a two step model: combinations would first be tested in acute seizure models 
(MES, Ptz) and in case of success in more labor-intensive models such as the amygdala- 
kindling model.
If combinations come through this animal testing successfully, they should be formally 
tested in humans. The patients probably most suited for polytherapy are the patients that 
need polytherapy in clinical practice i.e. patients with intractable epilepsy. In patients with 
newly diagnosed epilepsy, differences in efficacy are harder to demonstrate. The epilepsy 
syndromes which are most difficult to treat, such as the malignant childhood epilepsies and 
temporal lobe epilepsy, are obviously in need of high-quality polytherapy studies.
D. Which outcome measures 
Animals
Animal epilepsy models may differ in having either quantal or graded efficacy measures: 
the MES and Ptz have quantal measures, i.e. how much drug is needed to suppress a seizure 
(component) in 50% of the animals. Log probit analysis is used to analyze the data and to 
estimate ED50, TD50 and confidence intervals (92). In the WAG/Rij model a graded response 
is used, i.e. how much drug is needed on average to reduce the number of spike-wave 
discharges per animal with 50%. The ED50, TD50 and confidence intervals can be estimated 
by non-linear regression. It is important to keep this distinction in mind, but in both cases 
it is possible to make dose-response curves, to use the isobologram method and to use them 
for clinical decision making (31).
As for adverse effects, the behaviors which can be tested in animals are obviously different 
from those which can be measured in epilepsy patients (129). In animals the distinction 
between active and passive behavior, coordination and hypotonia may be evaluated, 
whereas in man coordination tests and very extensive neuropsychological testing are 
available (129). Three adverse effect “detection methods” were used in the study described 
in paragraph 5.1: grip-strength, rotarod and active/passive behavior. These methods have 
already been discussed by Kulig and Lammers (130).
The grip-strength and accelerod data showed large 95% confidence intervals, which may 
make them less suitable for future experiments. In contrast, the active/passive behavior data 
had small confidence intervals. However, a cautionary remark is in place. It has not been 
ascertained whether this finding holds true for all AEDs: Kulig et al. showed that PHT, PB,
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CBZ and VPA have different effects on rotarod performance and spontaneous behavior 
(129). Whereas PHT had no effect on rotarod performance at dosages up to 40 mg/kg, the 
other three drugs did have a negative influence at high dosages. Phenytoin, PB and CBZ 
impaired spontaneous behavior at serum levels which are in the therapeutic range in man, 
but valproate only did so at toxic levels. In more elaborate psychological tests, the effects 
of these drugs showed even larger differences (129). It is important to use such data in the 
selection of tests per experiment.
Furthermore, pharmacokinetic interactions, and possibly even brain concentrations, should 
be measured in these experiments. In two studies synergy was found when the authors 
looked at serum levels, whereas the brain concentrations in the same animals showed that 
there only was additive interaction (140, 184).
Humans
Clinimetric scales
In recent years, many papers have been published on outcome measurement in epilepsy. 
Two fine examples are reports by commissions of the International League Against 
Epilepsy (115, 116). In these reports recommendations are made for the evaluation of 
efficacy and toxicity. Although the methods used in our clinical trial, i.e. Composite Index 
of Impairments, QOLIE and FePsy, are all included in these recommendations, some 
remarks will be made regarding their use.
As was discussed in chapter 1, several clinimetric scales have been developed to measure 
seizure severity and adverse effects. These scales have been compared by Cramer and 
Mattson (43, 172). The VA scales and the Composite Index of Impairments have three 
important features that make them powerful research instruments: the scales express both 
seizure frequency and seizure severity, they are physician-based and the effect of treatment 
can be summarized in one composite score. The VA scale and the CII give a score for 
seizure frequency for each seizure type and points can be deducted per seizure type if 
modifying factors are present. Other seizure severity scales only express severity so that 
there is another variable next to seizure frequency to consider.
As was mentioned, patient-based as well as physician-based have been developed: the 
relative importance attributed to seizure severity and to adverse effects differs between 
patients and doctors. Regarding seizure severity, doctors tend to concentrate on loss of
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consciousness, generalization of seizures, falls and length of the ictal period, whereas for 
patients duration of unconsciousness, slow post-ictal recovery, unpredictability of seizures 
and circumstances in which they occur are more important (255). Regarding adverse 
effects, there are considerable differences between patients in the amount of adverse effects 
they accept and in which adverse effects they find unacceptable (e.g. ataxia, weight gain, 
sexual disturbances). Some patients find seizure control most important and are willing to 
accept adverse effects whereas others accept almost no toxicity. Although these are 
important issues for individual patient care and although patient-based scales are very 
helpful as screening instruments, for research purposes an “objective” doctor-based scale 
with a rigid scoring system may be preferable. Moreover, the physician may be more 
objective and experienced in scoring the severity of seizures and adverse effects.
The great advantage of having one composite score is that it expresses the overall 
impairments the disease and its treatment have for patients. However, Cramer and Mattson 
suggest that it is also important to look at the individual items of their toxicity scales (43). 
In the second VA trial VPA had a less favorable neurotoxicity score, and this could lead a 
reader to conclude that all aspects of neurotoxicity were involved, although only one 
measure (tremor) was more frequent with VPA than with CBZ (173).
The high percentage of adverse effects yielded with the CII in our trial does bring the 
question that was posed in paragraph 3.3 up again: is using clinimetric scales producing 
false-positive adverse effects ? The criticism one could have of the review article on which 
paragraph 3.3 is based, is that the dosages were higher in the trials which used clinimetric 
scales to detect adverse effects (53). However, in our double-blind trial a low-dose CBZ 
monotherapy group was studied, so the adverse effects in this group can now be compared 
with the literature data on CBZ monotherapy from paragraph 3.3. We will only show those 
adverse effects that were found more often in table 3.3a when an active approach was used. 
As in paragraph 3.3 it seems that the active approach does reveal a higher incidence of 
certain adverse effects: sedation, cognitive impairments, gait disturbances, and hair changes. 
However diplopia, nystagmus, tremor, sexual dysfunction and weight changes were not 
found to be more frequent in our trial compared to studies which used self reporting of 
adverse effects. These effects might have been due to the higher dosages used by Mattson 
et al. in their trials (173, 174). One may conclude that the data from our trial confirm that 
some of the differences in toxicity rates between self-reporting and clinimetric evaluation
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of adverse effects were due to methodology and not due to dosages. This could of
Table 7.4a Percentages ofpatients in selected papers with drug-induced adverse effects 
while on carbamazepine monotherapy
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Publication # refers 
to reference list 
N between ()
204
(178)
252
(130)
33
(131)
55
(139)
173
(231)
NDB
(196)
Mono-
p°iy
(53)
Method* a + c a + c a c + d d + e e e
Carbamazepine 
Mean Dose mg/day
516 450 600
median
? 722 762 450
Follow up (months) 36 36 ± 11 12 12-60 > 12 12
Gait disturbances 2% 4% 9% - 25% 6% 13%
Tremor 2% - - + 22% 11% 2%
Sedation 11% 19% 22% 32% 42% 41% 47%
Cognitive
impairments
2% 2% 3% - 18% 29% 23%
Gastro-intestinal
complaints
8% 4% 19% + 29% 3% 11%
Impotence - - - - 7% 0% 0%
Hyponatremia - - - - - 0% 0%
Weight change 1% 6% - - 32% 8% 4%
Hair loss/hirsutism 1% 2% - - 6% 11% 11%
The papers concerned can be found in the reference list: (33, 70, 173, 204, 252). * Methods of detection of adverse 
effects: a = self-reporting; b = physical examination; c = laboratory investigations; d = adverse effect checklist; e = 
specific toxicity scale. The "+" sign denotes "present", but no percentages given. The “-“sign denotes not mentioned in 
the paper. NDB = Nijmegen DataBase. Monopoly = trial reported in chapter 6.
course mean that using the self-reporting technique may result in under-reporting of adverse 
effects, which was also the experience of some other researchers (111, 212).
The QOLIE-10 was chosen as QoL scale, partly because of its brevity. The originators of 
the QOLIE-10 see this scale as a questionnaire which the patient can fill out in for example 
the doctor’s waiting room (44). One criticism of the scale may be that only one question is 
seizure-related, and although a patient can be very satisfied with a drug because of the 
seizure control, his or her QoL as measured by the QOLIE-10 may be worse because of 
adverse effects or circumstances not related to having epilepsy. Nevertheless, the scale was 
not designed to express AED effectiveness, and it may alert physicians to certain aspects 
which may otherwise remain unmentioned (44). For research purposes a more elaborate 
version of the QOLIE, such as the QOLIE-31 may be preferable.
Neuropsychological testing
Common problems with the clinical assessment of the cognitive impairments due to AEDs 
are that these impairments are often subtle at onset and that diminished learning and 
decreased speed of intellectual performance are hard to document (250). Moreover, directed 
action increases the level of attention, thereby overcoming sedation, and thus the doctor or 
the neuropsychologist may be deceived by the temporary alertness of the patient (250). It 
is a common observation that patients mostly do not complain of drowsiness at work, but 
of drowsiness at home (i.e. where they are challenged less, although pharmacokinetics may 
also play a role (111)). Another problem with many neuropsychological tests is that they 
have motor components, which complicates the recognition of cognitive changes, as AEDs 
may also have motor effects.
There does not appear to be international agreement on how to tackle these problems and 
on which standard tests should be used during AED trials. Cochrane et al. found that a 
‘plethora’ of tests is being used and that most of them were non-epilepsy specific (38). They 
recommend that first of all a battery of tests should be used that has proven reliability and 
validity and has been designed and standardized to assess people with epilepsy. Only these 
will have sufficient sensitivity to detect the cognitive changes induced by AED treatment. 
A minimum of measures would include assessment of motor speed, attention and 
concentration, learning, memory and higher executive functioning (38). The FePsy battery 
does meet the requirements set by Cochrane et al. .
As for the individual tests used in our trial, the tapping test was not found to be very 
sensitive in the first VA trial (231). The Discriminative Reaction Time test (a test which is 
somewhat similar to the Binary Choice task) on the other hand was very sensitive in 
discriminating between epilepsy patients and healthy controls. The Computerized Visual 
Searching Task is also thought to be a sensitive task: generally one could say that the more 
highly timed a test is, the likelier finding a significant drug effect is (38).
It should be noted that a high degree of sedation, as found in our trial, may result in 
decreased attention and subjective memory impairments. Furthermore, Vermeulen et al. 
claim that patient memory complaints do not accurately reflect disturbances that can be 
measured on standard neuropsychological tests. For this neuroticism and psycho-social 
factors may be held responsible, not the epilepsy itself or drug-related factors (254). 
Thompson et al. however, reported that patients tend to underestimate rather than
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overestimate the extent of these problems and that the nature of these impairments does not 
seem to be adequately detected by traditional memory tests (244).
For all of these outcome measures it is important to look at the scores of individual patients. 
In epilepsy treatment the majority of patients can be treated satisfactorily, and thus the 
minority which is not doing well may not be reflected well in group averages.
It might even be advisable to compare the number of patients doing poorly between groups, 
next to comparing group averages.
E. Which study designs 
Animals
Based on the papers reviewed in paragraph 4.2 and the experiments described in chapter 5, 
the following recommendations can be made for animal experiments on AED 
combinations:
- the determination of dose-response curves for both individual drugs and for the 
combination.
- the recording of baseline data for all animals (to normalize the experimental data in case 
of variability in baseline data between groups).
- use of the isobologram method to evaluate interactions between the drugs. When the dose­
effect curve is determined for several weight ratio’s of a combination, the interaction can 
be visualized by reponse surface modelling, which is a model which is alo based on the 
isobologram method (180).
- when animals are used repeatedly: use of a Latin-square, baseline recordings on each test 
day and sufficiently long intervals to eliminate carry-over effects.
- assessment of pharmacokinetic interactions (by measurement of serum levels) and 
possibly even measure brain concentrations in these experiments. The importance of this 
is particularly emphasized by two studies in which synergy was concluded when the authors 
looked at serum levels, whereas the brain concentrations in the same animals showed that 
there only was an additive interaction (140, 184).
Humans
The human study designs that have rendered the most definite results are the method in 
which patients who did not respond to drug A nor to drug B when given separately, are
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given the combination of A and B and the method used by Brodie et al. amongst others, 
where the addition of the investigational AED to different single conventional AEDs is 
compared (34). The concept of drug load could give insight into whether the increased 
effectiveness of a combination is due to an improvement in efficacy or tolerability: in case 
of improved efficacy, drug loads will be more or less equal between groups; in case of 
improved tolerability, it will be possible to increase the drug load in that treatment group 
more than in other treatment groups
7.5 Relevance for clinical practice
What is the direct relevance of our findings for clinical practice:
- adverse effects are related to several factors, and drug load, rather than the number of 
drugs, appears to be one of them.
- some adverse effects, such as sedation, may be under-reported if  not routinely asked for.
- The selection of AED combinations needs empirical testing as it is not possible to make 
recommendations on theoretical grounds.
- when monotherapy with antiepileptic drugs fails, combination therapy may offer 
advantages because of a larger therapeutic window, i.e. higher drug loads may be used 
before adverse effects become unacceptable. However, this may not hold true for all AED 
combinations. The trial described in chapter 6 is the only clinical study to date in which this 
has been proven for an AED combination, i.e. the combination of carbamazepine and 
valproate.
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8.1 English summary
Epilepsy is a generic term for the large variety of epilepsy syndromes that exist: each 
syndrome has its own characteristic spectrum of seizures, its own typical abnormalities on 
the EEG, its own degree of response to drug therapy etc.. Over the whole population of 
patients with epilepsy, it is estimated that with the use of antiepileptic drugs it is possible 
to control approximately 75% of patients. Drug trials in which several drugs were 
compared to each other demonstrated that ±70% of patients can be adequately controlled 
with a single drug (i.e. monotherapy). Thus combination therapy will result in adequate 
control in only an extra 5%. Moreover, polytherapy has been reputed to lead to increased 
toxicity, and thus at the present polytherapy is being avoided whenever possible.
In a 1995 study the Nijmegen Epilepsy Research Group (NERG) found however that, when 
monotherapy patients and polytherapy patients were compared that were being treated with 
equal total drug loads, there was no difference in adverse effects between these groups. 
Drug load is defined as the amount of drug exposure for a certain indication. In that study, 
the NERG used a clinimetric index to check for the presence of a range of adverse effects 
and, when present, to score severity of those adverse effects. The surprising finding that 
polytherapy was not per se more toxic than monotherapy, led to the research that is 
described in this thesis.
In chapter one the history of the monotherapy-polytherapy debate is discussed and the 
concepts of drug load and of clinimetric epilepsy scales are re-introduced. In chapter two 
background information is given on the methods used in this thesis (drug load, the 
clinimetric epilepsy scales adopted by the NERG, neuropsychological tests) for the 
interested reader.
Chapter three contains a number of papers in which these aforementioned methods are 
tested and re-examined. Paragraph 3.1 describes a literature study in which drug load was 
calculated for a number of published studies, and which showed that higher drug load is 
usually associated with increased toxicity. In paragraph 3.2 the theoretical basis for the 
drug load concept is discussed. The method our group has developed to calculate drug
loads, shows analogies to the isobologram method, which is the preferred method to 
analyze the effects of combining drugs in animals. In paragraph 3.3 the results of studies 
in which adverse studies were detected by clinimetric scales are compared to the results 
of studies which relied upon self-reporting for the detection of adverse effects. Active 
inquiry about specific adverse effects (i.e. the clinimetric approach) does increase the 
frequency with which certain adverse effects are found. This is in accordance with several 
reports in the literature that suggest that an active approach is needed for an accurate 
detection of certain complaints and symptoms. However, routine laboratory monitoring 
does not appear to be necessary for all patients using antiepileptic drugs.
In paragraph 4.1 the current knowledge about the mechanisms underlying seizures and 
about the mechanisms of action of the presently licensed antiepileptic drugs is 
summarized. There has been increasing attention in the last decade for “rational 
polytherapy”, i.e. the selection of AED combinations based on their pharmacological 
properties. However, uncertainty exists as to whether drugs with the same mechanism of 
action or drugs with different mechanisms of action should be combined.
The available polytherapy studies in animals and in epilepsy patients were reviewed in 
paragraph 4.2 to determine whether it is possible to combine AEDs based on mechanisms 
of action, and if so, which combinations may lead to increased effectiveness. It proved to 
be quite difficult to evaluate the results of the studies, animal studies as well as clinical 
studies, because of the diversity of methods used to analyze drug interactions. The results 
of only a limited number of studies were used to address the issue, because their designs 
were deemed to be of better quality than the others. Using this limited set of data, it was 
found that although there may be some promising “mechanistic” combinations, the 
knowledge concerning mechanisms of action and pathophysiology is still too incomplete 
to make definite recommendations.
The animal studies done as part of this thesis are described in chapter five. In the first study 
(paragraph 5.1) ethosuximide and valproate were administered to Wistar rats (i.e. a rat 
strain without epilepsy), alone and in combination. Possible adverse effects were evaluated 
by the use of three different methods, measuring strength, coordination and level of 
spontaneous activity. The isobologram method showed that the combination produced less
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passive behavior (which could be interpreted as sedation) than the drugs given alone. There 
were no significant differences in strength or coordination. This result suggests that giving 
two drugs at low dosages, may have advantages over giving either drug alone at higher 
dosages. In the second study (paragraph 5.2) the efficacy of the ESM-VPA combination 
in WAG/Rij rats (i.e. a rat strain which shares behavioral, electro-encephalographic and 
anti-convulsant profiles with human absence epilepsy) was compared to the efficacy of 
ESM alone and VPA alone. Although it did not reach statistical significance, the data 
suggested that the combination was less efficacious than the individual drugs. This may 
compromise the positive findings of the study described in paragraph 5.1.
The first double-blind clinical trial comparing monotherapy and polytherapy with AEDs 
is described in chapter six. A 125 patients were randomized to either carbamazepine 
monotherapy or a combination of carbamazepine and valproate, starting off on equal drug 
loads. The primary outcome measure (which is also used to calculate how many patients 
should be included in the trial) was neurotoxicity. Patients were interviewed and tested 
regularly during the trial to have a reliable record of seizure frequency, possible adverse 
effects and their quality of life. Patients were followed for up to a year, but could drop out 
because of insufficient seizure control despite dose increases or because of an unacceptable 
level of adverse effects. At the end of the trial, there were no significant differences in 
clinimetric scores for seizure frequency, neurotoxic adverse effects or systemic adverse 
effects. More patients on monotherapy were still bothered by sedation at the end of the 
trial, but more polytherapy patients had gained weight. More patients on monotherapy 
dropped out because of adverse effects, however this did not reach statistical significance.
In chapter 7, the findings of this thesis were discussed and can be summarized into four 
main points:
1. It was not demonstrated that drug load is more important than the number of drugs in 
producing adverse effects, but drug load is an important aspect to take into account when 
planning or analyzing (multi-)drug trails.
2. Some polytherapy combinations may offer advantages over their individual constituents, 
and, in the case of the combinations studied in this thesis, this was due to infra-additive 
toxicity.
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3. It may be that certain “mechanistic” AED combinations offer more advantages than 
others, however the present knowledge concerning mechanisms of action of AEDs does 
not allow us to pursue these. Therefore, a large range of combinations should be tested.
4. Recommendations are made concerning future polytherapy studies: specifically 
concerning possible AED combinations, study subjects to be studied, outcome measures 
and study designs.
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Epilepsie is een verzamelnaam voor het grote aantal vormen van epilepsie die voorkomen: 
vormen met elk een eigen spectrum aan eigen aanvalsuitingen, eigen afwijkingen op het 
EEG (“hersenfilmpje”), een eigen mate van reageren op therapie etc.. Over de hele groep 
genomen, kan men zeggen dat ongeveer 75% van de epilepsie-patiënten met succes 
behandeld kan worden met medicijnen die de aanvallen onderdrukken, de zogeheten. Uit 
geneesmiddelenonderzoek is gebleken dat de aanvallen van ±70% van de patiënten 
voldoende kunnen worden onderdrukt wanneer zij één middel (oftewel monotherapie) 
gebruiken. Het inzetten van combinaties van anti-epileptica levert dus maar bij een verdere 
5% succes op. Bovendien wordt gedacht dat het geven van meerdere anti-epileptica 
tegelijk (oftewel polytherapie) kan leiden tot meer bijwerkingen, and daarom wordt poly­
therapie tegenwoordig zoveel mogelijk vermeden.
In een onderzoek in 1995 vond de Nijmeegse Epilepsie Research Groep (NERG) echter 
dat, wanneer patiënten met monotherapie en patiënten met polytherapie eenzelfde drug 
load gebruikten werden vergeleken, er geen verschil in bijwerkingen bestond. Drug load 
wordt gedefinieerd als de hoeveelheid geneesmiddelen waar de patiënt aan wordt 
blootgesteld voor een bepaalde aandoening. In datzelfde onderzoek, gebruikte de NERG 
een zogenaamde klinimetrische schaal waarmee specifiek naar de aanwezigheid van 
bepaalde bijwerkingen wordt gevraagd en, indien een bijwerking aanwezig is, de ernst van 
bijwerkingen wordt gescoord. De verrassende bevinding dat polytherapie niet per se met 
meer bijwerkingen gepaard gaat, was de directe aanleiding voor het onderzoek wat in dit 
proefschrift wordt beschreven.
In hoofdstuk 1 wordt de geschiedenis van de controverse over monotherapie en 
polytherapie verteld en worden de concepten van drug load en klinimetrische epilepsie­
schalen opnieuw ten tonele gevoerd. In hoofdstuk 2 wordt achtergrondinformatie gegeven 
over de methodologieën die in het onderzoek zijn gebruikt (drug load, klinimetrische 
epilepsie-schalen, neuropsychologische tests) voor de geïnteresseerde lezer.
Hoofdstuk 3 bevat een aantal studies waarin deze methoden opnieuw worden hun waarde
moesten bewijzen. In paragraaf 3.1 wordt een literatuur-onderzoek beschreven waarbij de 
drug load werd berekend voor een aantal reeds gepubliceerde studies; hieruit blijkt dat in 
elk van deze studies een hogere drug load geassocieerd was met meer bijwerkingen. 
Vervolgens wordt in paragraaf 3.2 de theoretische basis voor het drug load concept 
besproken; dit betreft diens gelijkenis met de isobologram-methode, één van de beste 
methodes om bij dier-experimenten de effecten van het combineren van middelen te 
analyseren. In paragraaf 3.3 worden de resultaten van studies waarbij bijwerkingen werden 
gedetecteerd met klinimetrische schalen vergeleken met de resultaten van studies waarbij 
men vertrouwde op zelf-rapportage van bijwerkingen. Actief navragen van specifieke 
bijwerkingen (i.e. de klinimetrische benadering) blijkt hogere frequenties voor bepaalde 
bijwerkingen op te leveren. Ook andere onderzoekers hebben gerapporteerd dat een actieve 
detectie-methode nodig is voor een nauwkeurig opsporen van bepaalde bijwerkingen. Het 
lijkt echter niet noodzakelijk om bij alle patiënten die antiepileptica gebruiken 
routinematig bloed-onderzoek (naar leverfunctie-afwijkingen etc.) te verrichten.
In paragraaf 4.1 wordt de huidige kennis samengevat over de mechanismen in de hersenen 
die tot een epileptische aanval leiden en over de werkingsmechanismen van anti-epileptica. 
In de laatste 10 jaar is er aandacht ontstaan voor “rationele polytherapie”, d.w.z. de selectie 
van combinaties van anti-epileptica op basis van hun farmacologische eigenschappen. Er 
bestaat echter onzekerheid of juist medicijnen met dezelfde werkingsmechanismen of 
middelen met verschillende werkingsmechanismen moeten worden gecombineerd. 
Eerder verrichte onderzoeken naar verschillende combinaties van antiepileptica in 
diermodellen van epilepsie en bij epilepsie-patiënten worden in paragraaf 4.2 op een rij 
gezet. Dit om te bepalen of het mogelijk is om combinaties op basis van 
werkingsmechanismen te combineren (gezien het feit dat de meeste anti-epileptica 
meerdere werkingsmechanismen hebben) en zo ja, welke combinaties dan tot meer 
effectiviteit leiden. Het bleek echter vrij moeilijk te zijn de verschillende studies te 
vergelijken door de grote variëteit aan methodes die werden gebruikt om de effecten van 
het combineren te interpreteren. Alleen de resultaten van een beperkt aantal studies, met 
een studie-opzet die als kwalitatief hoogstaand werd beoordeeld, werden gebruikt om de 
genoemde vragen te beantwoorden. Met deze set van gegevens werd gevonden dat 
alhoewel er wellicht bepaalde veelbelovende combinaties zijn, de kennis omtrent de
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onderliggende mechanismen van aanvallen en omtrent de werkingsmechanismen van de 
antiepileptica nog te incompleet is om harde aanbevelingen te doen.
De dier-experimenten worden beschreven in hoofdstuk 5. In het eerste onderzoek 
(paragraaf 5.1) werden de antiepileptica ethosuximide en valproaat toegediend aan Wistar 
ratten (dit is een rattenstam die niet spontaan epilepsie ontwikkelt), alleen en in 
combinatie. Mogelijke bijwerkingen werden geëvalueerd door het meten van spierkracht, 
coördinatie en spontaan actief gedrag. Middels de isobologram methode werd aangetoond 
dat de combinatie tot minder passief gedrag leidde dan de afzonderlijke middelen, en dat 
er wat betreft kracht en coördinatie geen significante verschillen waren. De resultaten van 
deze studie suggereren dat het geven van twee middelen in lage doseringen voordelen kan 
hebben t.o.v. het geven van de afzonderlijke middelen in hogere doseringen.
In het tweede onderzoek (paragraaf 5.2) werd de werkzaamheid van de ethosuximide- 
valproaat combinatie in WAG/Rij ratten (een rattenstam die wel spontaan epilepsie 
ontwikkelt) vergeleken met de werkzaamheid van de middelen alleen in dit model. Het 
leek dat de combinatie minder werkzaam was in dit diermodel dan de afzonderlijke 
middelen, alhoewel dit statistisch significant werd. Dit resultaat van het werk beschreven 
in paragraaf 5.2 kan de mogelijke voordelen die ten aanzien van de combinatie werden 
gevonden in paragraaf 5.1, (deels) teniet doen.
In hoofdstuk zes wordt een dubbelblind onderzoek (d.w.z. zowel de betrokken arts als de 
patiënt wisten niet welke medicatie de patiënt gebruikte; deze code werd bewaard in het 
SEIN in Heemstede) beschreven. In totaal 125 patiënten kregen hetzij carbamazepine 
monotherapie of een combinatie van carbamazepine en valproaat, waarbij in beide 
groepen met een gelijke drug load werd gestart. Omdat de meeste verschillen werden 
verwacht in de neurotoxische bijwerkingen (zoals slaperigheid, hoofdpijn of 
evenwichtsproblemen), werden deze genomen als zogenaamde primaire uitkomstmaat 
(deze maat wordt gebruikt om uit te rekenen hoeveel patiënten er in een onderzoek moeten 
worden opgenomen om na afloop van het onderzoek met enige zekerheid conclusies te 
kunnen trekken). De patiënten werden in het jaar van deelname regelmatig gezien op de 
poliklinieken om een goed beeld te hebben over mogelijke aanvallen en bijwerkingen. 
Zoals werd verwacht vielen er ook patiënten uit voordat ze de medicatie een jaar hadden
Summary 163
gebruikt en dit gebeurde met name ten gevolge van bijwerkingen. De meerderheid van de 
patiënten nam wel een heel jaar deel, en bij hen werden er geen verschillen gevonden wat 
betreft aanvalscontrole of bijwerkingen in het algemeen. Wel hadden na 12 maanden meer 
monotherapie-patiënten nog last van slaperigheid en meer polytherapie-patiënten waren 
in gewicht aangekomen. Het leek zo te zijn dat er relatief meer monotherapie-patiënten 
gedurende het onderzoek uit waren gevallen vanwege bijwerkingen, maar dit was niet 
statistisch significant verschil.
In hoofdstuk 7 word het totaal van de bevindingen van het promotie-onderzoek besproken 
en worden deze samengevat in vier punten:
1. Het werd niet aangetoond dat drug load meer invloed heeft op het aantal bijwerkingen 
of de ernst van bijwerkingen, dan het aantal anti-epileptica heeft. Wel werd duidelijk dat 
drug load een belangrijk aspect is bij het opzetten of analyseren van geneesmiddelen­
onderzoek (zeker wanneer combinaties van geneesmiddelen worden onderzocht).
2. Sommige combinaties van antiepileptica kunnen voordelen bieden t.o.v. van hun 
afzonderlijke bestanddelen. In het geval van de studies die in dit onderzoek werden 
bestudeerd was dit dankzij het minder hebben van bijwerkingen. Dit is opvallend, omdat 
men juist altijd beweert dat polytherapie met meer bijwerkingen gepaard gaat.
3. Het kan zo zijn dat bepaalde combinaties van types anti-epileptica (lees: 
werkingsmechanismen) effectiever zijn dan andere. De huidige kennis van 
werkingsmechanismen staat echter niet toe dit met zekerheid te zeggen en daarom zou 
men wat dit betreft een groot scala van combinaties moeten testen. 4. Aanbevelingen 
worden gedaan voor toekomstig onderzoek naar polytherapie: welke combinaties moeten 
testen worden, welke diermodellen en welk type patiënten moeten worden bestudeerd, 
welke uitkomsten en studie-opzetten moeten worden gebruikt.
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Appendix A
COMPOSITE INDEX OF IMPAIRMENTS
SEIZURE ACTIVITY INDEX
Section A : Complete this section if patient has either primary or secondary gegeneralized tonic-clonic seizures.
1. Total number of seizures since last visit: ______
2. Total number of seizures since start drug: ______
Select the seizure frequency that applies to this patient and enter number of points on score line
a. Three or more seizures/12 months = 20 p. each se
b. Two seizures/first 3 months = 50
c. One seizure/first 3 months = 40
d. Two seizures/6 months = 45
e. One seizure/6 months = 40
f. Two seizures/6-12 months = 30
g. One seizure/6-12 months = 20
h. Two seizures/12-24 months = 20
i. One seizure/12-24 months = 10
j. No seizures/ last 24 months = 0
Score
3. Was seizure modified by an aura ? Yes O No O
If yes: reduce I.S. score with 20 %. Score
4. Was seizure(s) precipitated by unusual, remedial factors
( e.g. lack of sleep, alcohol, illness )? Yes O No O
If yes: reduce I.S. score with 50%. Score
5. Are seizures modified by known cyclic or diurnal pattern 
( e.g. nocturnal or early a.m. )
If  yes: reduce I.S. score with 40%. Score
Score A
Section B : Complete this section if patient has complex partial seizures ( with altered consciousness ) that do not 
generalize.
1. Total number of seizures since last visit: ______
2. Did seizures occur as a cluster ( more than 2 seizures within 24 hours ) ?
If yes: count only half of the seizures in that cluster.
3. Select the seizure frequency that applies to this patient and enter number of points on score line
a. Four or more seizures/month
b. Three seizures/month = 40
c. Two seizures/month
d. One seizure/month
e. One seizure/1-3 months
f. Less than one seizure/3 months = 10
g. No seizures in last 12 months
4. Was seizure modified by an aura ? Yes O No O
If yes: reduce I.S. score with 20 %. Score
5. Was seizure(s) precipitated by unusual, remedial factors
( e.g. lack of sleep, alcohol, illness )? Yes O No O
If yes: reduce I.S.score with 50%.
6. Are seizures modified by known cyclic or diurnal pattern 
( e.g. nocturnal or early a.m. ) ?
If  yes: reduce I.S. score with 40%. Score
7. Was patient able to resume daily activities within 15 minutes 
If yes: reduce I.S. score with 50%.
= 50 p. (+ 10 per extra seizure)
= 30 
= 20 
= 15
= 0 
Score
Score
Score
Score B
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Section C: Complete this section if patient has simple partial seizures ( without loss of consciousness ).
1. Total number of seizures since last visit: ______
2. Did seizures occur as a cluster ( more than 2 seizures within 24 hours ) ?
If yes: count one half of the seizures in that cluster.
3. Select the seizure frequency that applies to this patient and enter number of points on score line
a. Seven or more seizures/month = 33 p. (+ 3/extra seizure )
b. Six seizures/month
c. Five seizures/month
d. Four seizures/month
e. Three seizures/month
f. Two seizures/month
g. One seizures/month
h. One seizure/1-3 months
i. Less than one seizure/3 months 
j. No seizures in last 12 months
. Was seizure(s) precipitated by unusual, remedial factors 
( e.g. lack of sleep, alcohol, illness )? Yes O No O
If yes: reduce I.S.score with 50%.
. Are seizures modified by known cyclic or diurnal pattern 
( e.g. nocturnal or early a.m. ) ?
If  yes: reduce I.S. score with 40%.
. Was patient able to resume daily activities within 15 minutes 
If yes: reduce I.S. score with 50%.
= 23
= 13 
= 10
Score
= 30 
= 28 
= 25
= 20 
= 15
= 0 
Score
Score
Score
Score C
Score A  +  score B + score C = S.A. score
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Neurotoxicity rating scale
Instructions: all toxicity is scored relative to normal for this patient before starting this medication. Do not change the 
drug when toxicity occurs with high serum level; reduce the drug dosage. Circle all scores that apply and record on score 
line. Enter zero when no toxicity is present.
Score
1. Diplopia
a. Intermittent 15
b. Constant 30 _____
2. Nystagmus (not end point):
a. Horizontal 5
b. Vertical 10 _____
3.Dysarthria
a. Mild (intermittent slurring) 5
b. Moderate (constant slurring, no difficulty communicating) 10
c. Severe (understanding of speech difficult if  topic unknown to listener) 30 _____
4. Gait, normal walking
a. Slight ataxia (slowness or unsteady turning) 5
b. Mild ataxia (veer from side to side, difficulty with tandem gait) 15
c. Moderate ataxia (quite unsteady, walks with wide-based gait;
tendency to fall toward one side or other) 25
d. Severe gait disturbance (can walk only with assistance; unsteady sitting) 50 _____
5. Rapid alternating movements (hand on knee; flip side to side; grossly clumsy) 15 _____
6. Intention tremor (finger to nose, long reach; eyes open/ eyes closed)
a. Mild (large tremor seen as finger approaches nose; fingers misses nose)
b. Moderate (finger misses nose most of the time)
c. Moderately Severe (frequent or constant tremor, compromises to some degree: 
writing, fine motor movement, etc. )
d. Severe (disturbs everyday functioning: eating, writing, working)
Enter total for items 1-6 (if more than 1 score, multiply by 50%)
7. Sedation (level of consciousness)
a. Lethargic in early AM or PM
b. Occasionally sleepy during day
c. Often difficult staying awake
d. Stuporous
8. Affect and mood (depression; tension/agitation; anger/hostility; vigor/excitability; 
fatigue/apathy; confusion/thought disorder)
a. Mild (disturbance recognized by patient, but not interfering with usual life) 5
b. Moderate (mood disturbance results in reduced abilities) 15
c. Severe ((nearly) continuous mood disturbances interfering with normal life) 50
9. Cognitive function (attention and concentration)
10
35
50
25
5
10
25
50
a. Mild (symptoms recognizable, but no interference with usual life) 5
b. Moderate (interference with some daily activities) 10
c. Severe (interference with all daily activities) 50
. Dizzy/lightheaded (enter zero if categories do not apply) Occass. Often Often
after after during
med. med. day
a. Mild (symptoms recognizable, but no interference with usual life) 3 5 10
b. Moderate (interference with some daily activities) 5 10 25
c. Severe (interference with all daily activities) 10 25 50
. Drug-related Headaches (enter zero if categories do not apply) Occass. Often Often
after after during
med. med. day
a. Mild (symptoms recognizable, but no interference with usual life) 3 5 10
b. Moderate (interference with some daily activities) 5 10 25
c. Severe (interference with all daily activities) 10 25 50
12. Other neurotoxicity (describe):
Neurotoxicity Score (sum 7 to 13) Total score
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Instructions: all toxicity is scored relative to normal for this patient before starting this medication. Do not change 
the drug when toxicity occurs with high serum level; reduce the drug dosage. Circle all scores that apply and record 
on score line. Record the ‘0' value when no toxicity is present.
Score
1. Does the patient have any drug-related gastro-intestinal problems ?
(enter highest applicable score on score line; enter zero if categories do not apply)
Distress Nausea Vomiting Other
a. Transient or occasionally
after medication 3 5 10 ___
b. Often after medication 5 10 25 ___
c. Often during the day 10 25 50 ___
Systemic Toxicity Rating
2. Does patient have hematopoietic system problems ?
(enter a score for each of the following; enter zero if category does not apply)
a. Reduced platelet count < 75,000 (score 25 if under observation; score 50 if drug discontinued)
b. Reduced WBC < 2,000 (score 25 if under observation; score 50 if drug discontinued)
c. Other hematologic problems:_______________________
3. Does patient have dermatological problems ?
a. Transient general maculopapular rash (stopped with treatment) 15
b. Severe general maculopapular rash (did not stop with treatment) 50
c. Acne noticeable on face, trunk, limbs 10
d. Severe acne, excessive and bothersome to the patient 30 __
4. Does patient have problems with impotence (libido or potency) related to drug use ?
a. Transient, occasional or tolerable 20
b. Continuous or intolerable 50
5. Does patient have hyponatremia with serum sodium < 120 mol./l ?
If  yes, score 50
6. Does patient have drug-related liver disease with abnormal liver function tests (ASAT, ALAT) ?
a. Yes, under observation 25
b. Yes, drug discontinued 50 __
7. Has patient gained weight because of a drug-related increased appetite ?
Weight gain: small (4-6 lbs) 3
moderate (7-12 lbs) 10
large (>13 lbs) 20
8. Does patient have any changes in hair quantity or texture since starting drug ?
a. Hair loss: mild (hair in comb) 5
moderate (visible thinning of hair or hair loss in clumps) 20
severe (visible alopecia or exceedingly bothersome to the patient) 50
b. Hair texture change (becoming coarse, fine, curly) 5
c. Hirsutism: moderate (noticeable on face, trunk or limb ) 20
severe (excessive and bothersome to the patient) 50 __
9. Other systemic toxicity (describe):_________________________________________
Systemic Toxicity score Total score
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Composite Index of Impairments schaal
Patiënt:______________________________
Formulier ingevuld door:_______________
Patiëntnr.:
Datum:
SEIZURE ACTIVITY SCHAAL
Sectie A : Vul dit onderdeel in indien de patiënt een primaire dan wel een secundaire gegeneraliseerde tonisch-clonische 
aanval heeft gehad.
1. Aantal aanvallen sinds laatste bezoek:
Aantal aanvallen sinds start anti-epilepticum: 
. Selecteer de juiste aanvalsfrequentie:
a. Drie of meer aanvallen/12 maanden
b. Twee aanvallen/eerste 3 maanden
c. Eén aanval/eerste 3 maanden
d. Twee aanvallen/6 maanden
e. Eén aanval/6 maanden
f. Twee aanvallen/6-12 maanden
g. Eén aanval/6-12 maanden
h. Twee aanvallen/12-24 maanden
i. Eén aanval/12-24 maanden
j. Aanvalsvrij meer 24 maanden
= 20 p. 
50 
40 
45 
40 
30 
20 
20 
10 
0
elke aanval
3. Is er sprake van een aura? Ja O Neen O 
Indien ja: reduceer de IS score met 20%.
4. Worden de aanvallen door niet-alledaagse, vermijdbare factoren geprovoceerd 
(slaapgebrek, alcohol, ziekte, vermoeidheid, etc. )? Ja O Neen O
Indien ja, reduceer de IS met 50%. Score
5. Vinden de aanvallen plaats in een cyclisch of diurnaal ritme?
Dus alleen s’nachts of vroeg in ochtend ? Ja O Neen O Score
Indien ja, reduceer de IS met 40%.
Score
Score
Score A
Sectie B : Vul deze sectie in indien de patiënt een complex partiële aanval heeft gehad die niet tot een gegeneraliseerde 
aanval leidde.
1. Aantal aanvallen sinds laatste bezoek:
Aantal aanvallen sinds start anti-epilepticum:______
2. Kwamen de aanvallen in cluster ( = meer dan 2 binnen 24 uur )? Ja O Neen O
Zo ja, hoeveel aanvallen in het cluster: _________ Tel bij >3 aanvallen, slechts de helft van de aanvallen.
3. Selecteer de juiste aanvalsfrequentie:
a. 4 of meer aanvallen/maand
b. Drie aanvallen/maand = 40
c. Twee aanvallen/maand = 30
d. Eén aanval/maand
e. Eén aanval in 1-3 maanden
f. Minder dan 1 aanval in 3 maanden
g. Aanvalsvrij
4. Is er sprake van een aura? Ja O Neen O 
Indien ja: reduceer de IS score met 20%.
= 50 (+10 per extra aanval)
= 20 
= 15 
= 10 
= 0 Score
Score
5. Worden de aanvallen door niet-alledaagse, vermijdbare factoren geprovoceerd 
(slaapgebrek, alcohol, ziekte, vermoeidheid, etc.)? Ja O Neen O
Indien ja, reduceer de IS met 50%. Score _____
6. Vinden de aanvallen plaats in een cyclisch of diurnaal ritme?
Dus alleen s’nachts of vroeg in ochtend ? Ja O Neen O
Indien ja, reduceer de IS met 40%. Score _____
7. Kan de patiënt binnen 15 minuten na de aanval weer op het oude niveau functioneren ?
Ja O Neen O Indien ja, reduceer de IS met 50 % Score
ScoreB
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Sectie C: Vul deze sectie in indien de patiënt een elementaire ( simpel ) partiële aanval heeft gehad.
1. Aantal aanvallen sinds laatste bezoek:______
Aantal aanvallen sinds start anti-epilepticum:______
. Kwamen de aanvallen in cluster ( = 2 binnen 24 uur )? Ja O Neen O
Zo ja, hoeveel aanvallen in het cluster: _________ Tel bij >3 aanvallen, slechts de helft van de aanvallen.
. Selecteer de juiste aanvalsfrequentie:
a. 7 of meer aanvallen/maand = 33 ( + 3 p. voor elke extra aanval)
b. 6 aanvallen/maand = 30
c. 5 aanvallen/maand = 28
d. 4 aanvallen/maand = 25
e. 3 aanvallen/maand = 23
f. 2 aanvallen/maand = 20
g. 1 aanval/maand = 15
h. Eén aanval in 1-3 maanden = 13
i. Minder dan 1 aanval in 3 maanden = 10
j. Aanvalsvrij = 0
Score ______________
. Worden de aanvallen door niet-alledaagse, vermijdbare factoren geprovoceerd 
( slaapgebrek, alcohol, ziekte, vermoeidheid, etc. )? Ja O Neen O
Indien ja, reduceer de IS met 50%. Score ________________
. Vinden de aanvallen plaats in een cyclisch of diurnaal ritme?
Dus alleen s’nachts of vroeg in ochtend ? Ja O Neen O
Indien ja, reduceer de IS met 40%. Score ________________
. Kan de patiënt binnen 15 minuten na de aanval weer op het oude niveau functioneren ?
Ja O Neen O Indien ja, reduceer de IS met 50 % Score ______________
Score C
Score A  +  score B + score C = SA score
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Instructies: alle toxiciteit wordt gescoord in verhouding met wat normaal was voor deze patiënt voor de start van deze 
medicatie. Wijzig de medicatie niet wanneer er toxiciteit optreedt bij hoge serumspiegels, maar reduceer de dosis. 
Omcirkel die scores die van toepassing zijn op deze patiënt en vul deze in op de scorelijn. Vul nul-waarde in wanneer 
betreffende toxiciteit niet aanwezig is.
Neurotoxiciteits schaal
Score 
1. Diplopie:
2. Nystagmus ( niet eindpunt):
a. Intermitterend
b. Constant
a. Horizontaal
b. Verticaal
3. Dysartrie: a. Mild ( intermitterend slurring ): 5
b. Matig ( constant slurring, geen moeilijkheden met communicatie ) 10
c. Ernstig ( moeilijk te verstaan indien onderwerp onbekend )
4. Looppatroon, normaal lopen: a. Lichte ataxie ( traagheid of onstabiel draaien )
b. Milde ataxie ( loopt schommelend, moeite met lopen ) 15
c. Redelijke mate van ataxie ( redelijk onstabiel, loopt breed-basisch; 
neiging naar een of andere kant te vallen )
d. Ernstige loopstoornis (kan alleen met assistentie lopen; onstabiel zitten ) 50
5. Snelle alternerende bewegingen (hand op knie; beurtelings aanraken; slordig)
6. Intentie-tremor ( vinger-neus-proef met ogen open/dicht )
a. Mild (tremor; vingers missen de neus soms ) 10
b. Redelijk (grote tremor; vingers missen neus meestal ) 25
c. Redelijk ernstig (frequente of constante tremor)
d. Ernstig (verstoort dagelijks functioneren: eten, schrijven, werk) 50 
Vul totaal in voor items 1-6 (indien > 1 score, dan delen door 2)
7. Sedatie ( bewustzijnsniveau )
a. Lethargisch in vroege AM of PM
b. Af en toe slaperig overdag 10
c. Vaak moeilijkheden wakker te blijven
d. Stuporeus
8. Affect en stemming ( depressie; gespannen/agitatie; woede/hostiliteit; energierijk/ 
prikkelbaarheid; moeheid/apathie; verwardheid/gedachtestoornis )
a. Mild ( stoornis herkend door patiënt, maar interfereert niet met gewone leven ) 5
b. Redelijk ernstig ( stemmingstoornis resulteert in verminderd presteren ) 15
c. Ernstig ( continue of bijna continue stemmingsstoornis interfererend met normale leven ) 50
9. Cognitief functioneren ( attentie en concentratie )
a. Mild ( stoornis herkend door patiënt, maar interfereert niet met gewone leven ) 5
b. Redelijk ernstig ( stoornis resulteert in verminderd presteren )
10. Duizeligheid/licht in het hoofd (vul ’0' in als absent)
a. Mild ( symptomen herkenbaar, maar beïnvloedt niet normale leven ) 3
b. Redelijk ernstig ( resulteert in verminderd presteren ) 5
c. Ernstig ( interfereert met alle dagelijkse activiteiten ) 10
11. Hoofdpijn (vul ’0' in als absent)
a. Mild ( symptomen herkenbaar, maar beïnvloedt niet normale leven ) 3
b. Redelijk ernstig ( resulteert in verminderd presteren ) 5
c. Ernstig ( interfereert met alle dagelijkse activiteiten ) 10
12. Andere neurotoxiciteit ( beschrijf ):_______________________________
15
30
5
10
30
5
25
15
35
25
50
10
) 50
Soms Vaak Vaak
na na over-
med. med. dag
5 10
10 25
25 50_
Soms Vaak Vaak
na na over-
med. med. dag
5 10
10 25
25 50_
5
Neurotoxiciteits Score ( som 7 to 13 ) Totaal score
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Instructies: alle toxiciteit wordt gescoord in verhouding met wat normaal was voor deze patiënt voor de start van 
deze medicatie. Wijzig de medicatie niet wanneer er toxiciteit optreedt bij hoge serumspiegels, maar reduceer de 
dosis. Omcirkel die scores die van toepassing zijn op deze patiënt en vul deze in op de scorelijn. Vul nul-waarde in 
wanneer betreffende toxiciteit niet aanwezig is.
Systemische Toxiciteits Schaal
Score
1. Heeft de patiënt medicijn-gerelateerde gastro-intestinale problemen ?
(Vul de hoogste toepasselijke score in; vul ‘0' in als categorieën niet van toepassing zijn )
Ongemak Nausea Braken Ander
a. Voorbijgaand of soms na
medicatie 3 5 10 ___
b. Vaak na medicatie 5 10 25 ___
c. Vaak overdag 10 25 50 ___
2. Heeft de patiënt problemen van het hematopoietische systeem ?
(Vul score in bij elke categorie; vul ‘0' in als categorieën niet van toepassing zijn )
a. Verlaagd trombocyten getal < 75,000 ( scoor 25; scoor 50 als medicatie gestaakt )
a. Verlaagd leukocyten getal < 2,000 ( scoor 25; scoor 50 als medicatie gestaakt )
c. Andere hematologische problemen: ______________________________________
3. Heeft de patiënt dermatologische problemen t.g.v. de medicatie ?
a. Voorbijgaande gegeneraliseerde maculopapulaire uitslag ( reagerend op behandeling ) 15
b. Ernstige gegeneraliseerde maculopapulaire uitslag ( niet reagerend op behandeling ) 50
c. Acne op gelaat, romp en extremiteiten 10
d. Ernstige acne, excessief en lastig voor de patiënt 30
4. Heeft de patiënt potentie of libido problemen t.g.v. de medicatie ?
a. Voorbijgaand, soms en tolerabel 20
b. Continu of intolerabel 50 ____
5. Heeft de patiënt een hyponatriëmie met serum natrium < 120 mmol/l ?
Zo ja, scoor 50
6. Heeft de patiënt gestoorde lever-waarden (ASAT, ALAT) t.g.v. de medicatie?
a. Ja, onder observatie 25
b. Ja, medicijn gestaakt 50
7. Is het gewicht van de patiënt toegenomen door verhoogde eetlust t.g.v. de medicatie ? 
Gewichtstoename: gering ( 2-3 kg) 3
redelijk ( 3-6 kg ) 10
groot ( > 6 kg ) 20
8. Heeft de patiënt veranderingen bemerkt n de hoeveelheid en toestand van het haar ?
a. Haarverlies: mild (haar in kam ) 5
redelijk ernstig ( zichtbaar dunner of stukken haar in kam ) 20
ernstig ( zichtbare alopecia of zeer lastig voor de patiënt ) 50
b. Verandering in toestand van het haar ( grof, sluik, gekruld ) 5
c. Hirsutisme: redelijk ernstig ( op gelaat, romp en extremiteiten ) 20
ernstig ( excessief en lastig voor de patiënt ) 50 ____
9. Andere systemische toxiciteit ( beschrijf ) :_________________________________________
Systemische Toxiciteits score Totaal score
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